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Summary  
Name: Mr. Andras Sandor Solt 
Thesis title: Investigating the molecular signatures of β1-adrenergic receptor activation 
In this thesis I have investigated the molecular signatures of receptor activation, using the β1-
adrenergic receptor (β1AR) as a prototypical class A G-protein coupled receptor (GPCR). I have used a 
minimally thermostabilised turkey β1AR and expressed it functionally in insect cells using a baculovirus 
system. The work described here established the labelling, expression, purification and sample 
preparation of the receptor in LMNG detergent micelles for use in nuclear magnetic resonance (NMR) 
spectroscopy. GPCRs are highly dynamic molecular systems, and the use of solution NMR is highly 
suited to the study of fine structural changes that take place within the receptor as a consequence of 
receptor activation. To this end the receptor was selectively labelled with 13C at the methyl position 
of methionine residues. The labelling was carried out during insect cell expression, by supplementing 
methionine deficient media with the labelled amino acid. In this way the methionines throughout the 
receptor served as reporters. The radio frequency signals emitted by the nuclei of these labelled 
residues were monitored. NMR experiments were recorded on the receptor in the presence of ligands 
of various efficacies together with and without G-protein mimetic nanobodies, and changes in the 
signal were recorded. This allowed for a pattern of molecular signatures to be established, reporting 
on the effect ligands and G-protein mimetics have on the receptor. This identified two conformational 
equilibria, between an inactive and a ligand bound-pre-activated state and between a more and a less 
active ternary state when bound to a G-protein mimetic. Furthermore, it was also observed that ligand 
binding to the G-protein mimetic saturated basal active state elicits further changes on the receptor 
cytoplasmic side, demonstrating that ligand efficacy modulates the nature of receptor interaction with 
G-proteins, which may underpin partial agonism. It was also observed that ligand binding affects the 
dynamics and rigidity of the receptor, with a full agonist bound receptor exhibiting extensive µs to ms 
timescale dynamics, compared to a more rigid nanobody bound state. The increased dynamics suggest 
that full agonist binding primes the receptor for interaction with various downstream signalling 
partners. Once this coupling takes place, ligand efficacy determines the quality of interaction in this 
rigidified system.  
In addition to activation by ligands, certain proteins, such as antibodies can cause receptor agonism 
in the absence of a small molecule agonist. An example of this takes place in chronic Chagas’ heart 
disease, where anti-Trypanosoma cruzi antibodies inappropriately cross-react to β1AR, leading to 
chronic cardiac overstimulation and heart failure. In this thesis, the production of a published 
monoclonal antibody fragment was explored, in order to generate a tool for the study of this activation 
mechanism.  
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Chapter 1 – Introduction 
1.1 – G-protein Coupled Receptors 
G-protein coupled receptors are 7-trans-membrane alpha helical proteins. With over 800 human 
genes encoding GPCRs, they represent one of the largest families of integral membrane proteins in 
our genome (1). GPCRs are implicated in a wide array of signalling pathways, affecting a diverse palette 
of physiological functions such as smooth muscle and myocardial regulation, platelet activation, 
endocrine and metabolic regulation, immune system activation, synaptic transmission, sight and 
olfactory regulation, development and growth and cellular proliferation (2). It is therefore not 
surprising that GPCR dysregulation is associated with conditions spanning multiple disease areas, 
making GPCRs the single biggest family of drug targets. It is estimated that about 30% of current drugs 
modulate GPCR function (3). 
1.1.1 – GPCR Classification 
Several classifications of GPCRs exist and the methods used have evolved over time. The earliest 
classification grouped GPCRs on the basis of sequence homology and this was the basis of the well-
known A-F Class system (4). With the publication of the human genome, the dataset of GPCRs was 
expanded and a system of classification emerged based on phylogenetic analysis (5). This groups 
GPCRs into the families of Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin, and is hence 
known as the GRAFS system (6, 7). The two classifications overlap: the Rhodopsin family was known 
as Class A, the Adhesion and Secretin families both as Class B, Glutamate as Class C. Class D and E were 
separate groups of fungal mating pheromone receptors and cyclic AMP receptors respectively, and 
Frizzled receptors were initially designated Class O (other 7TM) and later Class F. Neither Class D nor E 
receptors were found in vertebrates.  
Although considerable variation exists in terms of primary and secondary structure between different 
classes of GPCRs, they all share the common hallmarks of seven stretches of 25-35 highly hydrophobic 
amino acids – which form the seven transmembrane helices – as well as the ability to interact with 
heterotrimeric G-proteins (htG-proteins) (1).  
The Rhodopsin family (class A) is the largest of the five and is the best structurally characterised. The 
family is divided into four subfamilies, these are α, β, γ and δ. Class A receptors are variable in primary 
sequence, but certain motifs such as the DRY motif and the NPxxY motif are highly conserved. The N 
terminal region is also relatively short and sequence-diverse. Interesting cases of Rhodopsin family 
GPCRs have been documented, where the N terminus plays a role in receptor activation. This can take 
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place in the form of N-terminal cleavage, as in the case of the human thrombin receptor (PAR1/ F2R), 
where cleavage at an N-terminal thrombin binding site reveals a tethered ligand, which in turn 
activates the receptor. PAR2 receptor is pre-activated by trypsin in a similar manner (8, 9). The N-
termini of some receptors, such as the LGR7, LGR8 (relaxin-binding receptors), FSHR (follicle-
stimulating-hormone receptor), LHR (leuteinizing hormone receptor) and TSHR (thyrotropin receptor) 
contain leucine rich segments, which take part in the interactions between the receptor and their 
glycoprotein ligands (10, 11). However these are unusual cases and most Rhodopsin family GPCRs bind 
their ligands through pockets formed by the extracellular loops and TM helices (12). 
The Rhodopsin subfamilies group receptors with a huge variety of ligands, but on the basis of 
phylogeny only. Thus, receptors belonging to different subfamilies share preference for a given ligand 
type. The α subfamily contains for example histamine receptors, dopamine receptors, serotonin 
receptors, adrenoreceptors, muscarinic acetylcholine receptors, muscarinic receptors, cannabinoid 
and prostanoid receptors amongst others. The β subfamily contains mostly peptide binding receptors, 
such as endothelin receptors, gonadotrophin-releasing hormone receptors, oxytocin receptors and 
neuropeptide receptors. The γ subfamily groups opioid receptors, somatostatin receptors amongst 
others. An interesting member of the group is chemokine receptor 5 (CCR5), a target of the drug 
maraviroc, which blocks the interaction between the HIV virus and CCR5, a crucial interaction in virus 
entry (13). The δ-group contains the aforementioned glycoprotein receptors, FSHR, LHR, TSHR, the 
protease-activated receptors as well as P2RY. This group also includes the largest number of 
mammalian olfactory receptors in the Rhodopsin family. 
The Secretin family derives its name from the first Class B receptor discovered (14), and it contains 
five subfamilies. These are the calcitonin receptors, corticotropin-releasing factor receptors, glucagon 
receptors, parathyroid hormone receptors, vasoactive intestinal peptide receptors and pituitary 
adenylate cyclase activating receptors (7). Typical of this family are a group of three highly conserved 
cysteine bridges, which have been shown to be important for ligand binding through stabilisation of 
the N-terminus (15, 16).  
Also previously grouped under Class B are the Adhesion family of receptors; the second largest family 
in the human genome. Like Secretin family members, Adhesion receptors possess a long N-terminal 
domain. A difference between these two groups is that Adhesion receptors contain a GPCR proteolytic 
(GPS) domain. Furthermore, these two families display differences in terms of the nature of the bound 
ligand, Secretin GPCRs bind peptide hormones and Adhesion receptors –  for which the ligand is known 
– have so far been extracellular matrix components (7). 
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Glutamate family receptors (abbreviated GRMs) (Class C) contain four main groups plus Class C 
orphans receptors: receptors for which the endogenous ligand has not been identified. These are 
calcium sensing receptors, GABAB (gamma-aminobutyric acid) receptors, metabotropic glutamate 
receptors and taste 1 receptors. Members of this family commonly have extended N-terminal 
domains, which forms the orthosteric ligand binding site (17). In the case of mGluR5 this cavity is 
formed by two lobes of the N-terminal domain, and ligand binding has been likened to a Venus fly trap 
mechanism (18). However many allosteric sites have been identified formed by extracellular loops. 
The TM regions of GRMs show a high degree of residue conservation, and highly conserved residues 
include non-polar hydrophobic amino acids, as well as a number of polar, charged and aromatic 
residues, which may be important for interhelical contacts. Conserved motifs have also been 
identified, such as the Rhodopsin NPxxY equivalent PKxY motif in TM7 and the WL motif in TM6 (1). 
The Frizzled/ Taste2 family groups together frizzled receptors, the smoothened receptor and a number 
of Taste2 receptors. Frizzled receptors bind the wnt family of small glycoproteins as their ligand, whilst 
the smoothened receptor is understood to function in a ligand independent manner. Frizzled 
receptors share a large extracellular domain ranging in length from 200 to 320 amino acids and contain 
nine conserved cysteines (12). Taste2 receptors (T2Rs) have been identified to recognise thousands of 
bitter taste compounds, a feat which may be explained by the wide spectrum of sequence 
conservation between different subgroups of T2Rs (19, 20).  
1.1.2 – GPCR signalling  
GPCRs serve to translate extracellular stimuli through the cell membrane. This stimulus can take form 
in a wide range of shapes, such as proteins, peptides, nucleosides, amines, ions and light.  Ligand 
binding induces structural changes within the receptor that allow the association of intracellular 
binding partners and thereby the relay of extracellular signals to within the intracellular environment 
(21). A typical feature of GPCRs is their basal activity (although exceptions exist, such as Rhodopsin), 
where a low-level downstream signalling activity takes place even in the absence of extracellular 
stimulus (22). In this regard, ligands can be categorised on the basis of how they modulate basal 
receptor signalling. Ligands which activate receptor signalling through downstream second 
messengers are called agonists and depending on the magnitude of the elicited signalling output, they 
may be full, partial, or neutral agonists (Figure 1.1). The latter in the case when ligand binding takes 
place but no increase above basal activity is observed. Ligands may also be able to decrease basal 
activity and these are known as inverse agonists. These too may be partial, or full in terms of the 
output of attenuation. Antagonists are ligands which modulate receptor activity by modifying the way 
or extent to which endogenous ligands are able to bind to the receptor. Hence antagonists may be 
 4 
inverse agonists, partial agonists or neutral in effect (23). Ligands may bind to an orthosteric or “main” 
ligand binding site, or they may bind away from there to an allosteric or “alternative” site, where 
ligand binding may modulate binding to the orthosteric site (24, 25).  
 
Figure 1.1 Schematic representation of ligand efficacy 
A comparison of ligands according to their maximum biological response attained allows 
their categorisation into full, partial or weak agonists. Ligands that abrogate any basal 
response observed in the apo state are called inverse agonists. Antagonists are ligands 
which modulate the effect of an agonised receptor in relation to another ligand.  
The traditional view of GPCR activation was understood in terms of a switch-like transition from the 
inactive R state to the active/signalling R* state. This has evolved to the current understanding of 
GPCRs as an ensemble of highly dynamic states, stabilised to different extents by various binding 
events. This theme will be explored further in this thesis.  
“Canonical” GPCR signalling takes place through interactions with heterotrimeric G-proteins (htG-
proteins). htG-proteins consist of an α and a non-dissociable β and γ subunits. Nucleotide binding and 
GTPase activity are intrinsic features of the α subunit. Signal transduction via htG-proteins takes place 
through a cycle of activation. In the basal state the α and βγ subunits form a GDP-associated 
heterotrimer. GPCR binding causes the exchange of GDP to GTP and the dissociation of the α subunit 
from the βγ complex. This allows the subunits to bind and regulate downstream signalling partners 
such as enzymes or ion channels. Subunit α GTPase activity will give rise to an eventual hydrolysis of 
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bound GTP to GDP, thereby terminating the signalling process. The GTPase activity has been shown 
to be increased by certain effectors known as GTPase activating proteins (GAPs) or regulators of G-
protein mediated signalling (RGSs). Following nucleotide hydrolysis, the α and βγ subunits reassociate, 
in preparation for another cycle (21). Figure 1.2 illustrates the cycle of htG-protein activation-
inactivation.  
 
Figure 1.2 Cycle of heterotrimeric G-protein activation 
Cycle of heterotrimeric G-protein activation. Binding of GDP associated G-protein to 
GPCR causes nucleotide exchange and the dissociation of α subunit from βγ complex, 
which interact with downstream signalling partners (effectors). Subunit α GTPase 
activity causes GTP hydrolysis to GDP, terminating the signalling process. Abbreviations: 
RGS, regulator of G-protein mediated signalling. Figure from (21). 
Heterotrimeric G-protein α subunits can be classed into four broad categories, Gαs, Gαi/Gαo, Gαq/Gα11, 
Gα12/Gα13. The mammalian htG-proteins are further assembled from a panel of five β subunits and 12 
γ subunits. The type of G-proteins activated by a given receptor has a defined consequence regarding 
the downstream signalling output due to the specific identity of effectors which that given G-protein 
will modulate. Which G-protein a certain GPCR will activate is not absolutely defined, as some 
receptors interact with multiple Gα subunits, but neither is it completely random as a strong 
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preference exists for a certain class of Gα in many GPCRs. For example the β1-adrenergic receptor 
couples exclusively to Gαs, whilst the β2-adrenergic receptor (β2AR) has been shown to signal through 
Gαs and Gαi as well (26).  
G-protein mediated signalling can be oversimplified to the Gα regulation of adenylyl cyclase, in turn 
modulating the levels of cyclic AMP (cAMP), activating PKA, which in turn affects a wide range of 
physiological functions. However it is important to consider that the Gα regulation of adenylyl cyclase 
is ubiquitous to GPCRs in general and depending on which type of Gα they interact with, the effect on 
the enzyme’s activity will be different. For example Gαs increases the production of cAMP, whilst Gαq 
causes the downregulation of adenylyl cyclase activity. Therefore to understand the complete 
significance of G-protein mediated signalling, the process has to be viewed in relation to the signalling 
activity of other receptors. This concept is illustrated in Figure 1.3 in the context of heart function 
regulation. Here, sympathetic cardiac activation is mediated by the primarily Gαs coupled βARs, whilst 
opposing parasympathetic regulation by the muscarinic acetylcholine receptor M2 via Gαi and Gαi/o 
causes adenylyl cyclase downregulation and the activation of the inward rectifier potassium channel 
and the regulation of the L-type calcium channel (21). 
 
Figure 1.3 G-protein mediated signalling in heart regulation 
G-protein mediated signalling concert in heart regulation, illustrating that G-protein 
mediated GPCR signalling is complex and integrative. Abbreviations: β1: β1AR, β2: β2AR, 
M2: muscarinic acetylcholine receptor M2, lf: pacemaker channel, GIRK: G-protein 
mediated inward rectifier potassium channel, VDCC: voltage-dependent calcium 
channel, PKA: protein kinase A.  
GPCRs interact not only with htG-proteins but also with β-arrestin and GPCR kinases (GRKs).  
Arrestins were first discovered in relation to rhodopsin and hence the first arrestin was later termed 
visual arrestin (arrestin 1). A homologous protein and a binding partner of the β2AR has soon after 
been identified and was called β-arrestin. Two types of β-arrestin have been found, β-arrestin 1 and 2 
(or arrestins 2 and 3) (27).  
 7 
Our understanding of the role of arrestins have evolved over time, but can be broadly ascribed three 
functions; as terminators of G-protein mediated signalling, as mediators of receptor internalisation 
and trafficking and as alternative non-G-protein mediated signalling partners in their own right.  
Arrestins were first described to be able to terminate the G-protein mediated signalling output of 
rhodopsin, β2AR and other GPCRs. The association of arrestin with the receptor prevents the coupling 
of G-protein and hence signalling through htG-proteins. Arrestin binding requires prior receptor 
phosphorylation by GPCR kinases (GRKs), of which seven have been identified to date (28). GRKs have 
been shown to phosphorylate serines and threonines on both the intracellular C-terminus as well as 
on other intracellular loops, mainly ICL2 (29, 30). Significantly, receptor phosphorylation takes place 
mostly in the active, agonist bound receptor state, hence arrestin recruitment serves to desensitise 
the active receptor.  
In 1996, the connection between receptor internalisation –  a major alternative form of receptor 
desensitisation to arrestin desensitisation – and arrestin binding have been made, establishing the 
role of arrestin in receptor internalisation (31, 32). Arrestins interact with clathrins to promote 
vesicular internalisation and from here GPCRs can be dephosphorylated and recycled in what is called 
re-sensitisation, or can be targeted for degradation. The most recent view on arrestin mediated 
receptor trafficking is that arrestins form the foundations of a scaffold of proteins, which determine 
the fate of receptors in the process of trafficking (33, 34).  
The third and most recently identified function of arrestins is the ability to activate non-classical 
signalling pathways as a consequence of receptor binding. This presents a whole new plethora of 
pathways through which GPCRs are able to modulate cellular function. The activation of three main 
signalling pathways have been linked to arrestins and these are: non-receptor tyrosine kinases such 
as cSrc, Hck, Fgr and Yes, secondly MAP kinase cascade components, including both the ERK and JNK 
pathways and thirdly signalling through PI3K and PKB/AKT (27). Receptor internalisation has shown a 
close association with the regulation of these signalling pathways both in terms of signalling activation 
and duration.  
GRKs have also been shown to be modulators of alternative GPCR signalling in their own right in 
addition to simply carrying out a function of receptor modification enabling arrestin binding. GRKs 
have been shown to phosphorylate multiple non-GPCR targets, thereby fine tuning the activity of 
downstream non-G-protein mediated signalling pathway components (28). Furthermore the 
recruitment of ubiquitin E3-ligase for the ubiquitination and degradation of β2AR has also shown GRK 
involvement (35). This gives GRKs a dual role in GPCR desensitisation, both in a short term manner via 
arrestin binding or in a long term fashion via receptor degradation.  
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The discovery of alternative GRK/arrestin mediated non-G-portein signalling pathways has introduced 
the concept of biased agonism. Biased agonists are GPCR ligands which are able to trigger the 
activation of these alternative signalling pathways. Biased ligands may be able to activate both G-
protein mediated and alternative pathways to a different extent, hence the nature of their bias might 
be called perfect or partial (23).  
1.2 – The β-adrenergic receptors 
1.2.1 – β1AR Signalling  
The β1-adrenergic receptor is a Class A, Rhodopsin family GPCR which is activated by the endogenous 
catecholamine ligands; adrenaline and noradrenaline. Three subtypes of the β-adrenergic subfamily 
have been identified in the human genome; the β1, β2 and β3 receptors. The existence of a fourth 
subtype, the β4AR has been proposed in turkey erythrocytes (36), however the pharmacological 
evidence supporting this proposal has been questioned and a β4AR is not considered to exist (37, 38). 
Agonist binding triggers a conformational change in the receptor, which causes the dissociation of the 
heterotrimeric G-protein binding partner (htG-protein) to Gαs and and Gβγ subunits. Gαs activates the 
enzyme adenylyl cyclase, resulting in elevated levels of the cytosolic second messenger cyclic AMP 
(cAMP). cAMP activates the regulatory kinase PKA, which in turn causes the phosphorylation of 
calcium-channel-regulatory proteins, leading to an efflux of Ca2+ ions from the sarcoplasmic reticulum 
into the cytosol. Increased Ca2+ levels in turn lead to myocardial contraction (39). Chronic Gαs 
mediated βAR signalling has been associated with heart failure and drugs designed to treat myocardial 
failure through the downregulation of such signalling are aptly called beta-blockers (40). 
β1AR has been shown to be able to activate β-arrestin mediated alternative signalling pathways 
described above. Recent studies of β1AR alternative signalling have highlighted its physiological 
significance in the context of cardioprotection. Here, the transactivation of the EGFR signalling cascade 
by β1AR through β-arrestin 1 and 2 has been shown to correlate with increased tolerance to 
catecholamine induced cardiomyocyte toxicity (41). The proposed signalling cascade includes receptor 
phosphorylation by GRK5/6 leading to arrestin recruitment of Src to the receptor. Src causes the MMP 
activated release of HG-EGF, a ligand of EGFR. The involvement of such non-G-protein mediated, 
multi-member signalling cascades has the potential to significantly increase the number of 
pharmaceutical targets for the treatment of heart failure.  
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1.2.2 – Crystallographic studies of the β-adrenergic receptors 
Until 2007, the only GPCR structure available was that of bovine rhodopsin (42). The crystallisation of 
the β2-adrenergic receptor in 2007 (43) and of other GPCRs since have been made possible by a 
number of technological advances as well as innovations in protein engineering (44). The major 
challenges were threefold, first to make available necessary quantities of receptor for structural 
studies, secondly to achieve crystal formation of GPCRs and thirdly to be able to collect high resolution 
diffraction data on crystals obtained. The high natural abundance of bovine rhodopsin in the rod outer 
segments of the retina, the ease of its isolation through non-chromatographic methods, and its high 
stability in membrane mimetic detergents was a luxury not available for other GPCRs. Hence 
considerable work has been done to find suitable heterologous expression systems, to maximise yields 
and to improve innate stability through the introduction of thermostabilising mutations, stabilising 
fusion partners (such as T4L, PGS, Rubredoxin, BRIL) or the engineering of stabilising antibody 
fragments (45).  
To aid crystal formations, novel detergents, alongside alternative crystallisation methods to the 
conventional vapour diffusion, such as lipid cubic phase (LPC), were developed (46–49). To increase 
functional homogeneity ligand affinity purification resins were created, which were able to purify 
GPCRs to a very high degree of functional purity (50). GPCR crystals have been much smaller in 
dimension than conventional non-lipid crystals and their manipulation for cryoprotection and high 
quality data collection is difficult. Methods to deal with microcrystals which are usually 10-20 µm in 
their longest dimension have been advanced. These include rastering, where the presence of small 
crystals can be automatically detected within a larger volume of lipid matrix which is not possible 
optically (51). The use of microfocus beamlines and more recently X-ray-free electron lasers have 
yielded high resolution crystal structures of a number of GPCRs (52, 53). Crystal structures for 52 
unique GPCRs have been defined to date, in various states of activation and with different ligands 
(Source: GPCRdb, retrieved: 25/Sept/2018). This breaks down to 45 Class A (Rhodopsin) receptors, 4 
Secretin class receptors, 2 Glutamate class and 1 Frizzled Class receptor. Several receptors have had 
their structure determined in complex with a G-protein. 
The majority of GPCR structures represent inactive states. Active state conformations have been 
obtained for rhodopsin (Gαt peptide stabilised), β2AR (nanobody and Gαs bound) and the M2 
muscarinic acetylcholine receptor (nanobody stabilised) (54–56). G-protein bound states have been 
determined for bovine rhodopsin (Gt bound), A2AR (bound to Gs and MiniGs), GLP-1 (Gs bound), 5-HT1B 
(Go bound), A1R (Gi2 bound), µ-opioid receptor (Gi bound). These have been determined by X-ray 
crystallography or cryo-EM (57–68). Additionally structures are available for the β1AR, α2-adenosine 
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receptor (A2AR), neurotensin type 1 receptor (NTSR1) and P2Y purinergic receptor 12 (P2Y12R), which 
show an active-like, partially activated conformation, but without the presence of any cytoplasmic 
binding partners (69–73). Furthermore the structure of human rhodopsin bound to mouse visual 
arrestin has also been determined (74).  
Of particular significance and relevance to this project are the eleven crystal structures of β2AR. 
Significantly the β2AR in complex with Gαs (PDB ID: 3SN6), was the first full Gα/GPCR complex and the 
first model of an active state adrenergic receptor. In this regard this β2AR structure and others can 
provide valuable insight into the activation process of the β1AR. The following table lists β2AR 
structures to date.  
Table 1.1 List of β2AR structures currently available 
PDB ID Construct Binding partner/ ligand Reference 
2R4R 
48 AA C-terminal 
truncation: β2AR365 
Fab5 (75) 
2RH1 β2AR-T4L in ICL3 Carazolol (inverse agonist) (76) 
3D4S 
β2AR(E122W)-T4L 
(Mutation for stability) 
Timolol (beta blocker, partial inverse agonist), 
cholesterol 
(77) 
3KJ6 13C-methyl-β2AR Fab5 (78) 
3NY8 
β2AR-ICL3-T4L 
ICI118,551 (selective antagonist) 
(79) 3NY9 Compund 2 (inverse agonist) 
3NYA Alprenolol (inverse agonist) 
3P0G β2AR-T4L 
Nb80 G-protein mimic,  
BI-167107 (full agonist) 
(80) 
3PDS 
β2AR(H93C)-T4L 
(Mutation for covalent link) 
Covalently bound FAUC50 agonist   (81) 
3SN6 β2AR-Nterm-T4L Gαs, Nb35, BI-167107 (82) 
4GBR T4L-β2AR-Δ-ICL3 Carazolol (inverse agonist) (83) 
4LDL β2AR365+Nb6B9 
Hydroxybenzylisoproterenol (high-affinity 
cathecolamine agonist) 
(84) 
4LDE β2AR365+Nb6B9 BI-167107 (ultra-high-affinity agonist) (84) 
4LDO β2AR365+Nb6B9 
Adrenaline (low affinity endogenous 
cathecolamine agonist) 
(84) 
4QKX β2AR(H93C)+Nb6B9 Covalent (nor)adrenaline derived agonist (85) 
5D5A β2AR 
Carazolol (crystallography method paper for 
LCP method) 
(86) 
5JQH β2AR+Nb60 Allosteric nanobody (87) 
5D6L β2AR 
Sample preparation method for LCP 
crystallography 
(88) 
5X7D β2AR 
Bound to Cmpd-15 intracellular allosteric 
antagonist 
(89) 
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The first crystal structure bound to the inverse agonist, carazolol (2RH1) was expected to represent 
the traditional inactive R state. The inactive state in rhodopsin features a so called ionic lock between 
Arg3.50 and Glu/Asp6.30 in TM3 and TM6, which is understood to lock the receptors in the inactive 
conformation (superscript: Ballesteros-Weinstein GPCR residue numbering). This interaction is also 
expected to be present in β2AR, as mutations of these residues render the receptor constitutively 
active (90). However the supposedly inactive crystal structure revealed the distance between R1353.50 
and E2686.30 to be too large for ionic interactions. The lack of an ionic lock in the inverse agonist bound 
state may explain the basal activity of β2AR, but more significantly it can be considered as evidence 
that the receptor explores multiple conformational states, and these are only transiently stabilised by 
for example inverse agonist ligand binding.  
The nanobody (Nb80) (3P0G) and Gαs (3SN6) stabilised active conformations of β2AR have revealed 
two structural hallmarks of the active state. Firstly the cytoplasmic end of TM6 displays a 14 Å outward 
movement measured at Glu2686.30 (Cα). Secondly a similar outward movement and extension by 7 
residues was observed for the cytoplasmic end of TM5. The second intracellular loop (ICL2) was also 
seen to adopt an α-helical conformation. These changes are illustrated on Figure 1.4. 
1.2.3 – Engineering the β1AR for crystallisation 
The turkey (Meleagris gallopavo) β1AR (tβ1AR) has proved to be an ideal candidate for providing 
structural insight into the β1-adrenergic receptor subfamily. It is (tβ1AR) 79% identical in sequence 
(dismissing N- and C-termini) to the human β1 receptor (hβ1AR) and its stability is superior over the 
hβ1AR. The melting point for tβ1AR was measured 10 °C higher at 31 °C, than for hβ1AR observed in 
0.01% DDM. In comparison, the wild type human β2AR (hβ2AR) was almost as stable as tβ1AR with a 
melting point of 30 °C (91). Without further modification, the human β1AR is hence unsuitable for 
crystallisation due to its instability.  
To further improve stability, conformational and structural heterogeneity and expression levels, a 
number of modifications were introduced to the tβ1AR sequence (92). The N-terminal residues 3-32 
were deleted, as well as residues 244-271 and 277-278 in intracellular loop 3 (ICL3), and the C-terminal 
was shortened between amino acids 368-483. The truncation of these flexible regions was aimed to 
assist crystal formation. To avoid heterogeneity arising from non-uniform palmitoylation, cysteine 358 
was mutated to alanine to remove the post-translational modification site. The C116L substitution 
was found to increase functional expression levels. The feasibility of thermal stabilisation of the 
receptor was explored by the iterative mutation of all residues to alanine or leucine (where alanines 
are present originally). This is known as alanine scanning. Any increases in thermal stability were 
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assayed through measuring the apparent melting point of the protein (Tm); the temperature at which 
50% of receptor molecules retain their ligand (antagonist in this case) binding ability after one hour. 
Residues showing potential in an initial alanine scan were then optimised by substituting a different 
class of amino acid to the hydrophobic alanine. On average, amino acid substitutions which brought 
about an increase in Tm did so by 1-3°C, however the Y227A mutation gave an 8°C shift. Mutations 
which increased stability were combined to achieve an overall Tm of 52.8°C. This construct, termed the 
β1AR-m23 mutant contained the thermostabilising mutations: R68S1.59, M90V2.53, Y227A5.58, A282L6.27, 
F327AICL3 and F338M7.48, as well as the other sequence modifications mentioned above and provided 
the first crystal structure of the receptor. 
Attempts to further increase receptor thermostability resulted in an ultrathermostable β1AR-JM3 
construct. The introduction of a salt bridge, which is present in β2AR between residues Asp192 and 
Lys305 (equivalent β1AR residues are Asp200 and Asp322) by the mutation D200E+D322K achieved a 
5°C increase in Tm alone. Further substitutions identified by leucine scanning increased the receptor 
melting point to 61.7°C (in DDM micelles), when combined with the salt bridge forming mutation. 
Hence β1AR-JM3 contained the stabilising mutations D200E, D322K, I129V and Y343L in addition to 
the β1AR-m23 mutations (93).  
The thermostabilised constructs were investigated for their agonist binding ability. Competition 
binding assays have shown β1AR-m23 to bind the agonists norepinephrine and isoprenaline 2470 and 
650 times weaker respectively than the non-stabilised, truncated β1AR32-424 construct. Similarly, the 
ultrathermostable JM3 construct bound noradrenaline and isoprenaline 4960 and 990 fold weaker 
than the non-stabilised receptor. (93, 94). Furthermore, the thermostabilised constructs are also able 
to bind and signal through intracellular G-proteins, albeit with a higher predicted activation energy 
(95). 
1.2.4 – Insights from β1AR Crystal structures 
Crystal structures of the thermostabilised turkey β1-adrenergic receptor have been obtained in the 
presence of various ligands, such as agonists, partial agonists, inverse agonists, antagonists as well as 
in the absence of any ligand. The following table lists the published structures to date alongside the 
nature and identity of any ligand present. 
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Table 1.2 List of β1AR crystal structures currently published 
PDB ID Bound Ligand Ligand agonism Reference 
2Y02 Carmoterol Full (69) 
2Y03 Isoprenaline Full (69) 
2Y00 Dobutamine Partial (69) 
2Y04 Salbutamol Partial (69) 
2Y01 Dobutamine Partial (69) 
2VT4 Cyanopindolol Partial (96)  
2YCX Cyanopindolol Partial (97) 
2YCZ Iodocyanopindolol Partial (97) 
2YCY Cyanopindolol Partial (97) 
4AMI Bucindolol (Biased)‡ (23) 
3ZPQ 20* Antagonist (98) 
3ZPR 19† Antagonist (98) 
4BVN Cyanopindolol Partial (99) 
2YCW Carazolol Inverse agonist (97) 
4AMJ Carvedilol Weak Partial (Biased)‡ (23) 
4GPO None - (100) 
4BVN Cyanopindolol Partial (101) 
5A8E 7-methylcyanopindolol Weak partial (102) 
5F8U Cyanopindolol Partial (103) 
 
*4-METHYL-2-(PIPERAZIN-1-YL)QUINOLINE 
†4-(PIPERAZIN-1-YL)-1H-INDOLE 
‡ Biased agonists show differential efficacies in the activation of G-protein mediated and 
alternative signalling pathways 
 
The overall topology of the β1AR was found to be very similar to the β2AR, with the RMSD of 296 
superimposed Cα atoms across all transmembrane helices being 0.25 Å (comparing carazolol bound 
β2AR – PDB:2R4R,  and cyanopindolol bound β1AR – 2VT4) (96). The second extracellular loop in both 
β1 and β2 structures have adopted a partially α-helical conformation, which is proposed to be stabilised 
by the associated Na+ ion visible in the β1AR structure.  
Intracellular loop 2 also adopts a helical conformation, which has not previously been observed in the 
β2 structure, probably due to perturbations owing to the presence of stabilising agents such as T4-
Lysozyme or a Fab fragment. An interesting feature of this short helix is its interaction with the DRY 
motif (D1383.49, R1393.50, Y1403.51) via a hydrogen bond between Y149 (ICL2) and D138. Mutagenesis 
studies of the M2 receptor have shown equivalent residues to be important for G-protein-receptor 
interaction, an observation that the presence of this hydrogen bond in β1AR may confirm (104).  
The antagonist cyanopindolol bound structure (2VT4) shows no evidence for the putative “ionic lock”; 
a salt bridge between residues Arg3.50 (in the DRY motif) and Glu6.30 which is observed in Rhodopsin. 
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The lock is proposed to be essential in stabilising the receptors in the inactive state by linking 
transmembrane (TM) helices 3 and 6. Upon agonist activation the lock breaks, permitting the 
characteristic outward shift of TM6. As the antagonist bound receptor is not considered to be in the 
active state, the absence of any ionic interactions between these residues questions its role in inactive 
state stabilisation.  
However more recent structures of β1AR with different crystal contacts revealed two consistent 
conformations of TM6, a bent form, which brings Glu2856.30 to a distance of 3.7-3.9 Å of Arg1393.50, 
compared to >6.2 Å in the straight conformation (97). It is only in the bent conformation that an ionic 
lock is observed, although the separation between the bonding residues is more than the equivalent 
distance in Rhodopsin, measured at 2.8-3.2 Å. These differences between a receptor with virtually 
none (Rhodopsin) and one with a relatively high basal activity (β1AR) seem to agree with the view that 
GPCRs are highly plastic molecules which rapidly sample multiple active and inactive conformations. 
Structures of β1AR bound to the agonists isoprenaline and carmoterol, and to the partial agonists 
salbutamol and dobutamine have been compared to the antagonist cyanopindolol bound structure, 
to investigate the molecular basis of agonist activation of the receptor (69). All classes of ligands were 
bound to the cathecolamine binding pocket almost identically and none displayed the outward shift 
of TM helix 6, characteristic of GPCR active states observed so far.  
Agonist binding causes Ser2125.43 to adopt a rotameric conformation where it can hydrogen bond to 
Asn3106.55, and agonists can also hydrogen bond to Ser2155.46, which was not observed for partial 
agonists or inverse agonists. A 1 Å contraction of the ligand binding pocket (Asn3297.39 to Ser2115.42 Cα 
distance) was also observed upon agonist binding. Although no further structural change is observed 
in TM5 below Ser2155.46, its hydrogen bond between Val1724.56 is replaced with the agonist, 
weakening the TM4-TM5 interface. At the same time, the TM5-TM6 interface is strengthened by the 
Ser2125.43-Asn3106.55 as well as by the ligand bridged link between Asn3106.55 and Ser2115.42. Together 
these interactions may be sufficient to set up a structural transition to the active state conformation. 
Figure 1.4 shows the superimposition of the antagonist (cyanopindolol) and full agonist (isoprenaline) 
bound β1AR structures as well as the inverse agonist (carazolol), and full agonist and Gαs bound β2AR. 
The active-like conformation adopted by the A2AR is also shown. The comparisons demonstrate that 
agonist binding alone does not induce the structural changes observed in the presence of G-protein 
and agonist, which are considered key features of the active state. The three different states also give 
insight into a conformational energy landscape that is different for each receptor, i.e. ligand binding 
alone causes different degrees of receptor conformational change. 
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Figure 1.4 Structural superpositions of the β2AR, A2AR and β1AR 
Structural superimposition of the inverse antagonist cyanopindolol bound β1AR 2YCY 
(blue) and the full agonist isoprenaline bound β1AR 2Y03 (pink), next to the A2AR bound 
to inverse agonist (cyan) and full agonist (orange). Overlay of the inactive carazolol and 
Nb60 bound β2AR (salmon) and the high affinity agonist and G protein bound β2AR 
(green).  
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1.3 – GPCRs are dynamic molecules 
1.3.1 – Receptor plasticity 
As mentioned above, the classical view of GPCR signalling envisaged a linear, agonist-binding induced 
transition to the R* active state, which enabled downstream G-protein mediated signalling. The 
desensitisation of the receptor by the interaction with arrestin, or the dissociation of ligand then 
causing the termination of receptor activity and a return to the inactive R state. This interpretation of 
GPCR activation/deactivation has been altered both by the emergence of a more complex picture of 
downstream signalling as well as the simultaneous emergence of high-resolution structural 
information about GPCRs. The discovery of alternative and tuneable signalling outputs of GPCR 
activation, such as cross pathway activation via arrestins, receptor desensitisation/re-sensitisation and 
degradation are difficult to explain via the switch on switch off R/R* transition model.  
This simplistic view is easy to reconcile with rhodopsin, the earliest GPCR to be studied in molecular 
detail, which has a very large activation energy barrier and virtually no basal activity (105, 106). Here 
the rhodopsin bound chromophore 11-cis retinal is isomerised to all-trans retinal upon photon 
absorption at an ultra-fast speed of 200 fs (107). The thermal barrier for this transition is around 
45 kcal mol-1, which translates to a single spontaneous receptor activation in 470 years (108).  
However other GPCRs such as β1AR and β2AR paint a very different energy landscape for the process 
of activation.  
First of all their energy landscape is much more intricate than a two state system. The first piece of 
structural evidence to illustrate this is the conformational heterogeneity of TM6 in β1AR in the inverse 
agonist bound state. This is described earlier in relation to two TM6 conformations, a bent one, where 
a salt bridge – typical of the inactive state rhodopsin family – is able to form compared to a straight 
conformation where this bridge is not observed. It is important to note that these variations were 
observed between receptors all binding the same ligand (cyanopindolol) and sometimes within the 
same crystal (97). This shows that the energy barriers between certain conformational states are very 
low and multiple states may be simultaneously sampled by a population of receptors. 
A second observation which suggests that the energy landscape is much more complex than proposed 
by a two state system is that none of the receptor structures crystallised in the presence of agonist 
alone and without intracellular binding partners show the hallmarks of the active state as described 
in section 1.2.2 based on the β2AR-Gαs and β2AR:Nb80 structures. A comparison of the β2AR ligand 
binding sites across the Nb80 (3P0G), Gαs (3SN6) and covalent agonist bound structures (3PDS) shows 
a contraction of 1.2, 1.4 and 1.3 Å respectively, suggesting that although the agonist alone has not 
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induced transition to the active state, no further significant changes are expected to take place within 
the ligand binding pocket during the transition between these states (109).  
Structures of the human adenosine A2A receptor bound to agonists NECA, UK432097 and adenosine 
have also yielded insight into the dynamic landscape of receptor activation (71, 110). Comparison to 
the inverse agonist (XM214385) bound structure has revealed that unlike for β1AR, agonists make key 
interactions with TM7 residues Ser2777.42 ad His2787.43, and not with TM5 amino acids (Ser2155.46 in 
β1AR) (111). In addition agonist binding alone has caused the 2 Å shift of TM3 in the extracellular 
direction, a bulging and 3 Å outwards movement of the cytoplasmic end of TM5 and a 40° outward 
rotation together with a 5 Å opening of the cytoplasmic end of TM6. These changes set the receptor 
up in a very similar configuration to the activated β2AR:Gαs structure, except that the opening of TM6 
is just too small to accommodate the insertion of the G-protein C-terminus (as observed in β2AR:Gαs) 
(109). This is a significant difference from the β1AR and β2AR structures, where agonist binding alone 
displayed no rearrangement on the cytoplasmic side. Therefore agonist binding positions the A2AR on 
an unexpected intermediate on the activation landscape and suggests that this may be completely 
different to the landscape transition by the β-adrenergic receptors in the process. 
Considering the insight that GPCR crystallography has lent to our understanding of agonist-induced 
receptor activation, a simplistic map of transition states can be drawn, coupled with a multi-minima 
energy landscape, which GPCRs have to traverse to change between inactive and active 
conformations. This is illustrated in Figure 1.5. Here agonist bound and agonist-free states change 
between active and G-protein bound states. Structures considered representative of each state 
obtained so far are highlighted. 
  
 18 
 
Figure 1.5 Extended ternary state model and representative GPCR structures 
Selected examples of various receptor transition states between an inactive receptor 
conformation (as judged by dark state rhodopsin 1F88) and between the G-protein 
coupled state (β2AR-Gs 3SN6). Abbreviations: RI: inactive state, RA: active state, L: ligand, 
IBP: Intracellular Binding Partner. 
It can be concluded that crystallography has provided valuable insight into the conformations GPCRs 
adopt en route from inactive to active states. However the field has opened up a gap for the study of 
dynamics between these observed states as well as for the characterisation of yet unobserved 
conformations, which may have been missed due to the tendency of lowest energy conformations to 
be represented in crystal structures.  
1.3.2 – Solution state NMR can provide insights into the dynamic nature of  
β-adrenergic receptors 
The study of GPCRs by NMR present a number of challenges. One of the most prohibitive is the 
apparent molecular size of detergent solubilised receptors. Large molecules suffer from long 
rotational correlation times, resulting in peak broadening and weak signals. Although the rate of 
molecular tumbling can be increased by temperature, this may not be permitted by receptor stability. 
Furthermore, residues undergoing conformational exchange on the µs-ms timescale in the 
intermediate time regime are likely to suffer first from the effects of peak broadening as peaks 
corresponding to such residues are already quite weak in intensity. Another factor is that the extensive 
α-helical nature of GPCRs gives rise to low spectral dispersion, in other words the chemical shift 
environment experienced by most TM helical residues is likely to be similar, causing spectral crowding, 
overlap (112).  
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NMR experiments rely on the presence of NMR active nuclei, and ones with half integral spin values 
such as 13C, 15N and 19F are ideal. Unfortunately such nuclei have to be introduced to proteins due to 
their low natural abundance, through the process of labelling. Labelling strategies extend on one hand 
from the heterologous expression of fully labelled proteins through selective labelling strategies, 
where only certain residues contain NMR active nuclei, to post-translational incorporation of probes 
into the protein.  
The expression of suitably labelled, functional receptors is also one of the challenges of studying 
GPCRs using NMR. Uniform 15N, 13C, 2H labelling in E. coli or E. coli based cell-free expression systems 
have yielded complete structures of 7TM receptors using solution state NMR, namely of sensory 
rhodopsin II (pSRII) and of proteorhodopsin (113, 114).   
Most GPCR crystallographic studies have however relied on the expression of functional protein using 
the baculoviral expression system in insect cells, but uniform labelling in this system remained 
prohibitively costly and difficult until recently (115, 116). Selective labelling approaches in insect cells 
have been successfully employed, however limitations due to the metabolic interconversion of amino 
acids, a phenomenon known as scrambling, must be carefully considered (117, 118). An interesting 
alternative to uniform labelling in insect cells is presented by recent advances in isotopic labelling and 
expression in the nematode C. elegans (119).  
NMR experiments of the β2-adrenergic receptor have provided valuable insight into the dynamic 
nature of the receptor, revealing receptor conformations not observed through crystallisation.  
The study by Nygaard et al. employed a selective 13C-methyl labelling of methionine residues in the 
β2AR transmembrane region, an area not accessible to other biophysical methods or to 19F tagging 
(120). The chemical shift spectra was compared across unliganded, inverse agonist bound, full agonist 
bound and full agonist and Nb80 (G-protein mimic) bound states. These spectra revealed that only the 
agonist together with Nb80 was able to stabilise a single active state and that the presence of agonist 
alone showed multiple dynamic conformations, but which were different from the ligand-free state 
chemical shifts.  
A similar earlier study also relied on the selective labelling of methionine residues in β2AR (121). Here 
a conformational equilibrium between two states was observed for both in the presence of partial 
agonists and of neutral antagonist.  
A 19F labelling strategy of two cytoplasmic cysteine residues in TM6 and TM7 has provided information 
about how the binding of biased agonists might induce G-protein or alternative signalling pathways. 
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A relatively slow conformational exchange between two states was observed for both TM cytoplasmic 
ends, which was differentially modulated by the binding of agonist or β-arrestin biased ligands (122).   
Owing to the nature of the technique, these dynamic conformations are unlikely to be captured by 
conventional crystallography, hence NMR can be employed to give additional detail to the current 
repertoire of crystal structures. The opportunity presents itself to investigate the nature of dynamic 
intermediates of β1AR 
Preliminary 2D [1H, 13C]-SOFAST-HMQC experiments recorded on 13C-ε-methionine labelled Met2-
β1AR, purified by Dr Tony Warne (LMB, Cambridge) proved the feasibility of the approach to study the 
β1AR using solution NMR. In such spectra, each peak corresponds to a 13C-ε-methionine residue. A 
comparison of the number of peaks and their relative intensities across samples in the presence of 
different ligands or the G protein mimic nanobody, can provide information about structural 
differences between various ligand bound and activated states. 
To interpret these spectra, is its essential that the peaks are assigned to the residue responsible for 
that peak. With this knowledge, these experiments can potentially yield information about local 
conformational changes during ligand or G-protein binding as well as about the relative timescales of 
these motions. It is possible to assign these peaks by mutagenesis, where one methionine is mutated 
at a time and changes in the spectra observed. 
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1.4 – GPCR-interacting antibodies 
GPCR binding antibodies have attracted great interest for three main reasons. First, antibodies, 
especially single chain camelid nanobodies have played a significant role in the structure 
determination of GPCRs.  They have been used to stabilise various receptor states, making them 
amenable to structural investigations by X-ray crystallography, cryo-EM and other methods. Second, 
antibodies have been exploited as therapeutic agents since the advent of the original hybridoma 
technology permitted the production of monoclonal antibodies (mAbs). Antibodies, as a form of 
biological therapeutics have been slow to enter the clinic in comparison to GPCR binding peptides, 
despite the R&D interest and a resulting rich pipeline of antibodies in development for the modulation 
of GPCR function. Third, antibodies are important components of the immune response against 
pathogens. Sometimes the pathogenic epitopes show resemblance to self-antigens, resulting in 
antibody cross reaction, which can manifest itself as part of an autoimmune disease. GPCR 
autoantibodies (including those against β1AR) have emerged as an area of interest, as understanding 
the mechanism of chronic antibody mediated receptor agonism holds therapeutic promise for the 
treatment of conditions like idiopathic dilated cardiomyopathy (IDC) or chronic Chagas’ disease to 
name two β1AR related diseases.  
I will discuss each of these three areas of interest in greater detail. 
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1.4.1 – Antibodies as tools for structural biology 
Conventional mammalian IgG antibodies are formed of heterotetramers of two heavy (H) chains and 
two light (L) chains, linked by disulphide bridges. The light chains are composed of two 
immunoglobulin domains, a constant (CL) and a variable (VL) domain. The heavy chain is formed of 
three constant immunoglobulin domains (CH1-3) and of a variable domain (VH), with a hinge region 
linking CH1 and CH2. The N-terminal regions of the heavy and light chains form the variable domains, 
which are responsible for antigen binding via the complementarity-determining regions (CDR). The C-
terminal CH domains are responsible for antibody mediated immune reactions, such as immune cell 
recruitment via Fc receptors, or complement activation via the classical pathway.  
Antibodies can be engineered to adopt various formats, each with different sizes and properties. The 
conventional full IgG can be cleaved by papain protease to release two Fab fragments (Figure 1.6). 
Cleavage by pepsin generates the F(ab’)2 dimer. This dimer can be chemically reduced by breaking the 
disulphide bonds to generate a Fab’ form. The VL and VH domains can be chemically linked (by 
heterologous single chain expression) to produce a single chain fragment variable (ScFv) domain. 
These can form dimers due to their chemical properties, to generate so called diabodies. Alternatively, 
ScFvs can be further linkered to generate di-ScFv molecules. Divalent antibodies can be generated by 
chemically cross linking two Fab fragments that have been generated from two different IgG 
molecules. These will have an affinity for two separate antigens. The smallest antigen binding domain 
of an antibody is a single VL or VH domain. This is called a nanobody. The CDRs or complementarity 
determining regions of an antibody determine its “paratope”: the molecular surface of binding. Its 
antigen equivalent is called the epitope, present on the antigen surface. In summary the epitope and 
the paratope form the surface of interaction between antibody and antigen (123).  
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Figure 1.6 Schematic representation of IgG antibody formats 
Depiction of IgG antibody formats. CH: Constant Heavy, CL: Constant Light, VH: Variable 
Heavy, VL: Variable Light. Double black lines represent disulphide bonds, red lines 
indicated chemical or peptide linkage. Modified from (124). 
 
The serum of the family Camelidae, which comprises camels, llamas and vicuñas constitute an 
exception from the serum immunoglobulins of other mammals. In addition to the aforementioned 
conventional (IgG1) antibodies, they also possess heavy-chain only antibodies (HCAbs). They are 
different in that they lack the light chain component as well as the first constant heavy (CH1) domain. 
The antigen binding portion is hence only formed of a dedicated VHH domain, and not by two halves 
of a VL and VH pair. The VHH domain is equivalent to an ScFv construct made from an IgG1 antibody 
and is referred to as a single-domain antibody (sdAb) or a nanobody (125). One of the major structural 
differences that exists between conventional Abs and nanobodies, is that the antigen binding 
paratope is formed of only three loops as opposed to six. These three loops are generally longer, 
especially loop H3, which is often linked to loop H1 via disulphide bonds, though to reduce the entropic 
burden of binding associated with a large flexible loop (126).  
Nanobodies have excellent stability and expression characteristics and high affinity binding clones can 
easily be screened for. Together with their small size (12-15 kDa), they have been exploited as tools in 
GPCR structural biology efforts. They have been used to lock GPCRs in selected conformations and to 
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stabilise transient states. A few examples where nanobodies and other antibody constructs have 
contributed to our understanding of GPCRs are outlined below.  
The β2-adrenergic receptor was the first non-rhodopsin GPCR to be crystallised, overcoming a number 
of challenges associated with GPCR crystallography. In a nutshell, wild-type GPCRs like other integral 
membrane proteins need to be supplied with membrane mimetic factors such as detergents to enable 
their study in isolation from the plasma membrane. This presents a major challenge, as most GPCRs 
exhibit low stability when extracted, (expressed in melting temperatures) owing partly to the 
conformationally dynamic nature of these receptors. We now know that GPCRs transition through a 
continuum of conformational states, which translates to a degree of inherent instability. In order to 
restrict and so stabilise GPCRs, modifications and manipulations such as the combinatorial 
introduction thermostabilising point mutations, use of fusion partners, stabilising ligands, binding 
partners or membrane mimetics are required (87, 93, 127, 128).  The stabilising properties of the 
plasma membrane are also challenging to reproduce. For example detergents that are mild enough 
not to cause denaturation tend possess longer hydrocarbon chains, so the detergent micelle ends up 
obscuring polar and other contacts crucial for crystallogenesis. 
A number of GPCR structures have been determined bound to antibodies, and a comprehensive list is 
given below (Table 1.3). 
Table 1.3 Comprehensive list of GPCR structures bound to an antibody 
Receptor Class Antibody (PDB code if complex structure exists) Reference 
US28 Class A Nb7 (4XT1, 5WB1, 5WB2) (129, 130) 
β2AR Class A Nb80, Nb6b9, Fab5 (2R4R, 2R4S) Nb35 (3SN6), 
Nb37, Nb60 (5JQH), A11 
(87, 131–135) 
A2AR Class A Nb35 (6GDG) (136) 
κ-opioid receptor Class A (6B73) (137) 
M2 Class A Nb8-9 (4MQS) (138) 
Glucagon receptor Class B mAb1 (5XEZ, 5XF1) (124) 
5-HT2B receptor Class A IgG P2C2-Fab (5TUD) (139) 
µ-opioid receptor Class A Nb39 (5C1M) (140) 
β1AR Class A Nb80, Nb6b9 (141) 
PAR2 Class A Fab3949 (5NJ6) (142) 
 
Figure 1.7 below depicts the binding interaction of some of the GPCRs listed in the table below. 
Antibodies have been used in various formats and their site of binding varies, depending on the 
intended application. Some of these complexes are discussed below in their molecular detail and 
functional properties.   
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Figure 1.7 Examples of GPCR-antibody interactions.  
The complexes show a range of antibody formats (Fabs and Nanobodies) and a range of 
binding sites. GPCRs shown in grey, antibodies and G-proteins (β2AR 3SN6) in colour.  
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Initial approaches to determine the crystal structure of β2AR followed two strategies. One strategy 
saw the insertion of the fusion protein T4-lysozyme into the loop between TM5 and TM6 (ICL3) and 
the other involved raising antibodies against a truncated receptor intracellular loop 3 (ICL3) and 
selecting immunoglobulins that bind preferentially to correctly folded, functional receptor. The aim of 
both was to provide hydrophilic packing contacts (75, 76). A suitable monoclonal antibody (mAb5) was 
identified, which was used in a Fab format (Fab5) to generate crystals. The resulting Fab5 and 
antagonist carazolol bound complex yielded a 3.4 Å model that revealed a well-ordered cytoplasmic 
side, however the extracellular regions beyond the membrane boundary above the ligand binding 
pocket were not possible to resolve.  
Despite the limitations of this complex, the resulting structure has revealed key structural differences 
in comparison to the only previously known GPCR structure of bovine rhodopsin. A highly conserved 
region called the ionic lock, defined by the E/DRY motif on TM3 and a corresponding acidic residue on 
TM6 which form an important ionic interaction between TM3 and TM6, has been identified as a 
hallmark of the inactive state. In the inactive bovine rhodopsin a salt bridge is observed between R135 
and E247, thereby restricting the movement of TM6 and locking it in an inactive conformation (143). 
In the active state opsin structure the arginine and glutamate residues are too far from each other to 
form an interaction, as TM6 is tilted outwards in the cytoplasmic direction (144). Similarly in the Fab5 
stabilised β2AR, the distance between R131 and E268 is 6.2 Å, too far to form a salt bridge. The lack of 
this association between TM6 and TM3 is in agreement with the high basal activity of β2AR, in contrast 
to bovine rhodopsin (131).  
Efforts to elucidate active state GPCR structures have historically proved challenging. The first β2AR 
crystal structure bound to a covalent agonist probe FAUC50 revealed a receptor in inactive 
conformation, similar to the β1AR in complex with the agonist levisoprenaline (69, 81). It seems that 
β-adrenergic agonists alone do not lend enough energy in the crystallised state (as opposed to in 
solution) to the receptor to stabilise a fully active state in the absence of any intracellular binding 
partners (IBPs). To raise nanobodies with the aim of stabilising an active state conformation, a high 
affinity, slow off-rate agonist (BI-167107) was identified and llamas were immunised with agonist 
complexed β2AR in liposomes. The resulting Gs-mimic nanobody candidate Nb80 was identified for its 
G-protein like properties. A bimane fluorescent tag attached at C2656.27, which reports differentially 
upon solvent exposure compared to being buried in a lipophilic phase showed a similar change to that 
observed with Gs. Furthermore, Gs binding has been shown to cause an increase in agonist binding 
affinity, and Nb80 elicited the same enhancement measured in competition binding assays with 
alprenolol. The T4L-β2AR in complex with Nb80 and agonist yielded a 3.5 Å model, representing the 
first active state non-opsin GPCR structure (80). The Nb80 bound receptor revealed major changes on 
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the cytoplasmic surface, namely the outward movement of TM5 and TM6 and an associated inward 
shift of TM3 and TM7. The shifted helices accommodate CDR3 penetrating into the resulting space, 
with TMs 5 and 6 making further contacts to a short CDR1. The case of Nb80 highlights the utility of 
nanobodies and other antibodies in stabilising transient receptor states, so that they can be amenable 
to structure determination.  
Similar to Nb80, nanobodies have been observed to bind conformational epitopes, or discontinuous 
segments of a primary sequence, that come into spatial proximity in various conformational states 
that might be higher or lower in potential energy and which as a consequence may be more or less 
transient. In contrast to conventional antibodies, nanobodies have been more frequently observed 
binding such conformational epitopes, due to a more convex paratope formed than that of six-CDR 
antibodies (145–151).  
A question the use of nanobodies’ raises is whether the conformations stabilised in nanobody-target 
complex structures are naturally occurring conformations or whether they are a result of induced fit 
caused by antibody binding. The B-cell mediated antibody response is a component of the adaptive 
immune system. The process of producing high affinity, secreted antibodies is the result of a process 
that starts with haematopoietic stem cell proliferation to produce progenitor B-cells, which undergo 
genetic recombination of the immunoglobulin loci to produce immunoglobulins with random variable 
regions. These immature B-cells then undergo a series of clonal selections. Negative selection ensures 
that cell surface immunoglobulins do not bind self-antigens in the marrow. Positive selection occurs 
when a B-cell engages its native antigen, causing that B-cell clone to proliferate. In the context of 
induced fit versus conformational stabilisation, B-cells that would bind an antigen in a forced 
conformation would have to pay a significantly higher energetic penalty in terms of enthalpy or 
entropy, than a B-cell-receptor that engages its antigen in a native conformation. This in turn would 
mean that B-cells which engage their antigen in an induced fit would have much lower chances of 
clonal selection (123, 152). Hence it is argued that nanobody stabilised GPCR conformations represent 
organic intermediates within the broad structural ensemble of receptor activation. 
This is further supported by the high degree of similarity between the Nb80 stabilised active state 
β2AR structure and the same receptor in complex with the heterotrimeric G-protein Gs. The root mean 
squared deviation (RMSD) between the receptor components of the two structures is a mere 0.6 Å, 
with the biggest differences concentrating at the tips of TM5 and 6, where the contacts between the 
two binding partners vary (54). As Nb80 has been screened for eliciting functional changes akin to 
those induced by the presence of Gs, it can be argued that the remarkable conservation of receptor 
conformation across the two models supports the idea that nanobodies stabilise naturally occurring 
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intermediates, which don’t necessarily occupy the lowest energy minima possible. This observation 
also validates Nb80 and similar IBP-mimetic nanobodies as tools for probing active-state and other 
intermediate conformations. This example reveals the intricate relationship between receptor 
structure and function, where a functional screen can identify a “stabilising scaffold protein” (i.e. the 
nanobody), which triggers the same molecular changes as does the native IBP (i.e. Gαs). 
The use of a nanobody in obtaining a crystal structure of the entire β2AR-heterotrimeric-Gs complex 
demonstrates a different application of antibodies as tools for structural biology in comparison to 
Fab5 exploited for promoting crystal contacts or Nb80 as a stabiliser of a high energy state. Although 
it was initially difficult to form β2AR-Gs complexes in detergent, the use of the non-specific purine 
phosphatase, apyrase was successful in alleviating the inhibitory effect of GDP to htG-protein-GPCR 
complex formation, released upon Gs association to the receptor (153). Heterogeneous stable 
complex were thus formed in a novel detergent called MNG-3 (commercially known as LMNG), 
however due to the large micelle size leaving inadequate amounts of extracellular surface exposed for 
contacts it was necessary to introduce a T4-lysozyme as an amino-terminal fusion. Despite these 
protein engineering interventions, significant structural heterogeneity was observed in the region of 
the nucleotide binding site, formed by the interface of the Ras-like GTPase domain (GαsRas) and the 
α-helical domain (GαsAH). The addition of the pyrophosphate analogue foscarnet achieved significant 
stabilisation, however the resolution of the resulting crystals could not be improved beyond 7 Å (82). 
To further stabilise the complex, a chemically cross-linked β2AR-Gs-heterotrimer was used to 
immunise llamas, and a nanobody was screened for that was able to prevent the dissociation of the 
receptor from the heterotrimer upon the addition of GTPγS. The resulting Nb35 was both able to 
stabilise the complex and provide crystal contacts, achieving a 3.2 Å structure. Nb35 was found to bind 
at the interface of Gα and Gβ, with the long CDR3 interacting with both subunits. Nb35 also aided 
crystal formation through interactions of its scaffold region with Gα subunits of adjacent complexes 
in the crystal lattice.  
Nb35 highlights a third use of an antibody in structural biology, where it is used to stabilise transient 
protein-protein interactions, making use of the unique propensity of camelid antibodies to be able to 
bind conformational or structural epitopes. The same strategy was employed to link the Gα and Gβ 
subunits in the cryo-EM structure of the adenosine A2A receptor-TrxA fusion bound to an engineered 
MiniGs protein (6GDG) (136). 
The value of conformational nanobodies in understanding receptor plasticity and the process of 
receptor activation is elegantly demonstrated by the β2AR binding nanobody Nb60. In contrast to 
Nb80, which was shown to stabilise an active receptor conformation, Nb60 shows bias towards an 
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inactive state conformation. The cooperative effect of Gs and Nb80 on the affinity of the full agonist 
isoprenaline in comparison to the IBP (intracellular binding partner) free receptor has previously been 
demonstrated by the 75-fold increase in affinity caused by Nb80 binding and a 33-fold increase by Gs 
respectively. This was presumed to reflect the difference between an inactive receptor and an active 
receptor state, however Nb60 was further able to reduce isoprenaline affinity by 70 fold. This indicates 
that the form the receptor adopts in the absence of Nb80 is perhaps not the lowest activity state, or 
that it is only one of many inactive states that simultaneously exist. The nanobody-dose dependent 
modulation of ligand binding in opposite directions of affinity describe these nanobodies as classic 
allosteric modulators. Hence Nb60 can be referred to as a negative allosteric modulator, while Nb80 
as a positive allosteric modulator. In pharmacological terms, the affinity of an agonist towards an 
uncoupled receptor (i.e. the absence of an IBP or effector) is referred to as a low-affinity state. 
However 19F NMR work on the β2AR describes this state as an ensemble of multiple low-affinity states, 
termed S1 and S2, which concurs with the aforementioned ability of Nb60 to further reduce full 
agonist affinity (154). The further decrease in affinity in the presence of Nb60 would then represent a 
very-low-affinity state, which resolves to one of the two observable spectroscopic states, namely S2 
(87).  
In structural terms, the S1 state represents an inactive state where residues R1313.50 and E2686.30 form 
a notable salt bridge referred to as the ionic lock, restricting the relative freedom of TM3 and TM6. 
The 3.2 Å crystal structure of β2AR bound to Nb60 and the inverse agonist carazolol (5JQH) is 
remarkably similar to the receptor structure bound to carazolol alone (2RH1), with an RMSD of 0.3 Å 
in the transmembrane region and the ligand binding site. However the carazolol bound structure 
shows the ionic lock to be in a disengaged state, while the CDR3 of Nb60, protrudes into the space 
between TM3, 4 and 6 and a tyrosine and a threonine residue engages the ionic lock glutamate and 
arginine thereby mediating the engagement of the ionic lock. These structural and spectroscopic 
observations are however only part of the clue to understanding receptor allosteric modulation.  
Radioligand binding experiments done on 12 ligands showed a strong positive correlation between Gs 
mediated efficacy and the Nb80 induced positive cooperative effect on affinity. In other words for 
these twelve ligands tested, the extent to which their binding affinity was increased by Nb80 was 
proportional to their efficacy. This observation implies that efficacy is a property that can stem from 
the modulation of ternary complex interactions alone, reflecting the allosteric effect of IBPs and 
ligands, and that it does not necessarily arise from the fine tuning of downstream signalling events. 
Unlike Nb80, Nb60 showed no correlation between efficacy and Nb60 enhanced negative 
cooperativity. It would make sense to observe an inverse correlation between Nb60 induced 
correlation and efficacy, however this was not the case with full agonists such as adrenaline, 
 30 
noradrenaline, isoprenaline and others displaying both strong positive and negative cooperativity with 
Nb80 and Nb60, and several partial agonists such as clenbuterol, zinterol, salmeterol displaying only 
weak negative cooperativity with Nb60 but strong positive cooperativity with Nb80. This implies that 
the interaction of different ligands must vary depending on how the receptor conformational 
ensemble is biased by different IBPs.  
To understand the relationship between negative and positive cooperativity the authors modelled the 
receptor as a simple two state system, interconverting between two allosteric conformations. This 
represents the receptor in an equilibrium between an Nb60 stabilised inactive conformation and an 
Nb80 stabilised active conformation, described by an equilibrium constant J and a ligand specific 
coefficient β, describing the effect each ligand has on the equilibrium. Agonists would hence be 
represented by larger β values, stabilising more of the Nb80 state. This two state assumption however 
fails to describe 30% of the ligands tested in terms of their effect on positive and negative 
cooperativity, and they cannot be described by an interconversion of two states.  
The authors then explore a three state model, where a separate equilibrium constant describes the 
equilibrium between an Nb60 state and an intermediate (J2), and the Nb80 state and that intermediate 
(J1). Each of these constants are in turn modulated by the same ligands differentially through the 
coefficients β2 and β1 respectively. This model now allowed the cooperativity of agonists to be 
predicted, as by having a large β1 coefficient, they stabilise active conformations, while having little 
effect on the stability of the inactive state as described by β2. This allows for the correlation between 
efficacy and positive allosteric modulation, where full agonists have a large β1, partial agonists have a 
small β1. The cooperativity of other ligands could now also be explained through having a different 
effect on both J1 and J2, and the authors therefore class ligands into different groups, depending on 
their tendency to moderate these two equilibria, with each group described by the same coefficients. 
This means, that ligands of similar efficacy but belonging to different groups must vary in their ability 
to stabilise active and inactive states. In other words ligands such as clenbuterol, zinterol and 
procaterol which are similar in their efficacy with respect to Gs activation, the receptor conformations 
they stabilise to achieve receptor activation must be different, as their cooperativity cannot be 
described by the same coefficients.   
In summary, the true value of conformationally selective nanobodies is demonstrated by this study of 
Nb60 and Nb80, in that they stabilise selected transient receptor conformations for long enough that 
they can be subjected to structural, spectroscopic and pharmacological investigation. In turn these 
allow the structure-function relationship of the receptor to be described by dissecting the 
conformational ensemble of receptor activation. These tools have moved our understanding of GPCRs 
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from being considered simple two state on-off systems, to much more complex mechanisms existing 
in a multitude of conformational states modulated by interaction partners such as ligands and IBPs. 
The value of this understanding is plain, as drug discovery efforts have provided a wide-range of tool 
compounds for the medicinal fine tuning of GPCRs without a clear understanding of the underlying 
structural processes, and now it is only fair to use these ligands and other tools, such as nanobodies, 
to improve this understanding for the betterment of the drug discovery process.  
The human cytomegalovirus chemokine receptor US28 has been co-crystallised with the 77-residue 
chemokine domain of CX3CL1 with (4XT1) and without (4XT3) nanobody 7 (Nb7), which has been FACS 
selected from a yeast-display screen of alpaca nanobody library (155). The only difference between 
the two models, is that helix 8 adopts a different conformation due to spatial hindrance by the 
nanobody, but that the transmembrane helices take on an active conformation even with the 
chemokine peptide alone. This suggests that the Nb7 recognises a pre-formed active state and locks 
the receptor in that conformation from the intracellular side. While in this instance the same active 
conformation has been stabilised by the chemokine peptide alone, this scenario illustrates that should 
ligand binding alone not confer enough energy towards a lasting active state conformation, 
nanobodies can bind conformationally sensitive epitopes, stabilising a given receptor state. Indeed 
this was achieved for a later crystallographic model of US28. Here the receptor was C-terminally fused 
with Nb7, which allowed the ligand free apo-form to be determined (5WB1) (130). US28 shows 
promiscuity towards ligand binding, as it has been shown to associate with thousands of chemokines 
with high affinity (156).  
The generation and use of the GPCR binding Nb7 has been indispensable to the understanding of US28 
chemokine binding promiscuity. By stabilising the apo-state US28, Nb7 permitted experiments where 
the binding of different chemokine sequences was possible to evaluate. This built a picture of a unique 
protein-protein interaction, where unlike for other promiscuous interactions with a flat and exposed 
binding interface, the viral receptor accommodates thousands of human chemokines by allowing the 
distortion of a binding pocket formed by the TM helices, in a sequence independent manner while the 
receptor N-terminus also forms interactions with the ligand.  
An additional observation afforded by the use of nanobodies is that another antibody, Nb11, showed 
impaired US28 binding to certain chemokine partners such as CCL5 and CCL3, evidencing intracellular 
allosteric modulation of ligand binding. Thus Nb11 and Nb7 appear to stabilise subtly different active 
states that preferentially couple to partially overlapping sets of ligands. 
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1.4.2 – Antibodies as therapeutic agents 
GPCRs represent a significant group of targets for therapeutic exploitation. In a recent review Hauser 
et. al. have counted the number of GPCR-targeting FDA approved drugs to be 475, representing 34% 
of all FDA-approved drugs (157).  This is in contrast to monoclonal antibody therapies, where out of 
the 83 mAbs approved in the EU or US, only Mogamulizumab (an anti-CCR4 IgG1 antibody) is approved 
in Japan for the treatment of CCR4 positive adult T-cell leukemia-lymphoma (158, 159). This was more 
recently followed by the approval of Erenumab (Aimoving) by the FDA at the time of this writing, an 
anti-CGRPR (calcitonin-gene related peptide receptor) mAb antagonist; the first and only FDA 
approved anti-GPCR mAb. This reflects the challenges associated with developing therapeutic 
antibodies against GPCRs, which primarily stem from the difficulty of preparing suitable antigens for 
immunisation and screening.  
Despite the slow emergence of approved anti-GPCR therapeutic antibodies into the clinic, they 
possess some clear advantages over small molecule drugs (SMDs) that make this approach worth 
pursuing. Although monoclonal antibodies are more expensive to manufacture than SMDs, they show 
higher success rates in clinical trials, less susceptible to inter-patient variability and depending on the 
antibody format, they may have a longer duration of action, requiring less frequent dosing (160). 
Antibodies may also be better placed to expand the current repertoire of therapeutically exploited 
receptors, seemingly out of reach of drug traditional discovery approaches. The current 475 drugs 
acting on GPCRs target 108 receptors, representing only a mere 27% of all human non-olfactory 
GPCRs. High-throughput screening (HTS) methods have a relatively high hit-rate for Family A 
receptors, but four-fifths of these will fail due to their poor drug like properties. HTS methods have an 
even poorer track record for Family B GPCRs and HTS screening has proved inapplicable to Adhesion 
or Frizzled family receptors despite an emerging function in inflammation and oncology (161). Of the 
399 non-olfactory human GPCRs 126 are classified as orphans, where no endogenous ligand has been 
identified to date (162, 163). Finding therapeutic molecules for this third of receptors remains an even 
greater challenge in the absence of tool compounds for functional screening, while they undoubtedly 
have a physiological role to play. This does not preclude them from the current drug development 
pipeline, as several GPCRs without endogenous ligand have been targeted in clinical trials. A few 
selected examples are listed below (Table 1.4). 
  
 33 
 
Table 1.4 A table of most advanced anti-GPCR antibody therapies 
Orphan GPCR Indication Compound 
Clinical trial 
stage 
Company 
LGR5 
multiple myeloma and 
colorectal cancer 
BNC101: 
humanised 
mAb 
Phase I Bionomics Ltd. 
GPR55 
Spasticity related to multiple 
sclerosis and epilepsy 
VSN16R (and 
GWP42003, 
GWP42006) 
Phase II 
(VSN16R) 
Canbex 
Therapeutics Ltd. 
(VSN16R) 
GPR84 
Ulcerative Colitis, Crohn’s 
disease, Colon Cancer 
GLPG1205 Phase II 
Medical University 
of Graz, Galapagos 
NV 
Source: clinicaltrials.gov and (157), orphan status: (162) 
  
Around 80 of these receptors are targeted with small molecules and about 30 or so with peptide 
biologics (164). Both of these types of drugs are often analogues of the natural ligands. The issue that 
many drugs face as a consequence of their similarity to natural ligands is poor selectivity between 
receptors in the same subfamily. Receptors within a GPCR subfamily, especially Class A receptors 
possess a large degree of sequence conservation in the region of the orthosteric ligand binding pocket, 
and the receptor-ligand interactions that are likely to be conserved when comparing natural ligands 
vs. small molecule drugs are the interactions between these conserved amino acids and the ligand 
(165). An emergent initiative of this issue of poor selectivity has been the search for allosteric 
modulators of GPCRs. These are molecules that bind to the receptor at a site away from the orthosteric 
ligand binding pocket. Allosteric ligands may exert a positive modulatory effect with regards to 
receptor signalling, in this case it would be referred to as a positive allosteric modulator (PAM). If a 
PAM is able to cause receptor activation in the absence of an orthosteric ligand, it is known as an ago-
PAM. Conversely, if an allosteric molecule has a negative effect on receptor activity, it is called a 
negative allosteric modulator (NAM). In the case of PAMs and NAMs, a cooperativity exists between 
the orthosteric binding site and the allosteric site, so that the presence of the allosteric modulator 
may enhance or prevent activation via the orthosteric ligand. If a NAM is unable to completely block 
receptor activity, it may be referred to as a partial-NAM. Therapeutic antibodies can offer a solution 
to the issue of selectivity, if their mode of action (MoA) is independent of engaging residues in the 
orthosteric binding pocket. 
The therapeutic utility of any raised antibodies depends on whether it is able to modulate receptor 
activity. The modulation of receptor function can take place either as positive process, where receptor 
signalling is enhanced, or as a negative process, where the extent of the signalling reaction is reduced. 
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The process of antibody-enhanced signalling may take place in different ways. An antibody may 
stabilise an active receptor conformation in the absence of a ligand, or it may trap the receptor in an 
active conformation with ligand, causing ligand binding to persist together with its associated 
signalling output. Antibodies formats such as divalent full length IgG, or diabody fragment formats 
(ScFv) may also cause receptor dimerisation and induce signalling through an active state homodimer 
(e.g. metabotropic glutamate receptor 7) or heterodimer (e.g. Class B GPCR in association with a 
RAMP) (166, 167). 
Similarly, the negative modulation of signalling can be envisaged in various ways. An antibody may 
prevent ligand association either through competition within the active site or by binding to an 
allosteric site and inducing a conformation which is unfavourable to ligand binding. It may also block 
ligand entry by hindering access to the binding pocket. An antibody could also downregulate signalling 
without interference to ligand binding, for instance by stabilising an inactive receptor conformation 
or by triggering receptor internalisation (168).  
Antibody therapeutics may offer an advantage over small molecules or peptides stemming from their 
limited ability to cross the blood brain barrier. Certain receptor targets such as opioid receptors are 
distributed throughout the body across both the central and peripheral nervous system. Long term 
morphine treatment of rats in the presence of paw inflammation has shown that tolerance does not 
arise from the stimulation of peripheral µ-opioid receptors, a key feature of addiction (169). Similarly, 
compounds selectively targeting peripheral κ and µ-opioid receptors were able to achieve 50-80% of 
the analgesic effect achieved with systemic administrations of opioid drugs (170). Hence antibodies 
with their limited CNS penetration offer favourable distribution, which may be exploited to limit 
undesirable side effects in CNS indications.  
Antibodies are native parts of the immune system and as such they perform their function in concert 
with other components. This means that unlike other therapeutic molecules, antibodies can, in 
addition to binding and modulating the structure/function of their target (“blocking” mode of action 
– MoA), exert a therapeutic effect through the modulation of the immune system.  
This can take form as antibody-dependent cellular cytotoxicity (ADCC), where cells bound by certain 
antibodies are recognised by effector cells such as natural killer (NK) cells, macrophages, neutrophils 
or eosinophils to bring about cell death of the antigen coated cell. This is triggered by the recognition 
of the Fc portion of the antibody binding to Fc-receptors on the surface of effector cells (171). At least 
8 mAbs employ ADCC as a mode of action, in addition to the first approved anti-GPCR mAb 
Mogamulizumab, where the Fc glycans have been devoid of fucose groups (afucosylation), in order to 
invite an ADCC response (172). Mogamulizumab binds to chemokine receptor 4 (CCR4) on the surface 
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of T-cells for the treatment of adult T-cell leukaemia-lymphoma. Another mode of action is 
complement dependent cytotoxicity (CDC). The circulating complement protein C1q is able to bind to 
the Fc region of antibody-antigen complexes, inducing a cascade that results in the formation of the 
membrane attack complex (MAC), which inserts into the lipid bilayer of the antibody-targeted cell, 
resulting in lysis. Together with ADCC, CDC is another MoA which lends therapeutic antibodies an anti-
cancer potential (173). NK cells can also be triggered to phagocytose antibody bound target cells 
through a process known as antibody dependent cellular phagocytosis (ADCP). This is another Fc 
mediated immune function that has been exploited as an anti-tumour therapy and has been identified 
as the MoA for Elotuzumab for the treatment of multiple myeloma (174). Antibodies may also be 
chemically coupled to small molecule payloads that can serve as diagnostic markers or as cytotoxic 
agents in their own right for an enhanced therapeutic potential. The delivery of small molecules in this 
fashion also limits distribution and goes towards minimising off-target toxicity. A mAb linked to 
another molecule in this way is referred to as an antibody-drug conjugate (ADCC). There have been 6 
ADCC mAbs approved to date predominantly against non-solid tumours such as lymphomas and 
leukaemia, with the exception of HER2 positive breast cancer (Ado-trastuzumab emtansine) (159, 
175).  
 The generation of antibodies against a specific target presents a number of prerequisites towards the 
nature and quality of the antigen used. The antigen must be as pure as possible, so that the antibodies 
raised are as specific to the target as possible, and it must be available in suitable quantities to permit 
the immunisation work to be carried out. The antigen has to be stable, so that the desired epitopes 
are present for long enough that an immune response can be raised, otherwise the latter will not be 
possible, or the antibodies generated will be against degraded or denatured versions of the target. An 
additional requirement is that the antigen is in the desired conformational state and that its structural 
distribution be as homogeneous as possible (176).   
GPCRs are not ideal candidates for fulfilling any of these basic criteria. As membrane proteins, the 
majority of the receptor sequence is embedded in the cell membrane, and is rendered unsuitable as 
a solvent accessible antigen. Intracellular epitopes have been targeted by so called intrabodies: 
antibodies that have been delivered to the cytosol through physical manipulation such as 
electroporation or microinjection or by transfection through vector plasmids. However intrabodies 
have so far not proven amenable to therapeutic exploitation (177). Other attempts to achieve 
antibody cell penetration relies on intracellular targeting sequences or clathrin-mediated endocytosis 
and release from endosomes into the cytosol (178–180), although these have not been exploited in 
the context of targeting GPCRs. GPCRs with large cytoplasmic domains such as the large extracellular 
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domains (ECDs) of family B GPCRs, or those with large N-terminal domains (NTDs) serve well as 
antigens, and those with short NTDs or minimal extracellular loops (ECL) are less ideal (181).  
The best source of antigen is a homologous preparation of purified protein, however for GPCRs this is 
not always easily achievable. Most native full length GPCRs exhibit a degree of instability when 
extracted from the native plasma membrane. The choice of detergent has to carefully balance the 
stability of the extracted protein versus the utility of the chosen system for the given application. For 
example short chain detergents such as SDS are highly potent in disrupting biological membranes and 
extracting membrane proteins, at the cost of losing tertiary structure. Longer chain, mild detergents 
such as dodecyl-maltoside (DDM), fare much better at preserving the integrity of the solubilised 
proteins, but they may occlude parts of the protein which are otherwise solvent accessible and would 
serve as useful antigens. When using detergents for the preparation of membrane proteins for 
immunisation, the critical-micelle-concentration (CMC) of detergents must be considered. The CMC is 
an empirically determined free detergent concentration above which micelles form under the given 
conditions (temperature, ionic strength, pH). The implication of this property is that detergent 
solubilised protein samples require the presence of some free detergent to allow the formation of 
protein bound detergent micelles. Free detergent can trigger an undesired immune reaction causing 
irritation and give rise to non-specific antibodies. GPCRs usually suffer from low levels of cell-surface 
expression and various approaches to protein engineering have been explored to boost both protein 
stability and expression levels. One method of thermostabilisation involves the introduction of a 
combination of stabilising point mutations into GPCRs to form StaR receptors, patented for use in drug 
discovery by Heptares Therapeutics (182, 183). Another method of stabilising GPCRs has achieved a 
26.8 °C increase in melting temperature (Tm) using a form of molecular evolution called CHESS 
(cellular high-throughput encapsulation, solubilisation and screening), for the neurotensin receptor 1 
in the apo state (184). Modifying native receptors for the gain of enabling the production of purified 
GPCR may run the risk of losing biologically important features such as post-translational modification 
(PTMs) or loops, which may otherwise be susceptible to cleavage and receptor degradation. In 
essence, modifications which enhance protein stability and which have been instrumental in 
crystallogenesis may not be compatible with preparing purified proteins for immunisation.  
Various alternative immunogen formats to purified protein have been explored. Peptide analogues of 
GPCR antigens are a convenient method of immunisation as peptides can be manufactured in 
milligram scale quantities with high purity. The structural conformation of peptide sequences may 
however not reflect that of the matching sequence as part of a larger protein, therefore the raised 
antibodies may recognise a linear epitope of the peptide as opposed to a structural epitope (185). This 
can be circumnavigated by training the peptide to a desired conformation as has been exploited by 
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Pepscan’s CLIPS technology (186). Even with a representative conformation the use of peptides for 
raising anti-GPCR antibodies should consider the utility of the selected peptide sequence as an 
analogue for the portion of the GPCR that the raised antibodies will target. For example, using a 
receptor N-terminal sequence peptide will likely generate antibodies which are able to modulate GPCR 
activation, where the given N-terminus plays a role in the process, such as for chemokine receptors 
which bind their chemokine ligands at the N-terminus (eg. CXCR4), or for protease activated receptors 
(eg: PAR2), where N-terminal cleavage reveals the tethered activating ligand (187).  
DNA immunisation is also an option. With an optimal choice of vector and the use of enhancing 
adjuvants (immune response enhancing compounds) DNA immunisation can trigger the host organism 
to translate the injected DNA at low but significant levels which can serve as antigens (188, 189). 
Because of low levels of expression this method is often used in combination with other antigen 
formats in a so called prime-boost scheme.  
Whole cells or prepared cell membranes without the cytoplasmic components can also be harnessed 
as antigens. Cell membranes preparations can be enriched for the overexpressed target protein in 
comparison to whole cells and are also more stable than intact cells which are susceptible to lysis. 
Membrane fractions on the other hand expose both intracellular as well as the desired extracellular 
epitopes, meaning that a counter-screening step with extracellular epitopes is necessary to eliminate 
these. Antibodies raised against intracellular receptor elements can be valuable for research and 
development purposes, but their utility as therapeutic agents remains limited for reasons of cell 
penetrance as discussed before (168).  
1.4.3 – Antibodies as natural modulators of GPCR function 
Antibodies are vital components of the immune system in binding foreign antigens for elimination by 
various immune processes. However sometimes this process gets dysregulated and autoimmune 
conditions arise from cross-reaction to self-antigens. This phenomenon has been noted in the context 
of GPCR binding autoantibodies in a wide range of indications (190–202). The β1AR is no exception to 
this phenomenon, and an example of this process in the context of chronic Chagas’ heart disease 
(cChHD) is discussed below. 
1.4.3.1 – Trypanosoma cruzi ribosomal P proteins are major antigens in Chagas’ disease 
Chagas’ disease is caused by a parasitic flagellated protozoan organism called Trypanosoma cruzi. Like 
many parasitic organisms, T. cuzi has a complex life cycle involving humans amongst other mammals 
as hosts. Blood sucking or haematophagous triatomine beetles of the Triatominae subfamily serves as 
the insect carriers of the parasite. The bugs acquire the parasite in its circulating trypomastigote form, 
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through taking a blood meal. Once inside the triatomine digestive tract it differentiates into a form 
called the epimastigote capable of reproduction through binary fission. As the parasite transits the 
gastric tract the differentiation continues in the hind-gut into metacyclic trypomastigotes. In this form 
the trypanosome is capable of being released in the faeces of triatomine bugs and can penetrate the 
mammalian host at the site of the insect bite. It is important to note that the protozoan does not 
penetrate its mammalian host through the triatomine mouth parts during the course of it taking a 
blood meal. It is the defecation onto the surface of the skin and the associated scratching behaviour 
of the host that “rubs” the trypanosome into the wound left by the bite. Consequentially T. cruzi 
penetrates local cells around the infection and takes on the amastigote form, replicating once again 
by binary fission. The resulting trypomastigotes are released into blood circulation, ready to be taken 
up by the carrier once again. Circulating trypomastigotes also carry out further tissue invasion, 
reproduction and cell lysis (203).  
The disease manifests itself in an initial acute phase with symptoms such as general malaise, fever 
enlarged spleen and lymph nodes. The site of parasitic entry is often associated with the regions of 
ocular mucosa, resulting in a characteristic swelling of the area surrounding the eyes. This is an early 
manifestation of Chagas’ disease called the Romaña sign (204). These early symptoms normally 
resolve spontaneously even in the absence of trypanocidal treatment. About 30-40 % of those infected 
go on to develop chronic Chagas’ disease within 10-30 years. The nature of this complication can be 
categorised as either cardiac, digestive or cardiodigestive, leading to cardiomyopathy, megacolon, 
megaoesophagus or a combination of these. The cardiac manifestation of chronic heart disease is 
referred to as chronic Chagas’ heart disease (cChHD). Globally there are 8 million people estimated to 
be infected with Chagas’ disease, translating to a mortality rate of about 12,000 cases per annum. 
(205). 
Antibodies that cross-react to self-antigens have been observed in the serum of chronic Chagas’ 
disease (cChD) patients, which suggested an autoimmune component to the disease (206–208). The 
cardiac manifestation, typical of chronic adrenergic receptor stimulation has prompted the 
investigation of adrenergic receptor epitopes as cross-reacting antigens in the autoimmune response 
(209, 210).  
The major antigens in the immune response against T. cruzi infection have been identified as the 
ribosomal P proteins, which make up the stalk of eukaryotic ribosomes (211–213). The ribosomal stalk 
is formed of the 34 kDa protein P0 and two closely related, but smaller P1 and P2 proteins, both 
approximately 11 kDa in size. All three share a highly conserved acidic C-terminus. Trypanosoma cruzi 
possesses two P1 and P2 subtypes: P1α/P2α and P1β/P2β. Its P0 C-terminal end deviates from the 
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conserved eukaryotic sequence and instead bears resemblance to the Archeal P0 substitute L10 C-
terminus (214). The presence of P proteins have been shown to be essential for the GTPase activity of 
the eukaryotic elongation factor 2 (e-EF2), which catalyses the transition of peptidyl-tRNA from the 
ribosomal A site to the P site (215). These proteins will be hereon referred to as TcP1/2/α/β. 
A sequence alignment of the C-terminus of the TcP2α (UniProt: P23632), TcP2β (P26795) and TcP0 
(P26796) proteins are shown below, together with the consensus sequence of the last 13 residues of 
these proteins referred to as the R13 peptide. 
 
Table 1.5 T. cruzi Ribosomal P protein C terminal sequences 
TcP2a AEEEEDDDMGFG-LFD 107 
TcP2b EEEEEDDDMGFG-LFD 112 
TcP0 EEEDDDDDFGMGALF- 323 
R13 --EEEDDDMGFG-LFD 13 
 
 
In eukaryotes this conserved C-terminus is suggested to mediate the toxicity of ribosome inactivating 
proteins (RIPs) such as sarcin, ricin and tricosanthin. These proteins have been shown to cause 
irreversible changes in the form of base purination in a region of the ribosome called the Sarcin/Ricin 
Loop (SRL), proximal to the GTP binding site. The crystal structure of trichosanthin in complex with the 
conserved P protein C-terminal sequence SDDDMGFGLFD revealed an electrostatic binding interface 
between the two proteins, through arginine and lysine residues (216). This is not at all dissimilar to 
the interactions between elongation factors and the P1/P2 C-termini, which extend up to 125 Å away 
from the N-terminal dimerisation domain, which links them to the P0 component of the stalk (Figure 
1.8). The hydra-like P1/P2 protrusions, binding and thus generating a high local concentration of 
elongation factors are also suggested to mediate RIP toxicity, by recruiting such toxins to the region 
of the SRL (217). 
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Figure 1.8 Structure and function of ribosomal P proteins 
Proposed mechanism of ribosome inactivating protein recruitment to the Sarcin/Ricin 
Loop (SRL) via the P1/P2 C-terminal domains (CTD). The structure of the eukaryotic stalk 
complex is docked onto the yeast ribosome. A single unit of P0 (cyan) binds two P1 and 
P2 proteins each through their N-terminal domain (NTD – purple). The conserved P1/P2 
CTDs (red) form electrostatic interactions between lysine and arginine residues of 
Trichosanthin (TCS – green) and the acidic residues of the CTD. The model therefore 
suggests that the P stalk is involved not only in elongation factor recruitment, but also 
the mediation of RIP toxicity. Figure taken from (217). 
 
The last 13 residues of the T. cruzi P1 and P2 proteins (α and β variants) follow the conserved sequence 
of EEEDDDMGFGLFD, which has been recognised as the major epitope in the humoral response in 
Chagas’ disease (218). Key studies establishing this are discussed in the section below.  
1.4.3.2 – Anti-TcP antibodies cross-react to β1AR extracellular loop 2 (ECL2) 
The recognition that chronic Chagas’ heart disease (cChHD) may be caused by an underlying 
autoimmune process was sparked by the histological observation of cardiomyocyte degradation 
alongside fibrotic lesions and mononuclear cell invasion (by T-cells, B-cells, NK cells) in the apparent 
absence of parasitic cells or tissue (219). Antibodies in the sera of cChHD patients were found to react 
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to β-adrenergic receptor (β1, β2) and to M2 acetylcholine receptor epitopes (mAChR M2), postulating 
a disease mechanism which is exerted through immune cross-reaction to these receptors (220–223).  
From earlier studies it was understood that these GPCRs were recognised at their extracellular loops, 
but the exact epitopes and the mechanism of action of these cross-reacting antibodies has not been 
fully understood. Elies et al. investigated the epitopes relevant to β1AR, β2AR and muscarinic 
acetylcholine receptor M2, by looking at cChHD patient blood serum: the supernatant left-over from 
clotted blood lacking clotting factors, but containing blood immunoglobulins. In the study, synthetic 
peptides from the extra cellular loop 2 (ECL2) of these receptors were prepared, and the total serum 
immunoglobulin fraction and the IgG fraction were tested for reactivity to each of these peptides 
(224). The table below shows a summary of ECL and other peptides. The nomenclature of these 
peptides is conserved throughout much of the relevant literature.  
Table 1.6 Peptides relevant to cChHD autoantibody cross reaction 
Peptide Protein of origin Sequence 
H26R β1AR HWWRAESDEARRCYNDPKCCDFVTNR 
H26Q β2AR HWYRATHQEAINCYANETCCDFFNTQ 
V25I mAChR M2  VRTVEDGECYIQFFSNAAVTFGTAI 
A7D β1AR          ARRCYND 
P0β T. cruzi P0     AESEE 
R13 TcP C-terminus      EEEDDDMGFGLFD 
 
Enzyme immunoassays (ELISA) performed on immobilised H26R, H26Q and V25I peptides showed a 
significant response for all three peptides for sera of Chagas’ positive patients (diagnosed by 
electrocardiogram tests – ECG) compared to healthy donors. The strongest reaction was observed for 
the β1AR peptide, followed by β2AR and for the M2 peptide. All three peptides also elicited a reaction 
for an isolated IgG fraction of the serum. The binding to both the β1AR and the M2 peptide was 
sensitive to the strength of the ionic buffer, with decreased binding observed for an increasing 
strength of salt, suggesting a strong electrostatic component to the peptide-immunoglobulin 
interaction. To evaluate direct binding the authors used surface plasmon resonance (SPR) with 
immobilised peptides and serum IgG fractions. The binding observed to the H26R β1AR peptide was 
much higher than for the β2AR or M2 peptides, which were both slightly higher than to the polyanionic 
control chips, suggesting that while cChHD patients’ sera contains higher levels of anti-polyionic IgG 
antibodies than that of healthy controls, but the major immune response is against the β1AR ELC2 
H26R peptide, with a minor component against the other two receptors.  
To evaluate the physiological effects of the antibodies the authors incubated the serum IgG fractions 
on spontaneously beating neonatal rat cardiomyocytes in culture. Five out of eight sera caused an 
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increase in the basal beating frequency, however in the presence of atropine, an M2 receptor 
antagonist, all eight patient’s sera converted to a positive chronotropic response. M2 agonism results 
in a decreased chronotropic effect, meaning that the abolition of this allows the positive effect caused 
by adrenergic receptor antibodies to manifest itself. Consequently, when the serum IgG pool was 
affinity purified using the H26R peptide, the resulting β1AR specific increase in beating frequency could 
be abolished by the β1AR specific antagonist bisoprolol, as well as by the T. cruzi P0 peptide P0β. This 
work has shown biophysical and physiological evidence of an interaction between cChHD patient 
serum and GPCR ECL2 peptides.  
The GPCR epitope sequences shown in the table above, which have been implicated by this study 
suggests that it is the charged stretch of residues which bear resemblance to the AESEE TcP0 protein 
and to the TcP2β R13 sequence component EEEDDD which are primarily responsible for the immune 
cross-reaction. This is homologous to the β1AR AESDE motif and to the mAChR M2 EDGEC sequence in 
reverse (CEGDE) (224).  
A subsequent study by Kaplan et. al. looked at the sera of 15 further cChHD patients and compared it 
against acute Chagas’ disease, which lacks a cardiac indication, idiopathic dilated cardiomyopathy 
(IDC) a hallmark of which is chronic heart stimulation by β1AR autoantibodies, systemic lupus 
erythematosus (SLE), which features anti human-ribosomal P-protein antibodies, all against reactivity 
to R13 peptide. The study aimed to confirm whether it is the humoral anti-R13 response that is 
responsible for the chronic heart disease component of Chagas’ disease (225). Additionally, the 
authors wished to discern, whether the anti-human ribosomal P0 C-terminus (hP0) autoantibodies 
prevalent in SLE contribute to a shared disease mechanism with cChHD. This was postulated by several 
preceding studies, which upon finding that SLE anti-hP0 antibodies showed a shared specificity to the 
homologous TcP0 peptide suggesting that the two diseases may share a common mechanism for 
generating the anti-P response.  
The results of this work showed that the anti-P antibodies in SLE reacted equally to TcP0 as well as to 
hP0, while anti-P antibodies in cChHD showed a clear preference for TcP0 whole protein and also did 
not bind to T. brucei P-protein. These observations translated to reactions against the R13 and H13 C-
terminal peptides of T. cruzi and human origins respectively, indicating that the parasite ribosomes 
are the most likely to be responsible for the cross-reacting anti-P antibodies in chronic Chagas’ disease. 
Furthermore acute patient sera showed no reaction to the R13 peptide. The difference in terms of 
species preference for autoantibodies in cChHD and SLE suggests that the two diseases do not share 
a common disease mechanism, as the serum response of cChHD did not recreate the typical anti-hP0 
response characteristic of SLE.  
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With regards to the comparison of the humoral antibody response in cChHD, SLE and IDC, only 
insignificant amounts of immune cross-reaction was observed for IDC sera, tested both with 
recombinant TcP1, TcP2β, hP1 and hP2 protein and with equivalent peptides.  
The physiological response of H26R and R13 affinity purified serum antibodies tested on 
spontaneously beating cardiomyocytes was as high as that elicited by the adrenergic receptor full 
agonist isoprenaline and showed significant reciprocal abrogation by H26R (for R13 purified Abs) and 
by R13 (for H26R purified Abs), as well as by bisoprolol. These findings establish the anti-P response 
as a critical biomarker for cChHD, and pinpoint the polyanionic, highly conserved C-terminus of the T. 
cruzi ribosomal P proteins as the major epitope for the humoral response raising cross-reacting 
antibodies (223, 225). 
Sepulveda et. al. present in vivo evidence to further validate the conserved C-terminus of TcP2β as the 
major antigen responsible for the cardiopathic element in chronic Chagas’ disease. They used mice to 
compare the immune response that arose from T. cruzi epimastigote infection and from immunisation 
with TcP2β purified protein antigen (226). The humoral response was probed with 25 twelve residues 
long fragments of TcP2β using an ELISA, to evaluate the relevant immunogenic epitopes. The authors 
observed that antibodies raised against the recombinant His-tagged TcP2β recognised peptides from 
several part of TcP2β, with two major clusters of epitopes at the hinge region and at the C-terminus. 
In contrast, the epitopes from the T. cruzi infected mice matched almost exclusively to the conserved 
C-terminus. This implied that the acidic C-terminus of TcP2β is the immunodominant epitope in 
cChHD. 
1.4.3.3 – A monoclonal antibody against cChHD relevant epitopes that cross-reacts to β1AR 
As discussed earlier, monoclonal antibodies are great tools as they allow the uniform modulation of 
their target for either therapeutic or research purposes. To investigate the disease mechanism 
mediated by cross-reacting antibodies in cChHD, Mahler et. al. immunised mice with recombinant 
MBP fusion TcP2β protein (227). A resulting monoclonal antibody candidate mAb 17.2 was identified 
and evaluated. mAb 17.2 was able to recognise all T. cruzi ribosomal proteins as well as human 
ribosomal proteins. Cross reaction was shown to β1AR in immunohistochemistry experiments. The 
antibody showed agonistic properties on spontaneously beating rat cardiomyocytes. It also caused 
chronotropic alterations of mice determined by ECG measurements (214, 225–232). The sequence of 
an agonistic ScFv format of mAb17.2 (ScFv C5) as well as a non-agonistic version (ScFv B7) are 
published, that have been used as a starting point for the investigation of this disease mechanism. 
  
 44 
1.5 – Aims and objectives 
The specific question this study seeks to answer is: what information can we gain about the activation 
mechanism of β1AR, by studying the conformational signatures of the process?  
The labelling strategy relied on 13C-methyl-methionine residues, as methionines do not show 
metabolic interconversion or scrambling in insect cells (233). Methyl groups are also highly sensitive 
reporters of changes in their chemical environment. Their flexibility in methionines offers a degree of 
relief from the long rotational correlation times experienced by micelle solubilised membrane 
proteins, which causes peak broadening.   
The objectives of this project are hence threefold: 
Firstly, to express 13C-ε-methionine labelled functional β1AR using the baculoviral insect cell method.  
Secondly, to establish a method for the purification of such expressed β1AR constructs. 
And thirdly to record 2D HMQC experiments on the isotopically labelled purified protein. Resonance 
peaks are to be assigned by mutagenesis. 
In the broader biological context this project aims to characterise the dynamic nature of β1AR 
activation, by describing the conformational transitions that take the receptor through its various 
activation states induced by interactions with ligands and other binding partners. In addition to these 
objectives, the preparation of an agonistic anti-β1AR antibody is sought, for studies of the ligand 
independent mechanism of activation.  
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Chapter 2 – Labelling, Expression and Purification for NMR 
experiments on the β1-adrenergic receptor (β1AR) 
2.1 – Aim 
The aim of the experiments detailed in the following section is to successfully express and purify 
thermostabilised β1-adrenergic receptor for the purpose of studying receptor dynamics using solution 
state NMR spectroscopy. Thermostabilisation makes the receptor suitable for spectral acquisition at 
higher temperatures which is necessary to counter adverse effects due to fast spin relaxation that are 
related to the slow tumbling experienced by large proteins. Baculoviral expression in insect cells has 
been successful in producing sufficient quantities of functional receptor for structural studies, for a 
number of different GPCRs, including the β2-adrenergic receptor. However uniform labelling in insect 
cells remains costly and expensive. In addition to these challenges, detergent solubilised membrane 
proteins experience very long rotational correlation times and fast relaxation which is particularly 
pronounced for the backbone positions. The extensive alpha helical nature of GPCRs mean a large 
degree of similarity in the chemical environment experienced by backbone amide positions, causing 
spectral crowding of the amide region. These factors contribute to the difficulties in backbone 
resonance experiments, making selective side chain labelling a more attractive approach to studying 
receptor dynamics. In this study 13C-methyl labelled methionine was used to this end. Preliminary 
NMR experiments (2D [1H, 13C]-SOFAST-HMQC) were recorded on 13C-ε-methionine labelled Met2-
β1AR, in our lab by Dr. Duncan Crick (PhD thesis, Cambridge, 2014), which showed intense but 
overlapping peaks in the region of the methyl proton chemical shift region (1.0-2.2 ppm). The narrow 
range of chemical shifts experienced by methyl groups can cause spectral overlap and to avoid this 
five methionines were mutated to other residues. This is referred to as the Met2-Δ5 construct. The 
remaining methionines were hence labelled.  
The construct used in this work is a variation of the β1AR-β44-m23 construct that was used for receptor 
crystallisation (69, 96, 234). The creation of the Met2 construct saw the reversal of selected 
thermostabilising mutations: V90M2.53, A227Y5.58, L282A (ICL3). As a result, only the following 
thermostabilising point mutations remained: R68S1.59, E130W3.41, F327A7.37 as well as mutations C116L 
and C358A for the removal of palmitoylation and for improved yield. Five methionines were mutated 
from the Met2 construct to alternative amino acids to reduce spectral overcrowding. These were: 
M44L, M48L, M179L, M281A, M338A, leaving the following methionines available for labelling: M1, 
M902.53, M153 (ICL2), M1784.62, M2235.54, M2836.28, M2966.41. This generated the Met2-Δ5 construct, 
sometimes referred to simply as Δ5. 
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Figure 2.1 Snake diagram of the β1AR Met2-Δ5 construct 
Positions of truncations, mutations, reporters and thermostabilisation as well as the 
positions of native disulphide bridges are highlighted. 
The six methionines (not including the N-terminal M1) retained are located in key positions of the 
receptor. These residues should be able to give information about local receptor dynamics and 
changes occurring in the presence of different ligands describing various receptor activation states. 
M902.53 in helix 2 is just beneath the ligand binding site. M153 is in the intracellular loop 2 (ICL2) near 
the N terminal end of helix 4. M2836.28 is located towards the N terminal end of helix 6, which is 
observed to undergo a 14 Å translation upon G-protein binding. M2966.41 is in the intramembrane part 
of helix 6 above M2836.28, facing helix 5. Located opposite in helix 5 is M2235.54, facing helix 6. The role 
of extracellular loops was investigated through the introduction of methionines at the L108 position 
in extracellular loop 1 (ECL1) and in the L190 position for ECL2. These are referenced as (Met2-)Δ5-
L108M or Δ5-L190M. 
To assign which peaks originate from which methionine, a range of constructs were generated with 
one residue mutated at a time. These are referred to as Met2-Δ6 mutants. 
Another important consideration for the purification of membrane proteins is the choice of detergent 
used for solubilising the expressed protein. Lauryl Maltose Neopentyl Glycol (LMNG) is a novel non-
ionic detergent, with a low critical micellar concentration (CMC) of 0.001% and a slow off rate. It has 
displayed superior stabilising properties for the β2AR and other GPCRs compared to other amphiphiles 
(49, 235). The low CMC reduces the amount of free detergent present in NMR samples, which reduces 
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the intensity of detergent associated peaks. The low off-binding rate is also preferential for NMR 
experiments as fast detergent dissociation has been shown to cause non-physiological conformational 
changes which are likely to result in peak broadening. 
2.2 – Baculoviral expression 
2.2.1 – Viral generation 
Baculoviral stocks can be stably stored at 4°C for extended periods of time. Should stocks get infected 
or degrade, viral reamplification is possible from P1 or P2 stocks. P3 viral stocks were prepared for the 
following constructs: Met2, Met2-Δ5, Met2-Δ6 constructs: M153L, M178A, M178S, M223I, M283A, 
M296V, M296A, M90A, M90V, L190M, L108M, M153A. Alternative substitutions of alanine, valine, 
isoleucine or serine in place of methionine were generated, should a given substitution cause serious 
instability issues. 
Sf9 insect cells were transfected both in suspension and in monolayer culture to generate a P0 viral 
stock. A separate GFP-only construct under the control of a late phase promoter was used as a positive 
control to monitor the rate of transfection. Overlaying a bright field image of the cultures with a GFP 
excitation image permitted the comparison of the ratio of GFP producing, i.e. cells that have taken up 
the bacmid DNA and started producing GFP, versus non-transfected cells. This is shown in Figure 2.2.  
In monolayer cultures the proportion of transfected (green fluorescing) to non-transfected cells (dark 
appearing cells) was much lower (Figure 2.2A). Cells which have not produced the virus continued to 
multiply, producing a very dense carpet of cells. In suspension culture, the ratio was much higher, 
partly because there was a lower density of cells present. This was in spite the fact that the starting 
culture density for suspension cultures was 0.8x106 cell/mL, double that of the monolayer culture; 
0.4x106 cells/mL. This implies that the culture has either stopped growing earlier or that a large 
proportion of cells have died, potentially due to viral lysis. Such cell lysis would release further virus 
particles, hence it is highly probable that the viral titre is much higher in the suspension culture than 
in the monolayer culture.  
P0 viral stocks are used to infect further cells, to generate a P1 stock, which is in turn used to make 
P2. This amplification is continued to P3. The effect of media types, namely SF4 and SF900III (both 
supplemented with 1% foetal calf serum), were compared on this viral amplification process 
(Figure 2.2B).  The ratio of GFP producing cells to non-fluorescent cells was noticeably higher in 
SF900III medium compared to SF4, making the former more desirable as a choice of medium for viral 
amplification. 
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Figure 2.2 Sf9 transfection with GFP control plasmid 
Sf9 cells were transfected with bacmid DNA, containing a GFP construct, as a positive 
control alongside other constructs. The bright field image was superimposed to a UV 
excitation image, which causes GFP fluorescence. A) Transfection cultures (P0) were 
seeded in suspension and in monolayers. Image taken five days after transfection. B) 
Viral stocks generated in suspension stocks were amplified to P1 and P2 amplification 
was compared in SF4 and SF900III media. Image taken 48 h after infection. 
2.2.2 – Protein expression 
Infection was carried out with 5mL of Sf9 cells at a dilution of 1x106 cells/mL being infected with 300µL 
of P3 virus stock (60 µL P3 virus/mL). Figure 2.3 shows that over the course of 48 hours, all three viral 
stocks (M296A, M153L, M283A) had a very similar effect on the cells. Cell viability dropped from 95% 
to 60-70% and a marked 2-3 µm increase in cellular diameter was observed. These are hallmarks of 
baculoviral infection. It is not uncommon for cells to keep dividing for the initial 24 hours after the 
infection, therefore the persistent drop in viability suggests that the virus to cell ratio was relatively 
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high.  
 
 
Figure 2.3. Sf9 cells infection by P3 baculoviral stocks 
The effect of the infection on cell viability (dashed lines) and diameter (solid lines) is 
shown across a period of 48 hours.  
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2.3 – Protein purification 
2.3.1 – Initial Purification Strategy 
The initial purification strategy can be summarised in the following diagram. 
 
Figure 2.4 Initial purification strategy 
Strategy based on a protocol by a previous lab member. Note the low NaCl 
concentration in the HisTrap Buffer A and the Gel filtration buffer. 
The thawed Sf9 cell pellets were homogenised and centrifuged three times in cell disruption buffer, 
then the membrane fraction solubilised in 2% LMNG detergent. The resulting solution, was loaded 
onto a nickel affinity column and eluted with a linear gradient of imidazole. The desirable fractions 
were then clarified over a size exclusion column into a 10 mM NaCl, low salt buffer. 
This initial approach was beset with two main issues that had to be overcome: 
1. Elution off the HisTrap column did not achieve reproducible separation under a linear 
gradient. 
2. Protein samples precipitated out of solution after gel filtration. 
  
Solubilisation
• Cell disruption in 20 mM Tris-HCl pH 8.0, 2 mM EDTA
• Solubilisation buffer: in 20 mM Tris-HCl pH 8.0, 3 mM 
Imidazole, 350 mM NaCl, 2% LMNG detergent
HisTrap
• Buffer A: 20 mM Tris-HCl pH 8, 10 mM NaCl, 3 mM 
Imidazole, 0.02% LMNG
• Buffer B: 20 mM Tris-HCl pH 8, 350 mM NaCl, 250 mM 
Imidazole, 0.002% LMNG
• Gradient elution
Gel filtration
• Superdex S200 (10/300) column 
• Buffer C: 20 mM Tris-HCl pH 8.0, 10 mM NaCl, 1 mM EDTA, 
0.001% LMNG
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2.3.1.1 – Nickel affinity chromatography 
Figure 2.5 shows representative UV 280 nm absorbance chromatograms of nickel affinity 
chromatography of M23-β1AR. The gradient length, that is the time it takes to go from 5% elution 
buffer B to 100%B in minutes, was varied and is shown above each curve. The flow rate in each case 
was 0.5 mL/min. In other words, a longer time implies a shallower gradient.  
  
Figure 2.5 Linear gradient HisTrap elutions in 10 mM NaCl  
280 nm absorbance chromatograms from Met2-β1AR HisTrap purifications with a  
10-50 minute, 5-100% Buffer B linear gradient elution. Gel inset: SDS PAGE gel from 
curve D. Elution fractions E5, E6 correspond to the first peak, and E8, E9 to the second 
peak (both highlighted in orange). 
The effect of a gradient of 50 minutes on separation, compared to shorter lengths (Figure 2.5 traces 
A, C, D) is noticeable with the evolution of a second peak (traces E and F). However in no case has 
complete separation been achieved as the absorbance is not given time to reduce to baseline levels 
between the two peaks. This has seriously hindered the efficiency of chromatographic separation.  
A – 20’ 
B – 45’ 
C – 10’ 
D – 40’ 
E – 50’ 
F – 50’ 
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In addition to the poor separation, the presence of a 26 kDa band in both peaks (Figure 2.5 SDS-PAGE 
gel, boxed in orange) would suggest that both peaks contain the target protein in sufficient quantities 
as to validate further purification of both peak fractions. However the inclusion of the first peak 
consistently resulted in aggregation, with the sample turning a yellow colour upon concentration for 
gel filtration.  
Furthermore, by analysing the two peaks on an anti-his-tag western blot, a signal was only observed 
for the second peak. This observation held true for both Met2-β1AR, Met2-β1AR-Δ5 constructs 
purified by gradient elution. A representative example is shown in Figure 2.6 below.  
The chromatogram shown in Figure 2.6C is typical in profile and presents two poorly resolved peaks, 
with peak 1 represented by fractions 8-12 and peak 2 by 13-20. The SDS PAGE gel (Figure 2.6A) shows 
a near 26 kDa band present in all fractions, with a near 34 kDa band trailing from peak 1 to 2. The 
western blot (Figure 2.6B) only shows bands in fractions 14-20, corresponding to the second peak. 
This implies that the 34 kDa band is either a misfolded or a co-purifying contaminant and should not 
be included in further purification steps. This was often the case in early purifications where the 
second peak was absent or minimal.  
 
Figure 2.6 SDS-PAGE and western of gradient elution product of HisTrap 
chromatography. 
Met2-β1AR-Δ5 purification by nickel affinity. A) SDS-PAGE gel. M: Marker, L: Load, FT: 
Flow through. Fractions 10-12 have been pooled and is represented in a single lane B) 
Western blot of the same gel as in A C) UV 280 nm chromatogram. Peak 1 corresponds 
to fractions 8-12, peak 2 to 13-20. 
  
 54 
2.3.1.2 – Size exclusion chromatography – observations and salt dependency 
The initial purification method made use of gel filtration to simultaneously remove any large sized 
aggregates and to exchange the protein into a low salt (10 mM NaCl) buffer. As mentioned above, this 
always resulted in protein precipitation from the solution. The major protein peak containing a 34 kDa 
construct (by SDS-PAGE, not shown) was consistently observed to elute off the column in a non-size 
typical fashion, very close to the salt fraction (Figure 2.7). This indicates that the protein is interacting 
with the column under these buffer conditions (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 1 mM EDTA, 
0.001% LMNG). 
 
Figure 2.7 Gel filtration of HisTrap purified M23-β1AR.  
Blue curve: UV 280 nm, Brown: conductivity 
In an attempt to prevent protein precipitation, the gel filtration step was carried out with an 
increased salt concentration of 100 mM and 350 mM NaCl. 
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Figure 2.8 Size exclusion chromatography into increased NaCl (100 mM) buffer 
Overlay of gel filtration chromatograms of M23-β1AR in 350 mM (A-blue) and 100 mM 
NaCl (B-pink) buffer (10 mM Tris-HCl pH8.0, NaCl, 0.001% LMNG). Conductivity traces 
are labelled with “Cond” and UV 280 nm traces with “A280”. 
Figure 2.8 shows UV absorbance (“A280”) and conductivity (“Cond.”) chromatograms for 350 mM 
NaCl (blue) and for 100 mM NaCl (pink) gel filtration. The protein sample loaded is present in 350 mM 
NaCl, carried forward from nickel affinity purification, which explains the level conductivity trace 
throughout 350 mM gel filtration and the conductivity spike at 23 mL (1 column volume) in 100 mM 
NaCl. It should also be noted that there is a shift from the elution volume of 20mL in 10 mM NaCl to 
13.5mL under higher salt concentrations. Consequently the purified protein was stable and non-
aggregating. 
The structural significance of Na+ ions in β1AR have recently been observed in high resolution (2.1 Å) 
crystal structures (99). Sodium ions have been found coordinated by residues Asp872.50, Ser1283.39 and 
by three water molecules within a network of interhelical water molecules. The absence of Na+ has 
been shown to decrease receptor stability, signified by a drop in receptor Tm of 7.5 °C. Equivalent 
residues coordinating sodium in β1AR have been found to form hydrogen bonds with each other in 
A – A280 
B – A280 
B – Cond. 
A – Cond. 
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the β2AR:Gαs structure, suggesting a loss, or rearrangement of Na+ coordination. This proposes that 
Na+ plays a role in stabilising the ligand-free state. 
Salt concentration is worthy of discussion not only for its effect on protein stability, but also on NMR 
experiments. NMR spectrometers can be equipped with cryoprobes, where the receiver and pre-
amplifier coils are cooled to cryogenic temperatures, thus reducing thermal noise in the 
measurement. Salts are critical components of buffers solutions both for maintaining pH and for 
stabilising proteins in a soluble state. However the increased dielectric conductivity caused by the 
presence of salts results in the attenuation of radio frequency power and the appearance of ring 
currents in the sample. This can lead to sample heating and increased pulse lengths. These effects 
abate the increased sensitivity offered by cryoprobes. The weight of this effect also increases with the 
strength of the magnetic field (236, 237). Therefore it is desirable to find a concentration of salt where 
a favourable compromise exists between protein stability and NMR sensitivity.  
Met2-β1AR and Met2-β1AR-Δ5 constructs have shown stability in 100 mM salt, however the Met2-
β1AR-Δ5-M90A construct precipitated after gel filtration in this condition. To find a suitable salt 
concentration, dynamic light scattering was used to detect aggregation in different concentrations of 
salt. The purified construct was dialysed from 350 mM salt to a range of salt concentrations and the 
ratio of various particle sizes was quantified and recorded as a portion of the total (Figure 2.9). 
 
Figure 2.9. Dynamic light scattering to determine optimal NaCl concentration 
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Ratio of three different particle size groups based on estimated molecular diameter; 
small, medium and large. GF0: empty buffer of 10 mM Tris-HCl pH 8.0, 0 mM NaCl, 
0.001% LMNG GF350: empty buffer of 10 mM Tris-HCl pH 8.0, 350 mM NaCl, 0.001% 
LMNG. β1AR-Δ5-M90A was dialysed into 350mM, 250 mM, 200 mM, 175 mM, 150 mM, 
125 mM and 50 mM NaCl containing buffer. The estimated average particle diameter 
(nm) is overlaid for each category of particle. 
Particles were classed as “small”, “medium” or “large” on the basis of average particle diameter (nm) 
and the variation in ratios was monitored in different salt concentrations. Blank buffer of 0 mM and 
350 mM NaCl was also measured (GF0 and GF350). The absence of small particles in buffer alone 
suggests that these correspond to receptor micelles. An increase in the 200 nm-800 nm particle ratio 
(medium particles) was observed under 150 mM NaCl, which correlates with the aggregative 
behaviour of the construct in 100mM salt. Hence 150 mM NaCl was trialled for β1AR-Δ5-M90A. No 
precipitation was observed. 90° pulses were in the range of 11.7 µs to 12.3 µs at -11dB. 
Purification of the β1AR-Δ5-M90A construct in 350 mM NaCl buffer achieved marginal increase in 
purity at the cost of time invested in the gel filtration process, coupled with losses associated with 
preceding protein concentration and the chromatography step itself. This can be illustrated by 
comparing the purity of the load fraction to the eluted protein on an SDS PAGE gel as shown below 
in Figure 2.10. The associated UV 280 nm absorbance trace was representative of a soluble non-
aggregating trace (see Figure 2.8 above). 
 
Figure 2.10. SDS PAGE of gel filtration fractions of Met2-β1AR-Δ5-M90A in 350 mM NaCl 
buffer.  
M: Marker, L: Load. Fraction numbers refer to collected elution fractions from a single 
symmetrical absorbance peak. 
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This therefore warrants the elimination of the gel filtration step from the purification process as a 
means of increasing purity. To achieve higher purity, an alternative, optimised nickel affinity 
chromatography was used.  
2.3.2 – Refined purification strategy 
Although the issue of protein stability in relation to salt concentrations have been explored resulting 
in stable protein preparations, the chromatographic separation of receptor from other impurities 
remained a challenge using the linear gradient conditions described above. This issue could have been 
resolved in one of two ways. One method would have been to extend the length of the gradient in 
time, where the elution conditions change slowly allowing more time for different species to separate. 
An inadvertent side effect of shallower gradients is peak broadening, in other words the separated 
proteins are diluted considerably. Protein concentration can take a considerable time and therefore 
it is preferable to achieve sharp elution peaks. 
Another method of improving resolution, which can also achieve sharp elution, is through stepwise 
gradients. The basic concept of chromatography is to separate individual mixture components through 
the induction of conditions which affect these components differentially. Increasing the imidazole 
concentration during elution rapidly, to a precise predefined level will likely achieve such differential 
conditions. Moreover, maintaining that condition until all proteins dissociated by it from the column 
have eluted, will avoid any unwanted mixing with species eluting at higher imidazole concentrations. 
This cannot be achieved by a linear gradient which changes continuously and too rapidly.  
The key to the successful implementation of a stepwise elution profile is the understanding of how 
much imidazole is needed to elute each mixture component. To this end an initial regime of 
consecutive 5, 10, 15, 20, 25, 50, 75 and 100% imidazole buffer steps were trialled (data not shown). 
This has shown that at 20% and above, receptor elution is observed (also observed on Figure 2.11B, 
25% corresponding to 52 mM imidazole). It is also important to allow the UV 280 nm trace to return 
to baseline after each elution step, so that all proteins dissociated under that step elute prior to the 
elution of tighter binding species in the next step. 
Elution from the affinity column in the up-flow direction, together with a 40% reduction in flow rate 
compared to loading flow rates can also achieve increased chromatofocusing, resulting in a sharper 
elution peak, hence faster elution, lower buffer use and more concentrated protein.  
This HisTrap strategy was hence followed with on column desalting of the sample into a lower salt 
buffer, suitable for NMR experiments. 
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The construct Met2-β1AR was purified with the above strategy. The HisTrap elution profile and the 
SDS PAGE gel is shown below (Figure 2.11).  
 
Figure 2.11 HisTrap purification of Met2 with a step gradient elution 
HisTrap purification of Met2-β1AR. (A) UV 280 nm absorbance spectrum shows that 
impurities are separated by a 16 mM, 28 mM, 40 mM and 52 mM Imidazole wash. The 
peak of interest is eluted with 250 mM imidazole and has an absorbance maximum of 
610 mAU. (B) SDS PAGE gel of the elution fractions. Fractions 62-64 show highly 
concentrated protein with minimal impurities. 
The isocratic elution allowed the UV trace to return to baseline, before the next step was initiated, 
hence maximising separation. The column upflow elution with a reduced flow rate (0.5 mL/min) 
compared to loading flow rates (1 mL/min) achieved a narrow elution peak. This was maximised by a 
pump fill prior to step initiation; this is where the required proportion of Buffer A and Buffer B is mixed 
and applied onto the pumps prior to injection onto the column. Fractions from a 40 mM and 52 mM 
imidazole wash also produced a highly pure preparation of the receptor (near 26kDa band). 
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Figure 2.12 Receptor buffer exchange over a HiPrep Desalting column.  
L: load fraction 
Buffer exchange was achieved by loading the HisTrap elution fractions onto a 150 mM NaCl buffer 
equilibrated HiPrep Desalting column. Figure 2.12 shows that purity remains unaffected. 
The final purification strategy is illustrated below. 
 
Figure 2.13 Optimised β1AR purification strategy. 
 
  
Solubilisation
• Cell disruption in 20 mM Tris-HCl pH 8.0, 2 mM EDTA
• Solubilisation: 1 hour on ice in 20 mM Tris-HCl pH 8.0, 3 mM 
Imidazole, 350 mM NaCl, 2% LMNG detergent
HisTrap
• Buffer A: 20 mM Tris-HCl pH 8, 350 mM NaCl, 3 mM 
Imidazole, 0.02% LMNG
• Buffer B: 20 mM Tris-HCl pH 8, 350 mM NaCl, 250 mM 
Imidazole, 0.002% LMNG
• Stepwise elution: 5%, 10%, 20%, 100% Buffer B
Desalting
• HiPrep Desalting Column
• Buffer GF150: 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 
0.001% LMNG
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2.4 – Protein quality 
2.4.1 – Mass spectrometry 
To confirm the identity of the purified protein, mass spectrometric analysis was used to assess the 
major 26 kDa band from an SDS PAGE resolved M23-β1AR construct by two alternative methods. The 
trypsin digested protein was analysed by: 
1. LC-MS, MS-MS analysis by Dr Mike Deery at the Cambridge Centre for Proteomics. The 
submitted band was trypsin digested and resolved by liquid chromatography. The resulting 
peptides were analysed for amino acid sequence by tandem MS. 
2. Peptide identification by MALDI-Fingerprinting, by Dr Len Packman at the PNAC facility. Here 
the resulting peptides are matched to expected protein sequences or candidates from the 
NCBI database.  
Both methods have identified expected fragments from the M23-β1AR protein sequence, and the 
results are summarised in the following table: 
Table 2.1 Summary of mass-spectrometry results. 
 LC-MS MS/MS MALDI-Fingerprinting 
Coverage 16.29% 24% 
Protein Score (-10*Log(P)) N/A 98 
p<0.05 significance level N/A 81 
Protein scores are given to peptide matches against a database, where a calculated probability 
threshold value is given to a match which occurs at random. Any scores above this are considered 
significant at that significance threshold. For MS/MS data, protein scores are calculated from ion 
scores to give a non-probabilistic tool for ranking the fragment hits.  
The following diagram shows a comparison of the peptide fragments identified by the two different 
techniques. Yellow residues were identified by MS/MS only, blue residues by MALDI Fingerprinting 
only and green residues by both methods. 
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Figure 2.14 Snake diagram of the β44-m23-β1AR construct for MS 
This construct was sent for mass spectrometric analysis.Blue residues were detected by 
MALDI fingerprinting only, yellow residues by tandem MS only. Green residues covered 
by both methods. Yellow lines link cystine pairs. 
Peptide fingerprinting has identified two additional fragments compared to MS/MS, and the C-
terminal end has also been successfully ionised (Figure 2.13). This establishes, that albeit with <25% 
coverage, both methods are suitable for identification of the purified receptor.  
2.4.2 – Ligand Affinity Chromatography  
Sepharose and agarose conjugated to the non-selective β-adrenergic antagonist alprenolol has been 
demonstrated as a tool for affinity purification of the β1 and β2 receptors (238).  
In this project, this tool has been used both preparatively and analytically. In a preparative setup, 
Met2-β1AR from a preceding HisTrap purification was loaded onto a packed 5 mL Alprenolol-
Sepharose column. Bound protein was eluted with 0.8 mM alprenolol. 
The column has demonstrated a very high purification factor, with all impurities eluting in the sample 
flow-through (Figure 2.14). The resulting population of purified protein has been selected on the basis 
of its ligand binding ability and is hence expected to be highly functional. The drawback of this method 
is that it generates alprenolol bound samples. This means that a dialysis step must be included to 
exchange the receptor to a ligand free state, ready for the addition of alternative ligands. 
Alprenolol has an absorbance spectrum that ranges from 225-290 nm with two major peaks at 230 nm 
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and at 280 nm. Hence the purification process cannot be monitored by absorbance at 280 nm. Instead 
the sample must be visualised on by SDS PAGE, or at alternative wavelength, such as 220 nm – 
indicative of peptide bonds. 
 
 
Figure 2.15 Ligand affinity chromatography SDS-PAGE 
SDS PAGE of alprenolol sepharose column purification of M23-β1AR. Bound protein is 
eluted with 0.8mM alprenolol. The step results in highly pure, ligand bound receptor. 
M: Marker, FT: Flow through, L: Load 
Under the assumption that binding to the ligand conjugated resin is a sign of functionality, alprenolol 
resin packed into spin columns can also be used analytically. This application is demonstrated below 
(Figure 2.15) for Met2-β1AR purified by nickel affinity chromatography. 500 µL of the selected 2 mL 
elution fraction was loaded onto 500 µL of alprenolol sepharose equilibrated with binding buffer. The 
sample was incubated in the capped spin column for 1 hour with mixing. Unbound sample was washed 
out with binding buffer under brief centrifugation. Bound protein was eluted with 0.8 mM alprenolol. 
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Figure 2.16. HisTrap followed by Ligand Affinity 
A) HisTrap purification of Met2-β1AR. Bound protein eluted as a single peak with 
175 mM Imidazole. B) Alprenolol spin column application of elution fraction E11 from 
HisTrap purification (panel A) C) Alprenolol spin column application of elution fraction 
E7 from HisTrap purification (panel A). M: Marker, L: Load fraction, FT: Flow through, W: 
Wash fractions E: Elution fraction, O/N: Elution after overnight incubation with 0.8 mM 
alprenolol.  
 
Figure 2.15 A and B confirm the presence of ligand binding receptor in both highly impure (panel A 
fraction 7) and relatively pure (panel A fraction E11) receptor fractions. Bound receptor was incubated 
with alprenolol for 15 minutes before elution. Six rounds of elution-centrifugation were applied, with 
a further overnight incubation with alprenolol. The absence of a protein band by elution fraction 6, 
and a reappearance thereof after an overnight incubation (panel B and C, “E O/N”) indicates that a 
period of incubation with free ligand before elution is desirable for maximum yield.  
These results confirm the use of the alprenolol resin in a spin column method as a quick tool for 
confirming ligand binding in purified samples. Furthermore, the samples applied are recoverable, 
albeit in a ligand bound state. 
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Assignment of Met2-Δ6 constructs  
In order to assign each methionine to the observed peaks in the chemical shift spectrum the 
following Δ6 mutants were expressed, purified and recorded: (Δ5)-M90A, M153A, M178A, M223L, 
M283A, M296A, L108M, L190M. The resulting spectra were compared to the Δ5 equivalent, where 
the assignment residue (which was mutated in Δ6 and therefore its associated peak absent) was 
present.  This comparison was repeated in the presence of ligand alone, with Nb6b9 or Nb80 alone 
or in a ternary complex with either nanobody, until every residue could be unambiguously assigned 
in all receptor states. This translated into a large number of possible assignment scenarios as 
represented below (Figure 2.17). 
 
Figure 2.17 Assignment possibilities: constructs, ligands and nanobodies 
The 6 methionines that were mutated for assignment were to be recorded bound to 
each ligand, and to nanobody. This created the possibility of 6 x 8 x 2, or 96 potential 
assignment states. This was reduced as much as possible depending on spectral 
similarities. 
Two main challenges made the assignment work more difficult. One was the spatial proximity of 
residues M223 and M296. The other was the spectral overlap of some residues, such as M283 and M1 
(Figure 2.19 e, g, n). The issue of spatial proximity is illustrated below in Figure 2.18. The methyl groups 
of M223 and M296 side chains in 4BVN are modelled at 6.3 Å away, close enough for changes in one 
residue to exert an effect on the chemical shift environment of the adjacent residue. This was also 
true for when either methionine was mutated for assignment, resulting in a change in the overall 
spectrum that was not solely due to the absence of the mutated assignment residue. This is illustrated 
in Figure 2.18 b, c and d, where the peaks indicated by an arrow assigned to M223 have moved 
chemical shift positions, in addition to the disappearance of the peak assigned to M296. 
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Figure 2.18 Spatial proximity of M223 and M296 and its effect on assignment 
(a) shows the side chains of the two residues in the structure of 4BVN. (b) assignment of 
Δ5-M296A in the apo state. (c) assignment of Δ5-M296A in the Nb80 bound state. (d) 
assignment of Δ5-M296A in the Nb80 and isoprenaline bound ternary complex state. 
Figure adapted with permission from Solt et al. (127). 
The full assignment panel is shown below in Figure 2.19 a-p.  
Figure 2.19 Methionine assignment spectra.  
(Shown overleaf across 2 pages.) 
The reference (Δ5) spectra is shown in red, and the mutated construct in black except 
where otherwise indicated (such as g, h). Depicted this way, the assignment residue 
shows as a red peak without any black overlap. Inset (e) shows a cross section of the 
spectrum in the indirect dimension along the dashed line projected as a 1D spectrum. 
Blue peaks indicate natural abundance peaks from a large excess of unlabelled 
nanobody (k-p). (p) inset shows M296 in the Nb80 bound state from a different 
experiment of the same state, where the receptor has been fully saturated by Nb80 as 
judged by the presence of M153c and no M153a peak. This required a 30-fold molar 
excess of Nb80, resulting in strong natural abundance peaks, hence (p) shows a non-
saturated state for Nb80 for clarity. 
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Chapter 3 – Molecular signatures of β1AR activation 
 
Declaration 
This work and the results presented in this chapter have been published (127). The raw data was the 
result of my own work, and the analysis was carried out in collaboration with a number of the co-
authors named. Their contributions are specifically highlighted throughout this chapter where 
relevant.  
3.1 – Aims 
GPCR crystallography has provided significant insight into the activation mechanism of these 
receptors.  G-protein bound crystal and cryo-EM structures as well as arrestin bound and antibody 
bound fully active structures (54, 74, 80, 139, 239, 240) have shown that receptors require the 
presence of an intracellular binding partner (IBP) to achieve a fully active state. Although these 
structural biology techniques have made significant progress in terms of our understanding of GPCR 
activation, they are limited in their ability to report on the dynamic transitions between these 
structural snapshots. NMR spectroscopy has proven itself as a valuable tool in the arsenal for the study 
of the dynamic processes and structural ensembles that form part of the complex conformational 
landscape of GPCR activation (120, 122, 154, 241–244). GPCRs have been demonstrated to be highly 
dynamic molecular entities, exhibiting a great degree of molecular plasticity.  
The aim of this work is to evaluate the molecular signatures that accompany receptor activation by 
small molecule ligands of varying efficacy, as well as by G-proteins using the G-protein mimic 
nanobodies Nb6b9 and Nb80, which have been shown to elicit the same structural changes as Gs-
binding. In the absence of an active state crystal structure for the β1-adrenergic receptor, the aim was 
to gain an understanding of the dynamic conformational changes that accompany receptor activation, 
by using 13C-methyl-methionine labelling and methyl detected 13C HMQC NMR experiments.  
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 3.2 –β1AR-receptor construct used  
The receptor construct used in this work is a variation of the β1AR-β44-m23 construct that was used 
for receptor crystallisation (69, 96, 234). The construct used, called Met2 and variations thereof, saw 
the reversal of selected thermostabilising mutations: V90M2.53, A227Y5.58, L282A (ICL3). As a result, 
only the following thermostabilising point mutations remained: R68S1.59, E130W3.41, F327A7.37 as well 
as mutations C116L and C358A for the removal of palmitoylation and for improved yield. This 
generated the Met2 construct, from which five methionines were mutated to alternative amino acids 
to reduce spectral overcrowding. These were: M44L, M48L, M179L, M281A, M338A, leaving the 
following methionines available for labelling: M1, M902.53, M153 (ICL2), M1784.62, M2235.54, M2836.28, 
M2966.41. This generated the Met2-Δ5 construct, sometimes referred to simply as Δ5. The role of 
extracellular loops was investigated through the introduction of methionines at the L108 position in 
extracellular loop 1 (ECL1) and in the L190 position for ECL2. These are referenced as (Met2-)Δ5-
L108M or Δ5-L190M. The spatial and sequential distribution of the labelled methionines as well as the 
position of other loop truncations retained from the m23 crystallisation construct are shown below 
on the snake diagram (Figure 3.1a) and on the crystal structure (PDB: 4BVN, Figure 3.1b).  
 
 71 
 
Figure 3.1 Snake diagram of β1AR-Met2-Δ5 
This shows the distribution of labelled methionines, truncations, thermostabilisation 
mutations in the Met2-Δ5 construct. The crystal structure of the closest construct (β44-
m23, PDB: 4BVN) highlights the spatial distribution of labelled methionines in red 
spheres. Figure adapted with permission from Solt et al. (127). 
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3.3 – NMR Timescales 
In order to understand the significance of the chemical shift changes that take place as a result of 
ligand or G-protein mimetic nanobody addition (hereafter simply nanobodies) it is worth noting how 
multiple resonances in equilibrium manifest themselves in an NMR spectrum. NMR chemical shift 
denotes the difference between the frequency of the specific nucleus and a reference frequency 
divided by the reference frequency. This is given in values of ppm. When two molecular states exist in 
equilibrium, the magnitude of the exchange constant (k) for the equilibrium in relation to the chemical 
shift difference between the two states (ω given in Hz) defines the way the two states appear in a 
chemical shift spectrum. In other words, the comparison of the exchange rate and the chemical shift 
difference of the states involved is known as the NMR timescale. In practical terms, if k is much lower 
than ω, then it means that the exchange process is slow enough for each state to be resolved in a 
spectrum, with the intensity of the peaks proportional to the population of each. This is then referred 
to as slow exchange. At the other extreme, where k is much greater than ω, the amount of time spent 
in each chemical shift environment is too short to resolve both peaks, and a single peak appears at 
the weighted average of the two populations. As the distribution of the two populations changes 
relative to one another, in other words the amount of time spent in each environment (a shift in the 
equilibrium), while k>>ω remains true, the chemical shift of the averaged resonance changes to reflect 
the new average. This shift in the equilibrium can occur due to changes in temperature, presence of 
ligand, or other factors which govern the equilibrium. Lying in between these two extreme scenarios, 
where k approaches ω, so called intermediate exchange occurs. This is represented by peak 
broadening and a loss of peak intensity.  
In the following discussion and description, the equilibria that are identified are hence described as 
slow, fast or intermediate in terms of this NMR timescale. 
3.4 – Molecular signatures of ligand bound β1AR 
1H, 13C HMQC spectra of labelled receptor samples prepared in LMNG detergent micelles were 
recorded in the presence of small molecule ligands of varying efficacy. The receptor was recorded in 
its ligand free (apo) state, and bound to the very weak partial agonist 7-methylcyanopindolol, the 
weak partial agonists carvedilol and cyanopindolol, the partial agonists salbutamol and xamoterol, the 
full agonist isoprenaline and natural full agonist adrenaline (Figure 3.2).  
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Figure 3.2 Ligand bound spectra ordered according to increasing ligand efficacy.  
Figure adapted with permission from Solt et al. (127). 
These ligand bound spectra were fully assigned as discussed before. An overview of these ligand 
bound states immediately shows some chemical shift differences. For example, methionine 902.53 
(M90) presents two conformations in the apo state, which resolves to a single state for ligands such 
as 7-methylcianopindolol and cyanopindolol. Salbutamol presents a unique conformation for M902.53, 
unobserved for any of the other ligands, and carvedilol resolves this residue into two peaks: the 90Ma 
conformation seen in the apo state and to a new conformation. M902.53 undergoes intermediate 
exchange for the full agonists, isoprenaline and adrenaline as well as the partial agonist xamoterol, 
and is not resolved at all.  
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M1784.62 in ECL2 sits in proximity to the core transmembrane bundle on the top of TM4. With the 
exception of cyanopindolol and carvedilol it resolves to two distinct peaks, implying that this portion 
of ECL2, tethering it to TM4, samples at least two conformations. 
The pharmacological properties of each of these ligands are given below in Table 3.1 as they have 
been identified by previous studies, in terms of their efficacy in comparison to isoprenaline (taken as 
100%), and their affinity to the thermostabilised turkey receptor (β36-m23, see Appendix A) (234, 245, 
246).  
 
Table 3.1 Pharmacological properties for ligands used in this study. 
‡Data taken from Baker et al. 2011. (234) 
†Data taken from Baker et al. 2010. (245) 
§Values for 7-methylcyanopindolol are taken from Sato et al. 2015. (246) 
Ligand name Abbreviation Classification Efficacy,  
3H-cAMP 
accumulation 
assays in CHO 
(% ISO 
activity)‡§ 
pKD from 
3H-CGP12177 
whole cell 
binding studies 
in CHO cells†§ 
7-Methylcyanopindolol 7mC Very weak 
partial agonist 
2.3±0.3§ 10.37±0.03§ 
Carvedilol CAR Weak partial 
agonist 
12±0.4 9.43±0.05 
Cyanopindolol CYP Weak partial 
agonist 
39±1 10.89±0.06 
Xamoterol XAM Partial agonist 61±7 6.58±0.02 
Salbutamol SAL Partial agonist 97±2 4.99±0.03 
Isoprenaline ISO Full agonist 100 6.86±0.08 
Adrenaline ADR Full agonist 110±2 6.01±0.04 
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The molecular structure of the applied ligands is shown below in Figure 3.3. Adrenoreceptors natively 
bind catecholamine ligands such as adrenaline, and with the exception of this latter ligand all others 
are synthetic molecules.  
 
Figure 3.3 Chemical structures of the ligands used in this study.  
Figure adapted with permission from Solt et al. (127). 
The figure below shows a detailed comparison of residues M902.53, M153 (ICL2), M2235.54, M2966.41 
and M2836.28 in their apo and ligand bound states (Figure 3.4). M2235.54 and M2966.42, both undergo 
significant chemical shift changes with the addition of ligands, both showing significant correlation 
between linear combined chemical shift changes (taking into account changes in both 1H and 13C 
dimensions) and ligand efficacy with R2 values of 0.830 and 0.683 respectively. The efficacy correlation 
plots were calculated as a linear fit between the 13C and 1H chemical shift of residues M2235.54 and 
M2966.41 in the ligand and apo bound states to the reported efficacy values (Table 3.1) using the 
equation: a(1H) + b(13C) + c.  
M2235.54 and M2966.41 residues are situated in the region of TM 5 and 6, which undergo an outward 
extension in the unified class A activation mechanism, hence this efficacy linked transition seems 
indicative of a receptor undergoing structural changes towards an active-like state. The fact that both 
M2235.54 and M2966.41 resolve to a single peak transitioning in the chemical shift spectrum with the 
addition of different efficacy ligands is indicative of a fast exchange process. Combined chemical shift 
calculations were carried out by Dr. Mark Bostock. 
Residue M90, which is located on TM2 facing the ligand binding pocket exhibits two conformations in 
the apo state denoted 90Ma, 90Mb. In the presence of cyanopindolol and 7-methylcyanopindolol only 
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90Ma remains, and a new conformation represented by 90Mc appears. Carvedilol and salbutamol 
trigger yet two different states. As mentioned earlier, full agonists and xamoterol did not resolve any 
peaks associated with M902.53, which is likely in an exchange broadened state.  
The equivalent residue to M902.53 in β2AR is M822.53, and this has been reported on by Kofuku et. al 
(241). M822.53 was also observed to resolve to multiple major and minor conformations, referred to 
as M82D and M82U. Unlike for M902.53, M822.53 demonstrated a pattern of efficacy linked chemical shift 
changes. Furthermore while M902.53 was broadened beyond detection in the presence of xamoterol 
and the full agonists isoprenaline and adrenaline, M822.53 resolved to a distinct and separate third 
state upon the addition of the β2AR full agonist formoterol. These comparisons set apart the 
observations near the ligand binding site for β2AR and β1AR, where for the latter the presence of 
multiple slow exchange conformations is observed with partial agonists, that change to intermediate 
exchange in the presence of full agonists (and xamoterol), giving rise to significant peak broadening. 
Methionines 153 in ICL2 and M2836.28 at the cytoplasmic end of TM6 showed much more modest 
chemical shift changes upon ligand addition, indicating that ligand binding on the extracellular surface 
does result in small but observable changes on the cytoplasmic end of the receptor, which are 
propagated through the transmembrane region.  
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Figure 3.4 Ligand bound states and equilibria 
Focus on ligand bound states and correlations between linear chemical shift and 
efficacy. b) Crystal structure (4BVN) showing the spatial distribution of methionine 
reporters. Chemical shift changes observed in the presence of different ligands for M90 
(a), M153 (c), M223 (e), M296 (f), M283 (d). Ligands in order of efficacy: (g). Panels (h) 
and (i) illustrate the correlation between ligand efficacy and combined linear chemical 
shift change for residues M223 and M296. Figure adapted with permission from Solt et 
al. (127). 
Isogai et. al. carried out a 15N-valine backbone labelled study of a more thermostabilised (see 
Appendix A for a comparison between TS-β1AR and Met2-Δ5) turkey β1AR construct, with an 
equivalent reporter to M2235.54 (V2265.57) showing ligand efficacy related correlation to chemical shift. 
 78 
Reporters in TM6 (V2806.25 and V2986.43) the latter being closest in position to M2966.41 did not show 
this correlation (244). Given that the cytoplasmic side of TM6 is extensively demonstrated to be 
undergoing conformational changes, this result may be due to the relative insensitivity of backbone 
reporters compared to side chain methyl groups. Alternatively the greater degree of 
thermostabilisation of the construct used may have contributed to this. In the aforementioned 
methyl-methionine labelling study by Kofuku on β2AR, M2796.41 did show efficacy related changes in 
the presence of ligands (241).  
3.4.1 – Temperature dependent effects reveal µs-to-ms timescale contributions to 
isoprenaline bound full agonist state 
The full agonist, isoprenaline bound receptor was measured at 308 K, as were all the other spectra 
presented here, but also at 298 K and 288 K. As established above, the nature of the chemical shift 
changes of residues M2235.54 and M2966.41 are indicative of a fast exchange equilibrium on the NMR 
timescale. Lowering the temperature has the effect of reducing the rate constant k. Since the 
exchange regime results from the relative values of k and the chemical shift difference (δω) this has 
the effect of pushing exchange processes towards a slower timescale. Hence fast exchange processes 
are pushed towards intermediate and slow exchange and intermediate exchange processes are 
pushed towards slow exchange. For instance, if a fast exchange process can be slowed down 
sufficiently a single peak separates to two overlapping peaks, where the nuclei now spend enough 
time in each environment for the two states to be identified. 
This proved to be the case for the full agonist bound state, where upon reducing the temperature to 
298 K, the M2235.54 and peak resolved to two separate ones, indicating the presence of intermediate 
exchange at 308 K (Figure 3.5). This was also accompanied by an increase in intensity, meaning that 
exchange broadening must be taking place at 308 K, and that at the lowered temperature this effect 
is reduced enough to identify two peaks. A further reduction in temperature to 288 K resulted in the 
retention of one of the two signals, and the signal intensity was still higher than that at 308 K. These 
effects are shown below, with the three spectra referenced to the signal of unbound isoprenaline. 
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Figure 3.5 Temperature dependence of the full agonist isoprenaline bound state.  
The Met2-Δ5-L190 construct was recorded at 288 K (blue), 298 K (orange) and 308 K 
(red). The spectra were aligned using the isopropyl methyl signal of unbound 
isoprenaline. Figure adapted with permission from Solt et al. (127). 
The qualitative parameters which describe these changes can be quantified in terms of signal to noise 
ratio (SNR). Peak broadening results in weaker signals, decreasing the SNR. Temperature also affects 
the molecular tumbling of the receptor and solution viscosity, factors which result in a decrease of 
SNR in their own right and need to be accounted for in order to quantitatively compare SNR values 
across different temperatures. This way the experimentally measured SNR at 298 K and 288 K can be 
back calculated to what it should be at 308 K, if no other major processes are at play which cause 
signal broadening, in this case that being the presence of µs-ms timescale exchange processes.  
The diagram below shows the measured and corrected SNR values for M2235.54 and M2966.41 in the 
isoprenaline bound state at 288 K, 298 K and 308 K (Figure 3.6). When corrected for the 
aforementioned effects of temperature and viscosity, the SNR shows that a drop in temperature 
reduces the effects of peak broadening leading to a loss of signal, thereby revealing the presence of 
µs-to-ms timescale exchange contributions at 308K.  
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Figure 3.6 Temperature effects on signal-to-noise in the full agonist state 
Temperature dependence of signal intensity in the full agonist isoprenaline bound state. 
Intensities shown as signal to noise (SNR) are plotted as M223 vs, M296. Corrected 
values (blue) take into account temperature effects and temperature associated 
changes in viscosity (η). In the natural full agonist adrenaline bound state no peaks were 
visible for M223 and M296. Figure adapted with permission from Solt et al. (127). 
This is significant as this indicates that µs-to-ms timescale exchanges take place in the full agonist 
bound state, in addition to the ligand-modulated fast exchange equilibrium demonstrated by the 
efficacy dependent chemical shift changes. These exchange contributions are even more marked for 
adrenaline, where M2235.54 and M2966.41 are exchange broadened beyond resolution at 308 K. This 
was a unique feature of adrenaline, as no other ligands showed such exchange broadening for these 
two residues (Figure 3.6).  
The SNR data was extracted by and the correction calculations were performed by Dr. Daniel 
Nietlispach.  
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3.5 – Receptor basal activity  
β-adrenergic receptors have been shown to display a degree of basal activity (247), giving physiological 
relevance to investigating the interaction between the receptor and G-protein mimetic nanobodies in 
the absence of orthosteric ligand, with the aim of gaining insight into the receptor basal activity 
complex. The allosteric enhancement of ligand binding affinity in the presence of G-protein and vice 
versa is a well-known phenomenon, and therefore the nanobody’s binding affinity was expected to 
be significantly reduced by the absence of agonist (87). In fact to achieve receptor saturation, a 2.6 
fold molar excess of Nb6b9 and a 31 fold excess of Nb80 was used in titrations.  
 
Figure 3.7 Nb6b9 titration experiment.  
Nb6b9 was added to the apo state receptor until no further chemical shift changes were 
observed.  
Titration of Nb6b9 to Met2-Δ5-L190M was able to reveal the molecular signatures of saturated and 
partially saturated states, as well as the amounts of nanobodies needed to achieve a saturated state 
for emulating the basal activity state (Figure 3.7). A Nb6b9 molar ratio of 0.43 to receptor (Titration 
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Point 1) reveals the slow exchange process of residues M2235.54, M2966.41 and M153, since two peaks 
are observed for each of these residues. The presence of a set of two peaks assigned to these residues 
corresponding to the apo and Nb6b9 saturated states at the same time (titration “start” and titration 
“endpoint peaks”) is indicative of two states, that change only in intensity as the titration progresses, 
each resolvable as a separate peak. This bears the hallmark of an exchange process where the 
exchange rate k is significantly lower than the chemical shift difference (δω) between the two states. 
This change therefore represents a slow exchange process on the NMR timescale as discussed earlier 
under NMR Timescales. These observations establish nanobody binding as a slow exchange process. 
The figure below shows the spectrum of Nb6b9 saturated β1AR-Met2-Δ5-L190M in comparison to the 
apo state, both in the absence of ligand (Figure 3.8).  
 
Figure 3.8 Chemical shift changes upon Nb6b9 addition to the apo state receptor.  
Figure adapted with permission from Solt et al. (127). 
This shows significant chemical shift changes for residues on both extracellular and intracellular sides 
of the receptor. On the extracellular side, M190 and M1784.62 show minor chemical shift differences, 
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while M2235.54, M2966.41, M2836.28 and M153 on the intracellular side, show major chemical shift 
changes on the slow exchange regime, on the NMR timescale, as explained above. 
 
3.6 – Ligand-nanobody ternary complexes  
The addition of ligand and G-protein mimic nanobodies together was used to observe receptor states 
that would correspond to a fully active G-protein bound state. 
The addition of saturating amounts of Nb6b9 to achieve this resulted in significant chemical shift 
changes compared to the full agonist bound receptor. Residues on the intracellular side, particularly 
M2235.54 and M2966.41, on TM5 and TM6 underwent large chemical shift changes similar, but slightly 
different to those observed for the Nb6b9-only bound basal active state. Residue M153 on ICL2, in the 
vicinity of the nanobody binding site also displayed a notable change characteristic of nanobody 
binding. M2836.28 on TM6 was largely obscured by the peak assigned to the N-terminal methionine, 
however it too shows a chemical shift change upon nanobody (Nb6b9) addition. Of the methionines 
on the extracellular side, M1784.62 on the base of ECL2 showed the largest difference, which has now 
resolved to a single peak as opposed to the two peaks present for the full agonist bound state. 
Extracellular loop residues M108 (ECL1) and M190 (ECL2) showed minor changes (Figure 3.9).  
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Figure 3.9 Full agonist and full agonist ternary complex states  
Spectra recorded in the presence of isoprenaline and isoprenaline and Nb6b9 for the 
Δ5-L190M construct. Inset shows Δ5-L108M construct for the region of difference. 
Figure adapted with permission from Solt et al. (127). 
These spectral differences between the full agonist bound state and the full agonist ternary complex 
state show that nanobody binding induces significant and widespread conformational changes 
throughout the receptor, that propagate to both the intracellular and extracellular sides (Figure 3.10).  
These changes are also more substantial than those observed for ligands alone, as represented by the 
full agonist bound spectra below (orange spectrum). This is typified by the differences observed for 
M153, M178A4.62, M2235.54, and M2966.41 upon Nb6b9 addition (pink spectrum) to the isoprenaline 
bound state (orange spectrum), in comparison to the changes observed for these residues when 
isoprenaline is added the apo state (blue spectrum). These signatures are characteristic of a 
significantly different receptor conformational ensemble to those that exist in the presence of 
orthosteric ligands alone. The largest changes seen for M2235.54 and M2966.41 are not unexpected, 
given the well described structural changes that occur on TM6 and TM5 upon G-protein binding.  
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Figure 3.10 Comparison of the apo, basal activity and full-agonist ternary complex.  
Most significant chemical shift changes are shown by arrows. Inset shows Δ5-L108M 
construct for the region of difference from the Δ5-L190M construct. Figure adapted with 
permission from Solt et al. (127). 
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Comparing the ternary Nb6b9 bound basal active state (green spectrum) to the ternary complex 
state (pink spectrum) and the apo state (blue spectrum) to the full agonist isoprenaline bound state 
(orange spectrum), it becomes apparent that the basal activity state bears close similarity to the 
ternary complex (Figure 3.11). This is discussed in more detail below, but the similarities between 
the apo and ligand bound states and the basal active and ternary states are symptomatic of 
conformational equilibria that link these states.  
 
Figure 3.11 Basal activity state is shows similarities to the ternary complex state.  
Figure adapted with permission from Solt et al. (127). 
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Experiments varying the order in which agonist and nanobody was added to generate the ternary 
complex showed that it does not matter whether the receptor is stimulated from the extracellular 
side by an orthosteric ligand or from the intracellular side by a nanobody first, with respect to the 
conformation of the eventual ternary complex. This does not imply that there can be no variations in 
the allosteric effects of stimulation from either receptor side, but simply that once both binding 
partners are present the conformational ensemble resulting bears no relevance to the pathway to its 
formation (Figure 3.12). 
 
Figure 3.12 Order of ternary complex formation 
The route to ternary complex formation does not bear relevance to the end state. Nb6b9 
and isoprenaline added to Met2-Δ5 construct in varying order of sequence. The resulting 
ternary state is identical irrespective of the order of ligand and Nb6b9 addition. Figure 
adapted with permission from Solt et al. (127). 
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3.6.1 – Ternary complexes show correlation between efficacy and chemical shift 
In addition to the full agonist bound ternary complex shown and discussed above, additional 
complexes were formed bound to adrenaline, salbutamol and cyanopindolol.  An overlay of the 
ternary complex states of Met2-Δ5-L190M with Nb6b9 are presented below (Figure 3.13). Variations 
in ligands (including the apo – Nb6b9-only – state) resulted in marked chemical shift changes for 
residues M178A4.62 on the extracellular side, as well as for residues M2235.54 and M2966.41 on the 
intracellular side. Smaller but significant chemical shift changes took place for M153 also on the 
intracellular side. 
 
Figure 3.13 Ternary complex states bound to Nb6b9 and different ligands. 
Ligands: adrenaline, isoprenaline, salbutamol, cyanopindolol. Figure adapted with 
permission from Solt et al. (127). 
Similar to the agonist-only bound receptor states, a plot of linear combination of chemical shift 
changes (i.e. combined chemical shift change in the direct and indirect dimensions) against ligand 
efficacy revealed a strong correlation for some residues (Figure 3.14). One of the peaks assigned to 
M1784.62 showed a strong efficacy dependent chemical shift correlation, with a coefficient of 
correlation (R2) of 0.817. The other M1784.62 peak did not show significant changes upon ligand 
addition to the ternary complex. M2966.41 also showed a clear and marked correlation between 
chemical shift change and efficacy, with a R2 value of 0.879. While the shift changes were much smaller 
in magnitude the correlation persisted for M153 (ICL2) and M2235.54, with coefficients of 0.805 and 
0.797 respectively. This is shown on the figure below, with (a) showing the two extreme states: the 
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Nb6b9 bound basal activity state and the full agonist isoprenaline bound complex. Diagrams (b, c, f-h) 
show each of the mentioned residues in detail. The combined chemical shift calculations were carried 
out by Dr. Mark Bostock.  
 
Figure 3.14 Ternary complex states and efficacy correlations 
Ternary complex states and efficacy correlation to combined linear shift changes. The 
overall spectral change between Nb6b9 bound and isoprenaline bound ternary states 
are shown in (a). Chemical shift changes for residues M296 (b), M178 (c), M223 (f), M153 
(g), M190 (h) are shown independently in the presence of various ligands of different 
efficacies (k). Correlations between linear chemical shift change and ligand efficacy are 
plotted for M178 (d), M296 (e), M223 (i) and M153 (j). Figure adapted with permission 
from Solt et al. (127). 
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3.6.2 – Lower temperature experiments indicate a ligand dependent ternary complex 
equilibrium in fast exchange 
As discussed earlier in the context of temperature dependent effects on ligand-only bound receptor 
states, lowering the experiment temperature has the potential to alter the rate of exchange processes, 
changing the relationship between the exchange rate constant k and the chemical shift difference 
between the two exchange states (ω). In this way, the presence of processes leading to exchange 
broadening, taking place on the intermediate NMR timescale were revealed for the full agonist bound 
receptor in the presence of isoprenaline and adrenaline.  
In the case of ternary complexes, recording the partial agonist salbutamol and Nb6b9 bound ternary 
complex at 308 K and at 293 K showed evidence indicating that the ligand-modulated equilibria 
present in the ternary complex receptor state takes place on the fast exchange regime on the NMR 
timescale (Figure 3.15). The two spectra below show the salbutamol ternary complex at 308 K and at 
298 K referenced to M153 (ICL2). This shows that M2235.54 and M2966.41 both shift noticeably towards 
the basal activity state, away from the full agonist ternary complex chemical shift value.  
 
Figure 3.15 Temperature dependence in the ternary complex state 
Receptor bound to Nb6b9 and salbutamol. Figure adapted with permission from Solt et 
al. (127). 
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The relative intensity values were measured for these two residues, taking M153 as a reference (with 
a set value of 1). This shows a degree of peak broadening at the lower temperature. The signal to noise 
ratios (SNR) were also measured at both 308 K and at 293 K. A number of factors play a part in 
modulating the SNR upon temperature change, such as viscosity, and the presence of intermediate 
timescale exchange processes, which result in peak broadening. The effect of temperature per se and 
viscosity can be corrected for, by back compensating for it through a back calculation of what the SNR 
value should be at 308 K based on the 293 K data, if no other processes influence SNR. In a simplified 
context it was assumed that factors such as the presence of detergents and protein concentration 
differences did not influence SNR. The 298 K SNR values were multiplied by the ratio of viscosity values 
of pure water at 308 K (η308=0.7192 cP) over that at 293 K (η293=1.002 cP), multiplied by the 
temperature difference: (η308/η293)*(308/293), giving a compensation factor of 1.465. The ratio of the 
back-calculated SNR value at 308 K compared to the measured SNR at 308 K gives an indication of the 
presence of exchange contributions on the µs-ms timescale, corresponding to the intermediate 
regime on the NMR timescale. If these ratios are close to 1, it indicates the lack of such processes. If 
the 293 K/308 K ratio is less than 1, it indicates the presence of exchange contributions at this 
timescale. For M153, this ratio was close to 1, meaning that over this temperature range no significant, 
detectable change has occurred in the exchange regime. For M2235.54 and M2966.41 however this ratio 
was now less than 1, indicating that the exchange rate has been slowed down, with the appearance 
of some intermediate timescale contributions. This infers that at 308 K the exchange process likely 
takes place on the fast exchange timescale. This provides evidence, that the ligand modulated efficacy 
dependent equilibrium that has been identified in the receptor ternary complex follows a fast 
exchange regime.  
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The table below lists the SNR and relative intensity measurements corresponding to the salbutamol 
ternary complex. This analysis, together with the SNR and intensity measurements were done by Dr. 
Daniel Nietlispach.  
 
Table 3.2 SNR values for ternary complex state 
 
1AR-Met25 with salbutamol / Nb6B9 
 
relative 
intensity 
signal-to-noise ratio (SNR) 
 
(reference 
M153) 
uncorrected 
corrected for T and η 
(back-calculated to 308 K) 
Temperature M223 M296 M223 M296 
M153 
(ref) M223 M296 
M153 
(ref) 
308 K 0.59 0.36 130 80 219 130 80 219 
293 K 0.46 0.29 64 45 145 94 65 212 
ratio  
293 K vs 308 K 0.78 0.81    0.72 0.81 0.97 
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3.7 – Peak intensity as a measure of µs-ms dynamics 
GPCRs have been shown to be highly dynamic molecular entities, undergoing motion on a range of 
timescales [refs]. The exchange broadening observed for several residues (M902.53, M2235.54, M2966.41) 
upon the addition of agonists is symptomatic of motion on the µs-to-ms timescale, reflecting a high 
degree of receptor motility reflecting the functional state of the receptor. It is therefore valuable to 
be able to describe and compare the nature of receptor dynamics that take place as a consequence of 
receptor activation by ligands or G-protein mimetic nanobodies (and via inference by other native 
intracellular binding partners). NMR spectroscopy offers itself as an ideal toolkit for the investigation 
of protein dynamics in the form of spin relaxation techniques, however several parameters of the 
protein used here confer severe limitations to these types of experiments. Relaxation experiments 
require a high degree of sensitivity, which demand extended measurement times. The reduced 
thermostabilisation and low protein concentrations in the NMR samples of β1AR measured both pose 
limitations to sample stability, meaning that sample lifetimes are insufficient for these experiments. 
The size of the receptor in LMNG micelles has been measured at around 80 kDa (by calibrated SEC). 
Larger particles such as these experience longer rotational correlation times, reducing T2, translating 
to a loss of signal. Additionally, in the absence of deuteration, undesirable dipole-dipole coupling 
results in fast T2 relaxation. Deuteration is able to counter short T2 relaxation. However this is very 
limited in insect cell expression, and is not a widely available tool for the study of GPCRs, which do not 
express well in other expression systems where perdeuteration is technically feasible (such as E. coli 
expression). Insect cells do not have a high tolerance to growing in D2O. Therefore, the effect of dipole-
dipole interactions and short T2 timescales result in rapid signal decay and low sensitivity, making it 
impossible to use techniques such as CPMG relaxation experiments for a direct quantitative 
assessment of receptor dynamics.   
Another method of gaining information on µs-to-ms timescale dynamics, which result in line 
broadening is the measurement of peak linewidths. Unfortunately, in the 13C HMQC experiments 
conducted, the resolution in the 13C dimension (indirect dimension) was reduced in order to allow an 
increased number of scans, improving signal-to-noise. This resulted in significant signal overlap in the 
indirect dimension, which is immediately obvious from the overview of the ligand bound spectra alone 
as shown above. This made it impossible to obtain precise linewidths for use in the estimations of 
dynamics on the timescales resulting in peak broadening.  
As a substitute, the peak intensity values of the assigned residues were still able to be used as a means 
of observing methionine methyl dynamics. This provided a semi-quantitative assessment of how the 
overall receptor dynamics change as a consequence of ligand and nanobody binding.  
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Methyl groups are particularly useful tools for the study of large macromolecules, as the rapid rotation 
around the methyl head group causes a partial decoupling of the group from the overall tumbling of 
the larger macromolecule. This is described by low S2 order parameters (high degree of local motion) 
and results in favourably longer T2 relaxation times, which manifest themselves in sharper signals. The 
long spin lifetime of methyl residues makes them sensitive to changes in dynamics on the slower 
timescales, such as those on the µs-to-ms timescale. In this way methyl signals are qualified reporters 
of conformational exchange processes which result in exchange broadening and the loss of signal 
intensity, which is used in this work. These advantages however are not enough to overcome the 
challenges of relaxation measurements. 
It is important to note, that when discussing receptor states as being more or less dynamic, based on 
the estimates obtained from signal intensities, these descriptions refer to motions on the NMR 
timescales that cause a change in signal intensity. These NMR timescales coincide with µs-to-ms 
timescale motions. It is crucial to note that the description of motions on this timescale is separate 
from motions on a much faster timescale, which cause a sharpening of signals either because of lower 
internal correlation times (lower S2) or because of a reduction in motional order parameters when the 
molecule becomes more dynamic.  
Peak intensities for a specific residue can be compared in one of two ways. In a relative comparison, 
the peak intensity for a specific methionine was compared to a given reference in a spectrum, such as 
residue M153, and the intensity of other selected residues measured in relation to the reference (set 
as a value of 1). This allows the comparison of residue intensities across the same spectra. 
Alternatively the relative intensities can be normalised against each other across different sets of 
spectra (different experiments on the same construct), with the most conformationally restricted 
state set a value of 1, and all other intensities scaled to this. In either approach, peaks with a lower 
intensity value display increased peak broadening, showing increased dynamics on the µs-to-ms 
timescale, which is responsible for this effect as discussed.  
3.7.1 – Dynamics in the apo, ligand bound and ternary complex states 
The observation of peak intensity changes showed a large variation for residues M902.53, M2235.54 and 
M2966.41. As discussed earlier, M902.53 is completely undetectable from the spectrum of xamoterol, 
isoprenaline and adrenaline bound receptor, indicating the presence of conformational exchange at a 
similar rate to the NMR timescale. The tables below show the intensity values obtained for residues 
M2235.54 and M2966.41 in receptor bound to a range of ligands with and without Nb80 or Nb6b9. All 
relative intensities were measured from 13C, 1H HMQC experiments recorded at 308 K at 800 MHz. 
Intensity values were calculated relative to the well resolved M153 residue. For each construct (Met2-
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Δ5-L109M and Met2-Δ5) the intensity values were normalised against the highest intensity peak for 
that construct, and this was given an intensity score of 1. In this ranking, lower values represent 
increased peak broadening and increasing µs-ms dynamics. Peak intensities were measured and 
graphed by Dr. Daniel Nietlispach. 
 
Table 3.3 Peak intensities for M223 and M296 
Relative peak intensity of methyl resonances M2235.54 and M2966.41 for  
β1AR-Met2-Δ5-L190M, β1AR-Met2-Δ5 
 
Relative peak intensities Normalised peak intensities 
 
Met2-Δ5-L190M Met2-Δ5 Met2-Δ5-L190M Met2-Δ5 
Ligand     M223 M296 M223 M296 M223 M296 M223 M296 
Adrenaline (ADR) 
  
0.06 0.04   0.1 0.11 
Isoprenaline (ISO) 0.08 0.12 0.05 0.10 0.14 0.31 0.08 0.28 
Salbutamol (SLB) 
  
0.16 0.22   0.27 0.61 
Cyanopindolol (CYA) 0.28 0.24 0.25 0.23 0.49 0.62 0.42 0.64 
7-Methylcyanopindolol 
(7mC) 
  
0.27 0.21   0.45 0.58 
Apo 0.26 0.21 0.27 0.22 0.46 0.54 0.45 0.61 
Carvedilol (CVD) 
  
0.27 0.25   0.45 0.69 
Apo/Nb80 0.38 0.36 0.44 0.29 0.67 0.92 0.73 0.81 
Apo/Nb6B9 0.43 0.36   
 
0.75 0.92    
ADR/Nb6B9 
  
0.60 0.35   1 0.97 
ISO/Nb80 0.57 0.39 0.59 0.35 1 1 0.98 0.97 
ISO/Nb6B9 0.57 0.39   
 
1 1    
SLB/Nb6B9 
  
0.59 0.36   0.98 1 
CYA/Nb6B9 0.47 0.37   
 
0.82 0.95    
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The figure below shows the relative intensities of M2235.54 and M2966.41 plotted against each other 
(Figure 3.16 c, d). This allowed the direct comparison of the two residues in terms of their 
conformational dynamics. The normalised intensities (Figure 3.16 a, b) are also shown, and this allows 
the comparison of different receptor states and constructs.  
The full agonists adrenaline and isoprenaline bound receptors show consistently lower peak 
intensities for M2235.54 and M2966.41 than they do for partial agonist cyanopindolol, 7m-
cyanopindolol, salbutamol, carvedilol or the apo form. The adrenaline bound state was even more 
mobile than the isoprenaline bound state, even though both exhibited a significant conformational 
exchange.  
Peak intensity ratios for nanobody bound ternary complexes showed significant increases in signal 
intensity, showing that these receptor states correspond to a more rigid form, experiencing much 
less conformational exchange on the µs-ms timescale. 
Nanobody-only bound receptor states showed more rigidity than the ligand bound or apo states, but 
showed more dynamics resulting in peak broadening than did the ligand plus nanobody bound 
ternary complexes. Both Nb80 and Nb6b9 showed this effect.  
The pattern revealed by normalised peak intensities and by relative peak intensities persisted across 
the two types of analyses. Similarly, the construct used (Met2-Δ5 and Met2-Δ5-L190M) did not 
change this either.  
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Figure 3.16 Peak intensity analysis 
Peak intensities show changes in receptor dynamics on the intermediate NMR timescale. 
Relative peak intensities (a,b) were calculated relative to the M153 signal in each 
spectrum. These can be converted to normalised peak intensities (c,d) by assigning a 
value of one to the most intense peak in each spectra. Higher values represent an 
absence of conformational fluctuations leading to peak broadening and lower values 
correspond to increased dynamics on the µs-to-ms timescale. Figure adapted with 
permission from Solt et al. (127). 
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3.8 – Effect of thermostabilising M902.53A mutation 
The mutation of residue M902.53 to an alanine has been established to increase the melting 
temperature (Tm) of the antagonist alprenolol bound receptor (construct: β1AR34-324, see Appendix A) 
by 8 °C (94). The introduction of this mutation not only assisted the assignment of residue M902.43, but 
also showed insight into the effect of thermostabilisation. NMR spectra were obtained for the Δ5-
M90A mutant in a number of receptor conformations. Comparing the apo state Δ5-M90A and Δ5 
constructs (Figure 3.17a) showed an identical picture implying little change in the apo state 
conformation due to the mutation. This was in contrast to the ligand bound states (Figure 3.17b). The 
signals for residues M2966.41 and M2235.54 in the M90A construct when bound to the full agonist 
isoprenaline (red and light blue spectra) are shifted in contrast to the Δ5 construct signals in the 
direction of chemical shift displayed by lower efficacy agonists. These effects persisted for the lower 
efficacy agonist salbutamol (purple and green signals).  
Peak intensities (Figure 3.17c) of the Δ5-M90A construct in the presence of salbutamol and 
isoprenaline were compared. This showed significantly higher intensity values for Δ5-M90A compared 
to Δ5, indicating a more rigid and less exchange broadened receptor state attributable to the 
thermostabilisation. The magnitude of intensity difference also seemed to increase with efficacy; the 
change in the relative intensity for the apo states is the smallest, followed by the difference for the 
salbutamol bound states, with the full agonist bound states showing a considerable difference in 
relative intensity.  
A comparison of the isoprenaline bound ternary complexes also showed that the peaks for M2966.41 
and M2235.54 are slightly shifted in the direction of the partial agonist ternary complexes 
(Figure 3.17d). Peak intensities for the ternary complexes show that the Δ5-M90A construct adopts a 
less rigid conformation in the full agonist ternary complex, compared to the Δ5 full agonist ternary 
complex. This has previously been observed to be the case for the low efficacy ternary complexes, 
such as the basal activity state or the cyanopindolol bound complex. Peak intensity values were 
measured by Dr. Daniel Nietlispach.   
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Figure 3.17 Effects of the M90A thermostabilising mutation 
(a) Apo state spectra of Δ5 and Δ5-M90A constructs. (b) Comparison of isoprenaline and 
salbutamol bound states. (c) comparison of peak intensities across various states of the 
Δ5 and Δ5-M90A constructs. (d) comparison of isoprenaline+Nb6b9 bound ternary 
complex states of Δ5 and Δ5-M90A. Figure adapted with permission from Solt et al. 
(127).  
These observations suggest that increased thermostabilisation affects the ligand dependent equilibria 
that has been observed in the ligand bound and ligand-ternary complex states, in a way that they are 
shifted towards the less active (I) and (AG-) states (Figure 3.19).  
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3.9 – Comparison of βAR crystal structures with methyl rotational conformations 
Unlike structural biology techniques such as crystallography or cryo-EM, which generate structural 
models of receptor conformations, the 13C-HMQC NMR experiments used in this work report on the 
molecular signatures of conformational ensemble of various receptor states. This means that it is not 
possible to directly back-calculate a structural model of the detected conformational ensembles to a 
structural model from the information provided by these experiments. NMR spectroscopy can achieve 
this through other more suitable experiments performed on uniformly labelled (13C, 15N) protein 
samples, where through the sequential assignment of residues and through measurements of NOE or 
other through-space constraints a structure can be calculated. The nature of the system used in this 
work and the limitations posed by this do not make this a possibility and to date the only GPCR or 
GPCR analogue structures that have been determined purely by NMR data alone are that of rhodopsin 
(248, 249).  
However, 13C methyl resonances are sensitive reporters of the methionine χ3 rotamer conformation, 
while the methyl 1H chemical shifts are sensitive to perturbation by ring currents from nearby aromatic 
residues. Rotations around the χ3 bond position the CH3 head group in what is referred to a gauche 
conformation (between χ3 angles of -67 ° and +67 ° with respect to the Cγ-S bond plane) or a trans 
conformation (χ3 near 180 °) (Figure 3.18c). The effect of the χ3 rotation angle on the 13C chemical shift 
has been modelled by Butterfoss et al. and is shown below (Figure 3.18b) (250).  
The chemical shift values of M2235.54 and M2966.41 in the apo state, isoprenaline bound state and 
isoprenaline-Nb6b9 ternary complex state receptor are plotted. This shows M2966.41 undergoing a 
trans to gauche conformational change as a consequence of ternary complex formation, predicting a 
χ3 rotamer angle of -67 ° (Figure 3.18a). The aromatic residues which can have an effect on M2235.54 
and M2966.41 are Tyr5.58, Phe6.44 and Tyr7.53. In all of the published β1AR structures Y2275.58 is mutated 
to an alanine, however our construct contains this tyrosine (See Appendix A). An observation of the 
β2AR crystal structures, comparing the inverse agonist carazolol bound state (2RH1 2.4Å resolution) 
(Figure 3.18d) and the full agonist BI-167107 and Gs-bound structure (3SN6 3.2Å resolution) (Figure 
3.18e) shows marked changes in the position of the mentioned aromatic residues in relation to 
M2235.54 and M2966.41. In the NMR spectra of the ternary complex, M2235.54 experiences a significant 
change in 1H chemical shift, which can be explained by the increased proximity of aromatic residues 
(distances measured in Å are shown in yellow) to M5.54. These observations link those obtained by 
NMR spectroscopy to the crystallographic evidence of conformation changes upon receptor 
activation. 
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Figure 3.18 χ3 rotamer associated chemical shift changes 
M223 and M296 χ3 rotameric changes and effects of nearby aromatic residues. Methyl 
13C chemical shift positions are sensitive reporters of χ3 rotamer conformations, while 
1H shifts are influenced by nearby aromatic ring currents. (a) shows a [1H, 13C] correlation 
spectrum for residues M223 and M296 in various receptor states together with the 
approximate trans, trans/gauche exchange and gauche rotamer positions as expected 
from the 13C chemical shift signature and as shown in (b). A simulation of the 13C 
chemical shift change associated with the χ3 rotamer conformation is shown in (b) as 
taken from Butterfoss et al (250). The possible χ3 conformations are shown in (c) in the 
context of methionine side chains with the preferred gauche and trans regions 
highlighted. (d) shows the inverse agonist carazolol bound β2AR (2RH1) while the active 
state full agonist BI167107 and Gs-bound β2AR (3SN6) is shown in (e). The equivalent 
methionines of M2155.54 (to M2235.54) and M2796.41 (to M2966.41) are shown on both (d) 
and (e) in green and yellow. The aromatic residues which are in proximity to influence 
1H chemical shifts are Tyr5.58 (orange), Phe6.44 (blue) and Tyr7.53 (red). In all available β1AR 
crystal structures Tyr5.58 is mutated to alanine, while it is present in Met2-Δ5. Figure 
adapted with permission from Solt et al. (127). 
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3.10 – Proposed model of β1AR receptor activation 
The following diagram condenses the results described into the framework of the ternary complex 
model of receptor activation.  
 
Figure 3.19 Proposed ternary complex model based 
Ligand binding modulates equilibria between an inactive (I) state and a more active (A) 
state that is more predisposed to coupling to Intracellular Binding Partners (IBPs) such 
as Gs. Upon formation of a ternary complex, ligands modulate a second equilibrium 
between a more signalling competent and a less competent AG+ and AG- states. Figure 
adapted with permission from Solt et al. (127). 
Firstly, a ligand efficacy dependent equilibrium was observed, which was particularly pronounced for 
residues M2235.54 and M2966.41 on the cytoplasmic side of the receptor. This establishes an equilibrium 
that takes place in the fast exchange regime in terms of the NMR timescale, between two states: an 
inactive state – termed (I) – and a pre-active state, the (A) state. In this manner, the (I) state is a 
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signalling incompetent, state, unable to bind G-protein. The pre-active (A) state represents an “active-
like” conformation with a highly dynamic cytoplasmic side. The apo state would represent a 
conformational equilibrium predominantly in the (I) state. Ligand efficacy determines the shift in this 
equilibrium, and this is indicated by the averaged chemical shift of the population distribution across 
the (I) and the (A) states. 
Peak intensity analysis as a proxy to estimating µs-to-ms scale exchange dynamics revealed a highly 
exchange broadened full agonist-bound state and a series of less dynamic partial agonist bound states. 
The recovery of signal intensity at lower temperatures in the full agonist state showed that in addition 
to the fast exchange (I) ⇌ (A) equilibrium, governed by ligand efficacy, the pre-active state undergoes 
additional exchange that is closer to the NMR timescale in its exchange rate. This means that the pre-
active state represents a highly dynamic (on the µs-ms timescale) conformational ensemble, sampling 
a number of active-like states. These are denoted as (A’), (A”) and (A’”), which may be predisposed to 
coupling to different intracellular binding partners (IBPs). This implies that the ability of the pre-active 
state to explore different conformations may be significant for the receptor to engage with different 
IBPs. Lower efficacy ligands or the apo state maintain a dynamic receptor ensemble, but this is more 
rigid in comparison to the full agonist complex. 
The binding of nanobody on the intracellular side caused significant chemical shift and intensity 
changes throughout the receptor, extending all the way to the cytoplasmic side. This demonstrates 
the allosteric outward intramolecular signalling effect of IBP coupling, which contributes to the 
increase in orthosteric ligand affinity (87). A similar inwards allosteric effect has also been observed, 
where in the absence of agonist nanobody affinity was substantially reduced in comparison to the 
reported nM affinity (84).  
Nanobody and ligand bound ternary complexes have revealed a second fast exchange equilibrium 
modulated by ligand efficacy. Two predominant models have been described for ligand dependent 
efficacy (251, 252). Kobilka & Deupi propose that partial agonists induce distinct states in the ternary 
complex which are different from the inactive and fully active states and achieve a lower level of 
activity than full agonists (251). Lape et al. suggest that partial agonists modulate an equilibrium 
between an inactive and an active ternary complex form (252).  
The results presented here show that partial agonists govern both the equilibria between the inactive 
and pre-active states, as well as between a less active ternary state (AG-) and a fully active state (AG+), 
both in fast exchange. In this form, the (AG-) conformation is represented by the ligand free nanobody 
bound conformation, i.e. the basal activity complex. Signal intensity analysis has shown these ternary 
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complexes to be more rigid than the basal active state, suggesting a more conformationally restricted 
state (though not absent of dynamic structural changes) appropriate to a given IBP interaction. 
The phenomenon of basal activity is accommodated in this model though the assumption that the 
nanobody-only bound receptor corresponds to a very weak (AG-) conformation, owing to the good fit 
of the chemical shift of this state to the ternary complex efficacy correlation. This implies that the apo 
form, predominantly in the (I) state must sample the (A) state at least a fraction of the time, to allow 
complex formation to take place. This would explain the significant nanobody affinity reduction in the 
absence of orthosteric ligand.  
Hence this model takes into account the phenomena of partial agonism and basal activity, as well as 
the additional exchange parameters of the active-like state. Accordingly, ligand efficacy is converted 
into a distinct conformational output on the cytoplasmic side of the receptor, affecting the quality and 
nature of interaction with the IBP. In this way it could be envisaged that orthosteric ligands can 
regulate the guanosine-nucleotide exchange factor function of Gαs through modifying the quality of 
this interaction, thereby directly modulating the downstream signalling output. 
 
  
 105 
3.11 – The proposed model in the context of other NMR investigations of GPCRs 
To date, six distinct GPCRs have been studied by NMR spectroscopy: the A2AAR, β1AR, β2AR, BLT2, NTS1 
and µOR, in a range of detergent and lipid nanodisc settings. These works are summarised below in 
Table 3.4.  
Table 3.4 List of NMR studies of GPCRs 
Table adapted with permission from Bostock, Solt, Nietlispach, COSB, 2019 (253). 
Receptor 
Expression 
system 
Solubilisation 
system 
Labelling NMR experiments Reference 
A2AAR P. pastoris LMNG 19F-BTFMA 19F; 1D, STD (254) 
A2AAR P. pastoris LMNG 
19F-BTFMA; 
metal ions 
19F, 23Na+, 25Mg+; 1D, 
CPMG 
(255) 
A2AAR P. pastoris LMNG/CHS 
U-15N, ~70% 
2H 
1H,15N TROSY (256) 
A2AAR P. pastoris LMNG/CHS 
U-15N, ~70% 
2H 
1H,15N TROSY (257) 
A2AAR P. pastoris DDM 
13CH3 Ile δ1 / 
2H 
1H,13C HMQC, 3Q-
relaxation 
(258) 
β1AR Sf9 or Sf21 LMNG 13CH3-Met 1H,13C-HMQC (259) 
β1AR High five DM 15N-Val 1H,15N HSQC (260) 
β2AR 
β2AR: 
expressSF+ 
 
C-terminal tail: 
Escherichia coli 
POPC/POPG 
nanodiscs 
β2AR [2H-9AA, 
αβγ2H-,13CH3- 
Met] 
C-tail: U-[ 2H, 
13C, 15N] or 
13CH3 Thr γ2 & 
Ile δ1 
1H,13C-HMQC; 1H,15N 
HSQC; cross-
saturation 
(261) 
β2AR Sf9 DDM 13CH3-Met 1H,13C HSQC (262) 
β2AR Sf9 DDM/CHS 19F-TET 19F; 1D (263) 
β2AR expressSF+ DDM 
13CH3-Met or 
α,β,β-2H3-
,13CH3-Met 
1H,13C-HMQC (264) 
β2AR expressSF+ 
POPC/POPG 
nanodiscs 
2H-9AA, 
αβγ2H-, 13CH3-
Met 
1H,13C-HMQC (265) 
β2AR Sf9 LMNG 19F-BTFA 19F; 1D, T1, T2 (266) 
β2AR Sf9 DDM/CHS 19F-TET 19F; 1D, 2D EXSY (267) 
β2AR Sf9 
DDM/CHS or 
LMNG 
19F-3-bromo-
1,1,1-
trifluoroaceto
ne 
19F; 1D, T1, T2 (268) 
β2AR Sf9 DDM 
13CH3 -Lys 
(reductive 
methylation) 
STD-filtered 1H,13C 
HMQC; 1H,13C HSQC 
(135) 
β2AR Sf9 LMNG 19F-BTFA 19F; 1D, CPMG, STD (269) 
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BLT2 E. coli 
DMPC/CHS 
nanodiscs 
u-2H, 12C Ile-
[δ1-13CH3], 12C 
Met-[ε-13CH3] 
1H,13C-HMQC (270) 
NTS1 E. coli DDM 13CH3-Met 1H,13C-HMQC (271) 
μOR Sf9 LMNG/CHS 
13CH3 -Lys 
(reductive 
methylation) 
1H,13C-HMQC (272) 
μOR Sf9 LMNG/ CHS 
2H-8AA, αβ-2H-
13CH3-Met 
1H,13C-HMQC (273) 
 
The pathways of receptor activation and interactions with ligand or IPBs are explained as a series of 
equilibria forming the ternary complex model (109, 274). This is illustrated below in Figure 3.20.  
 
Figure 3.20 Ternary complex model: a series of equilibria 
Abbreviations: R: receptor (A: inactive, I: active), L: ligand, IBP: intracellular binding 
partner.  
The model proposed in this thesis, described in Figure 3.19, offers an explanation for partial agonism 
in the way the equilibria is modulated by ligand efficacy between the RI-RA:L equilibrium and between 
the RA:IBP-RA:L:IBP equilibrium. Observations of efficacy correlated and ligand induced changes in 
conformation have been observed in other studies of the β2AR and β1AR (121, 275). Such observations 
have been made for V2265.57 (β1AR, backbone amide, Figure 3.21d) and for M822.53 (β2AR, methionine 
methyl, Figure 3.21b). These results revealed a fast exchange equilibria on the NMR timescale, while 
studies of the β2AR in high density lipoprotein (rHDL) nanodiscs, showed a slower exchange rate on 
the order of milliseconds (241). Similarly, exchanging conformations were also observed on the 
cytoplasmic side of β2AR studied by 19F tagged cysteines on TM6 and TM7; here the population of two 
peaks, assigned to an more inactive or more active receptor state, were modulated by the efficacy of 
the bound ligand (Figure 3.21e) (276).  
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Figure 3.21 Ligand induced conformational changes observed by NMR spectroscopy 
A) The region of a generic GPCR showing the location of reporters studied by each case 
study (B-G). Ligand abbreviations: DOB (dobutamine), ISO (isoprenaline), CYA 
(cyanopindolol), ALP (alprenolol), SLB (salbutamol), CAR (carvedilol), ATE (atenolol), 
7mC (7-methylcyanopindolol), CVD (carvedilol), XAM (xamoterol). Figure adapted with 
permission from Bostock, Solt, Nietlispach, COSB, 2019 (253). 
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Various IBP mimetic proteins have been used to study the structural changes induced by IBP binding 
to GPCRs. These include nanobodies (e.g. Nb6b9, Nb80, Nb60, Nb35 or the Gα-c-terminal peptide). 
While small ligand specific changes have been observed in ternary complex structures, they are overall 
very similar (84, 277–279).  
NMR studies which observed ternary complex states have all converged on noting large chemical shift 
changes between a ligand bound and a ternary complex state. One of the major contributions of the 
work presented in this thesis is the observation of a ligand efficacy modulated equilibrium in the 
ternary complex state, which was hitherto not demonstrated. This demonstrated a mechanism for 
modulating the nature and quality of the receptor-IBP interaction, which may have repercussions with 
regards to downstream signalling.  
Future studies building on these findings should expand into looking at the effect of the membrane 
environment in modulating the dynamics and equilibria of receptor conformations.  
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Chapter 4 – Preparation of ScFv C5, an anti-TcP2b antibody with 
agonistic immune cross-reactive properties to β1AR 
 
4.1 – Aim 
The aim of the work below was to clone, express, purify and evaluate the ScFv C5 construct, an ScFv 
version of the mAb 17.2 antibody discussed in the Introduction chapter. The longer-term outlook of 
this work seeks to use the prepared antibody as a tool in evaluating the activation mechanism of the 
β1AR in the absence of an orthosteric small molecule agonist in the context of Chagas’ disease and in 
broader terms too.  
4.2 – Construct Design 
The construct was synthetically ordered (Biomatik) based on the published sequence and in 
consultation with Dr. Karina Gomez (INGEBI CONICET, Buenos Aires, Argentina) (280).  The published 
protein sequence is shown below: 
EVQLEESGGRLVQPKGSLKLSCAASGFSFNTNAMNWVRQAPGKGLEWVARIRSKINNYSTYYADSVKD
RFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRGTTYWGQGTLVTVSGGSGGELVMTQSPLTLSVTIGQ
PASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEA
EDLGVYYCWQGSHFPYTFGGGTKLEIKRAAAHHHHHHGAAEQKLISEEDLNGAA 
Segments underlined and in bold indicate the 6 CDR sequences. The VL and VH chains are connected 
by a 5 residue GGSGG sequence (green). The construct is tagged by a His-6 (red) and a Myc tag (blue).  
The construct was to be cloned into the pMAL1-Nb vector, with the aim of using a maltose binding 
protein (MBP) tag for affinity purification as well as for its periplasmic export sequence. The oxidising 
conditions of the gram negative bacterial periplasm in contrast to the generally reducing environment 
of the cytoplasm allows for the formation of necessary disulphide bonds. Together with the lower 
levels of protease activity, the periplasm constitutes an ideal compartment for the soluble expression 
of antibody fragments (281). The pMAL1-Nb vector has been used to increase the yield of poorly 
expressing nanobodies (282).  
The synthetic construct was codon optimised for E. coli expression and was designed with an N-
terminal HRV 3C (Prescission protease) cleavage site, a C-terminal reversed TEV cleavage site and a 
His-8 tag, flanked by recognition sequences for the restriction endonucleases EcoRI and HindIII at the  
5’ and 3’ ends (N and C termini) respectively.  
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The final construct produces a 71.8 kDa protein, where the MBP fusion is linked to the ScFv construct 
via a poly-N linker, an enterokinase and a HRV 3CP cleavage site. The intention is to produce the ScFv 
through 3CP cleavage, producing a 43.68 kDa MBP fragment and a 28.13 kDa ScFv fragment as shown 
below (Figure 4.1).  
 
Figure 4.1 Schematic representation of the ScFv C5 MBP fusion construct 
The final sequence of the synthetised ScFv segment is shown below.  
LEVLFQGPGGSGEVQLEESGGRLVQPKGSLKLSCAASGFSFNTNAMNWVRQAPGKGLEWVARIRSKIN
NYSTYYADSVKDRFTISRDDSQSMLYLQMNNLKTEDTAMYYCVRGTTYWGQGTLVTVSGGSGGELVMT
QSPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWLLQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSG
TDFTLKISRVEAEDLGVYYCWQGSHFPYTFGGGTKLEIKRAAGQFYLNEAHHHHHHHH* 
4.3 – Expression of the MBP fusion construct 
Bacterial protein expression can yield high quantities of heterologously expressed protein, which may 
either be in a soluble form, or packed into inclusion bodies in an often denatured, insoluble form. The 
latter requires refolding, which may or may not be feasible. Soluble expression can take place in either 
the cytoplasm or the periplasm as mentioned above. When a protein is synthesized by the ribosome 
it is the conditions experienced by the nascent chain which determine its propensity for adopting the 
correct folded conformation we refer to as the soluble form. If conditions of the environment such as 
pH, temperature, hydrophobicity, ionic potential, presence of chaperones, redox potential, presence 
of post-translationally modifying enzymes as examples, are not ideal there is a chance for misfolding 
and aggregation resulting in insoluble expression. In E. coli such proteins are packed into inclusion 
bodies, as a mass of high-density insoluble protein. In order to establish conditions that maximise the 
soluble yield over insoluble expression for a given construct, parameters such as temperature, length 
of expression, media, cell type and induction method can be varied.  
To find the optimal temperature for soluble expression, 0.5 L autoinduction expression cultures were 
grown in superbroth at 18 °C, 25 °C and at 30 °C, using MH140 E. coli cells. The pellet from 1 mL of 
culture was used to evaluate the level of soluble expression (Figure 4.2). A western blot of the soluble 
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fraction shows that all three temperatures yielded soluble expression, confirmed by the presence of 
a c. 70 kDa band (Figure 4.2A). It also appears that the size of this band is smaller in the 30 °C culture 
compared to the 18 °C and 25 °C cultures, however this assumes an identical efficiency of lysis and 
equal cultural densities at the time of harvest for all three samples. In fact the densities at harvest 
measured at 600 nm were 4.95 AU (18 °C), 2.6 AU (25 °C) and 2.6 AU (30 °C), meaning that the overall 
yield was the greatest at 18 °C, and the amount of protein expressed per cell may not have been 
maximal at this temperature.  
As discussed above, undesired insoluble expression takes place at the expense of soluble expression. 
To evaluate the ratio soluble to insoluble expression at 25 °C, the insoluble pellet left over after cell 
lysis was solubilised with 10% SDS and visualised on a western blot (Figure 4.2B). 
 
Figure 4.2 ScFv-C5-MBP expression analysis at different temperatures 
Anti-His western blot of MBP fused ScFv C5 expression at 18 °C, 30 °C, 25 °C and at 13 °C. 
(A) shows the result of probing the soluble fractions of expression at different 
temperature. (B) shows the evaluation of soluble and insoluble expression at 25 °C 
compared to the amount of soluble expression at 18 °C. (C) shows that the level of 
insoluble expression is reduced at 13 °C compared to 25 °C.  
This shows significant quantities of his-tagged material in the insoluble fraction. In order to reduce 
this, expression was trialled at 13 °C, for 40 hours. This has achieved successful expression for an EGFR 
transmembrane construct, which only produced inclusion bodies at higher temperatures (283). 
Reducing the expression temperature to 13 °C significantly lowered the amount of his-tagged protein 
in the insoluble fraction, while the 70 kDa band in the soluble fraction remained comparable to that 
at higher temperatures (Figure 4.2C).  
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It can therefore be concluded that while significant levels of soluble expression can be achieved at 
temperatures up to 30 °C, the amount of insoluble protein can be minimised at little expense of 
soluble expression by reducing the temperature to 13 °C and extending the length of culture to over 
40 hours.  
4.3.1 – Purification of the MBP fusion construct 
Having established the presence of a his-tagged band of the expected size on a western blot, the 0.5 L 
cultures expressed at 18 °C and 25 °C were processed for purification. An initial Nickel affinity 
chromatography step using a 1 mL HisTrap FF column with a load rate of 0.5 mL/min did not show any 
bound protein to the column upon elution with up to 250 mM of imidazole.  
This was unexpected as when designing the MBP fusion expression construct, the available 
crystallographic data was considered. The Fab format of mAb 17.2 has been crystallised by Pizzaro et. 
al. and this allows us to consider the secondary structure of the C-terminus of the ScFv C5 construct.  
 
Figure 4.3 ScFv C5 structural model 
Structure of Fab 17.2-R13 peptide complex (3SGE), with the VH-VL region in focus 
(dashed circle). An in silico model of the region forming the ScFv region is shown on the 
right, extracted from 3SGE. The R13 peptide is shown in space fill, the VH region in blue, 
VL in orange and the tail region forming the ScFv C-terminus or the linker to the CL in the 
Fab is shown in green. 
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As shown above, a highlight of the variable regions of Fab 17.2 in complex with the R13 peptide, the 
variable light (VL) region which connects to the constant light (CL) domain adopts no defined 
secondary structure in the region of sequence which is still present in our ScFv C5 construct (Figure 
4.3 – ScFv model). This is shown as a green “tail” on the right. It would therefore make sense to expect 
an affinity tag sequence placed at this C-terminus to be exposed for purification.  
The observation of poor or no binding to the nickel affinity column, in the face of a detectable anti-his 
signal on a western blot, must mean that the tag is somehow obscured or its binding to the resin 
sterically hindered in solution. If this obstruction is the result of a reversible process, and that the tag 
exists in an equilibrium between an obscured and an available form, then if the loading rate onto the 
packed column happens at a faster rate than the transition between these two states, then a reduction 
in the flow rate and increase in the on-column residence time may increase the binding efficiency. This 
could make a nickel affinity step a viable form of purification for this construct. 
To get around the limitations posed by the apparent unavailability of the his-tag as a means of 
purification the maltose binding property of the MBP fusion partner can be exploited for purposes of 
affinity chromatography. Consequently the HisTrap flow through was reserved and purification was 
attempted using the MBP tag using a 1 mL capacity MBPTrap column, which consists of packed dextran 
Sepharose beads, using 20 mM maltose as the eluting agent.  
 
Figure 4.4 MBPTrap purification of the ScFv C5 expressed at 18 °C.  
The eluted fractions from expressions ate 25 °C and at 18 °C are shown on an SDS-PAGE 
gel. 
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This yielded a significant elution peak for both the 18 °C and the 25 °C culture. Typical of affinity 
chromatograms using stepwise elution, the elution profile shows a single peak, which contains species 
of multiple molecular weights (Figure 4.4). As mentioned earlier, the fusion construct corresponds to 
a 71.8 kDa band, which appears present in both purifications. In addition to this band there is a strong 
band appearing between the 40 and 55 kDa markers, which likely corresponds to MBP with some of 
the linker sequence, which has a minimal size of 40.2 kDa. This suggests that for some copies, the 
protein translation terminated prior to the ScFv sequence, producing significant quantities of MBP on 
its own.  
In order to separate these different molecular mass proteins, size exclusion chromatography (SEC) (or 
gel filtration – GF) was used as a second step purification. The eluted fraction from the MBPTrap 
column was concentrated and loaded onto a Superdex S200 Increase column. The resulting 
chromatogram and gel is shown below (Figure 4.5). 
 
Figure 4.5 Size exclusion chromatography of the MBPTrap purified ScFv-MBP construct.  
The load fraction as well as peaks A and C are shown on an SDS-PAGE gel. 
Peak A elutes at 8.69 mL, which is shortly after the void volume of 8.465 mL for the S200 10/300 
Increase column. This corresponds to a molecular weight of 1048 kDa, likely representing large 
molecular weight aggregates or oligomers of mixed species. The corresponding gel of peak A also 
indicates a mix of very high molecular weight proteins. Peak C elutes at 15.36 mL, representing a 46.8 
kDa size molecule. This likely corresponds to MBP alone with some of the linker sequence between 
MBP and the ScFv, corresponding to a size of about 43 kDa. The measured difference may arise from 
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the unknown position of cleavage/truncation, or from the fact that SEC only takes into account the 
hydrodynamic volume of proteins, not their molecular mass.  
Using MBP as an affinity tag exploits a very specific protein-protein interaction, therefore the relative 
impurity of the resulting eluate is likely due to truncated expression, proteolysis or oligomerisation. In 
order to purify the intended ScFv construct from this mixture, it had to be cleaved from the MBP fusion 
partner. The designer construct affords this opportunity either through an enterokinase site or a 3CP 
site. The latter is considered more specific, cleaving at the LEVLFQGP sequence between the glutamine 
and glycine residues, therefore 3CP was chosen.  
3CP, like TEV is a cysteine protease and it its activity requires a reducing environment (284). This can 
be achieved through the addition of reducing agents such as DTT or TCEP into the cleavage reaction 
mixture. The mixture eluted from the MBPTrap column was subjected to parallel cleavage reactions, 
using 3CP and 2 mM DTT, 3CP and 2 mM TCEP and just reducing agents without enzyme. 25 µg of 3CP 
was used per reaction, which represented a large excess in terms of minimal recommended amounts 
of commercial PreScission protease (GE) for the given amounts of substrate. The cleavage was 
monitored by resolving the end product mixture on an SDS-PAGE gel and by gel filtration (Figure 4.6). 
 
Figure 4.6 Cleavage of the MBP fusion ScFv C5 construct 
SDS-PAGE, and western blot of SEC peaks obtained from ScFv-MBP cleavage by 3CP 
protease. (a) SDS-PAGE gel of the pre- and post-cleavage products as well as of the 
various SEC peaks shown on the right-hand side chromatogram (b). (c): western blot is 
of the SDS-PAGE (a). (d) shows a superposition of the SDS-PAGE and western blots for 
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the lanes containing the SEC peaks. (b) SEC traces: green: 3CP only control, pink: 
TCEP+MBP fusion control, lilac: DTT+MBP fusion control, red: 3CP+TCEP cleavage 
reaction, blue: 3CP+DTT cleavage reaction. 
The SDS-PAGE profile of the cleavage reactions shows that the presence of the enzyme changes the 
profile of the MBPTrap eluate starting mixture, with the noticeable disappearance of very high 
molecular weight bands. The mixture resolves to a major 40-55 kDa band corresponding to the 
43.68 kDa MBP product and a minor band at 25-35 kDa, likely matching to the 28.13 kDa ScFv product. 
The result was very similar for both 3CP cleavage reactions with DTT and TCEP. Reactions omitting the 
protease show no change in the gel profile compared to the starting material, indicating that the 
reducing agents alone do not cause a significant change in the species present. A his-probe western 
of the same samples shows no band that corresponds to the presumed MBP product, which serves to 
verify its identity as that portion of the construct lacks a his-tag. There is however a band under 35 kDa, 
which is likely the ScFv product, containing the his-tag.  
The four reactions were then analysed for their composition using gel filtration, with the aim of 
separating the cleaved ScFv from the MBP part. This is shown above; the four reactions were 
concentrated and separated on an S200 10/300 Increase column, alongside an equal amount of 3CP 
stock to that used in the reactions. This is shown by the green chromatogram, displaying an almost 
negligible amount of protein in comparison to the other traces. The traces of the DTT and TCEP only 
mixtures (pink and lilac) are identical to the chromatogram of the MBPTrap eluate trace shown earlier 
(Figure 4.5), with two predominant peaks A and C. These are not shown on the gels above 
(Figure 4.6b) as they were identical to the MBPTrap eluate peaks A and C as shown before. The cleaved 
end-product once 3CP is present shows a different profile not just on the gel but also on gel filtration 
(red and blue traces). Peak A has almost completely disappeared for both the 3CP+DTT and 3CP+TCEP 
reactions, which corresponds well to the abrogation of large molecular weight bands on the gel.  Peak 
C has increased considerably, which matches the large amount of MBP fragment generated. This 
strong band does not show up on the western, and this is easily visible on the composite gel-western 
overlay figure on the bottom right. In addition to these changes to peaks A and C, two small peaks, B 
and D also appear. B shows up as a faint band on the gel and appears as a very strong band on the 
western. This is very likely to be 3CP, which also has a his-6 tag. The position of 3CP is shown above 
on the small gel labelled 3CP, aligned with the molecular weight markers of the adjacent gel. This 
shows that 3CP runs at an identical position as peak B. Band D does not present on the SDS-PAGE gel, 
but it shows as a 25-35 kDa band on the western. It elutes at 19.21 mL, translating to an estimated 
molecular weight of 7.7 kDa. To put this into comparison, salts and other small molecules elute at 
about 22 mL on this column, hence peak D either represents an unfolded state with a non-globular 
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conformation, which may explain the discrepancy between the size on the gel and western and the 
size in solution. The same band between 25-35 kDa also appears on the western for peaks A and C, 
and it matches the band previously noted in the cleavage product mix (on the left hand side of western 
blot – Figure 4.6c). It is likely therefore that this band is the ScFv fragment, however it is completely 
missing from the gel in the quantities expected based on the amount of MBP fragment present. This 
was puzzling as it can be seen from the gels and westerns (overlaid composite image) the ScFv 
fragment is present in peak A and in the cleavage end-mixture,  but disappears in observable form 
during gel filtration.  
Reducing agents such as DTT or TCEP are essential for the activity of cysteine proteases like 3CP. This 
is shown below (Figure 4.7), as 3CP in the absence of any reducing agent does not result in cleavage, 
and the size of peak A remains unchanged. While reducing agents are crucial for protease cleavage, 
they may adversely affect crucial disulphide bonds in other proteins. Hence it is a possibility that the 
vanishing act of the ScFv cleavage fragment may be due to the susceptibility of the 2 disulphide bonds 
present within the molecule in the presence of 2 mM TCEP or DTT. An alternative method of achieving 
the right conditions for cleavage is using a redox shuffle system, where oxidised and reduced versions 
of the same molecule are supplied together, creating a tuneable redox environment. An example of 
such a system is based on the oxidised (GSH) and reduced (GSSG) form of glutathione. Redox shuffle 
systems can also be used to rearrange disulphide bonds in misfolded proteins. The ratio of the two 
redox forms must be empirically optimised to achieved the desired conditions, as the redox potential 
of the system depends on both the concentration and ratio of the two species (285, 286).  
A cleavage reaction with an equimolar ration of GSSG/GSH at 0.3 mM produced identical results to 
cleavage in the absence of reducing agents. A ration of 10:1 GSSG to GSH (3 mM to 0.3 mM) however 
successfully repeated a chromatogram observed for cleavage with DTT and TCEP as shown earlier. 
This reduced peak A, and produced a peak C (identical to previous peak Cs) and a significant peak D 
(Figure 4.7c). The corresponding gel shows the emergence of a 25-35 kDa band in the post cleavage 
reaction, but yet again this band does not appear in either peaks A, C or D (Figure 4.7b). The western 
blot corresponding to the post cleavage band confirms the presence of a his-tagged product, making 
it highly likely that this is the 28 kDa ScFv C5 fragment. Furthermore, when compared to the western 
blot lane of the MBPTrap eluate, this band is missing, implying that it was released as the consequence 
of cleavage. The nature of peak D was uncertain, as it didn’t show up as any material on the gel, not 
even at the very low molecular weight section (cropped). GSSG was the only new component present 
in larger quantities in comparison to the 1:1 GSSG/GSH reaction. It is not known if GSSG absorbs at 
280 nm. 
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At this point the identity of the 28 kDa band (shown below in dashed square) was verified by mass 
spectrometry fingerprinting against the expected protein sequence (Figure 4.7d).  
 
Figure 4.7 ScF-MBP fusion cleavage with alternative reducing agents 
3CP cleavage in the absence of reducing agent and with the glutathione redox shuffle 
system. (a) and (c) shows corresponding gel filtration chromatograms. SDS-PAGE and 
anti-his western blots of the redox shuffle cleavage reaction are shown in (b). Mass 
Spectrometry fingerprinting confirms the presence of cleaved ScFv C5 (d). 
The red segments of sequence shown above represent peptides that have been detected from the 
reference sequence. To estimate the certainty of the match protein scores are given to peptide 
matches against a database, where a calculated probability threshold value is given to a match which 
occurs at random. Any scores above this are considered significant at that significance threshold. The 
protein score for this analysis was 714, with a score of 33 or above considered significant at the 95% 
confidence interval. The experiment and analysis was carried out by the PNAC facility at the 
Biochemistry Department.  
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This verifies for the first time that this 28 kDa band is the ScFv fragment and that it has been expressed 
and cleaved successfully. It however remained a challenge to isolate it in any purity from the cleaved 
mixture by the purification strategy of MBPTrap, cleavage and gel filtration.  
4.4 – Cell-free expression of a non-MBP fusion ScFv C5 construct 
To solve the problem of being unable to separate the cleaved ScFv fragment from the MBP fusion 
construct, an alternative approach was sought. The ScFv construct was subcloned into a cell-free 
expression vector (pIVEX2.3d), without a fusion partner. This was done simultaneously to subcloning 
into a periplasmic expression vector (pET28b) using the same restriction enzyme sites. While the 
intention was to use periplasmic expression in large scale bacterial cultures, delays in the cloning into 
the pET28b vector meant that in the meantime the cell-free construct proved a useful tool in trying to 
obtain ScFv C5 by any means.  
A19 E.coli extracts (S12) prepared by Henry Chih-Ta Chien and Niclas Frei were used to express the 
ScFv C5 construct in pIVEX2.3d, as shown below, which is intended to produce a 27.7 kDa protein with 
a TEV cleavable His-8 tag. Redox shuffling was achieved using 0.3 mM GSSG and 3 mM GSH, in a 1 mL 
reaction mix.  
The reaction mixture was incubated overnight at 30 °C. To try and purify any expressed ScFv, a 50% 
slurry of nickel-sepharose beads were equilibrated in 20 mM Tris-HCl, 150 mM NaCl and 200 µL beads 
were added to the cleared cell-free supernatant, with the precipitate also retained and solubilised 
with SDS. The beads were incubated with the product by end-to-end mixing for 1.5 hours. The flow 
through was then collected and the beads were washed with the previous buffer yielding a wash 
fraction. The beads were then washed with buffer supplemented with 250 mM imidazole, yielding 
elution fractions 1 and 2. These fractions were then analysed using SDS-PAGE and western blot as 
shown below.  
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Figure 4.8 Cell free ScFv C5 expression 
Cell free expression construct of ScFv C5 (top) and SDS-PAGE and western blot of the 
ScFv C5 cell free expression reaction (bottom). 
The anti-his western blot has shown a band at the expected size in the load fraction, confirming that 
protein expression has taken place, with a considerable amount in the pellet, representing insoluble 
expression or crashed out aggregates. This band was even stronger in elution fractions 1 and 2, 
meaning that for the first time it was possible to bind the ScFv to nickel beads, making it a viable option 
for purification. It must be noted that the long batch binding mode incubation was likely a contributing 
factor, as was perhaps the lack of the MBP fusion partner which may have previously taken a role in 
obscuring the His-tag. The gel also shows a band of the expected size in the elution fractions, indicating 
that even at this low scale of expression, significant quantities of ScFv can be produced.  
This endeavour hence provided two significant observations that encouraged further attempts of 
expression in large scale E. coli cultures. These were the observation of binding to nickel beads, and 
that the yields, even at this small scale, were non-negligible, building an expectation that with scaled 
up bacterial expression, the yields may make this protein amenable to structural biology projects, such 
as NMR experiments. 
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4.5 – Bacterial expression of a non-MBP fusion ScFv Construct 
The successful cloning of the ScFv construct into the pET28b expression vector allowed for the 
periplasmic expression of the antibody fragment via the PelB export sequence. The pIVEX2.3d vector 
lacks the necessary gene for the lac repressor (LacI) necessary for lactose induced expression. It only 
contains a T7 promoter and a ribosome binding site (RBS) upstream of the gene of interest and lacks 
the lac operator sequence between the T7 promoter and the RBS, which is the site of lac repressor 
binding. In this arrangement, inserts in the pIVEX2.3d cell-free vector are not under the control of an 
inducer such as IPTG or lactose, making it an ideal system for cell free expression. The inducible 
expression permitted by the pET28b vector makes it possible to scale up the bacterial culture and for 
protein production to commence at the desired time, when temperature, culture density and culture 
size are right. This setup also benefits from the possibility of employing autoinduction, which can 
achieve culture densities far superior to those under IPTG induction, where the culture usually only 
doubles after induction. With autoinduction densities of 10 OD600 or more can be achieved.  
 
Figure 4.9 Analysis of periplasmic ScFv expression 
Expression analysis of the soluble and insoluble fraction of ScFv periplasmic expression 
in LB and AIM (autoinduction media) 
Two 0.5 L cultures were expressed at 25 °C, as a starting condition, in IPTG induced LB media and in 
autoinduction media (AIM) superbroth (AIM-SB). A 1 mL sample was taken for expression analysis and 
the soluble and insoluble fractions analysed by SDS-PAGE and western blot (Figure 4.9). This showed 
successful soluble expression in large quantities in AIM-SB, with a significant amount of insoluble 
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expression. This was also the case for LB media, but with a lower yield. The faint LB band on the 
western blot of the soluble fraction was the result of a compromise in exposure time, to balance the 
intensity difference of the two bands. The conclusion from this analysis is that the construct expresses 
well in this system and that the soluble yield would benefit from a lowered temperature, as observed 
for the MBP construct.  
Having observed that nickel bead binding is possible for the ScFv construct without a fusion partner, 
a HisTrap chromatography step was tried as first round of purification. A very low flow rate of 
0.1 mL/min was used, and the lysate was re-circled for 16 hours (overnight). The column was washed 
with PBS and eluted with PBS+250 mM imidazole. This achieved a very low purity preparation that 
was further analysed by gel filtration in PBS buffer. This is shown below (Figure 4.10). 
 
Figure 4.10 Assessment of ScFv C5 oligomerisation state by SEC 
SEC assessment of the dimerisation status of the expressed ScFv C5. The elution fraction 
of ScFv C5 purified by HisTrap columns was concentrated and separated according to 
size on an S200 Increase column. Selected fractions were further separated using an S75 
gel filtration column, revealing two peaks which correspond to the same -band on an 
SDS-PAGE gel. 
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Separating the HisTrap combined eluate pool on an S200 Increase column revealed that fractions 11-
14 contained a band that matched to the expected 27.9 kDa construct. These fractions also showed a 
His-tagged band at the expected size. 
ScFv C5 is published as a dimeric fragment of the mAb 17.2 antibody. It differs from another fragment 
version called ScFv B7 in that C5 has a five amino acid sequence linking the VH and VL chains, compared 
to the 15 amino acid linker for B7 (230). In all other respects including their CDR sequence, the two 
fragments were identical. This difference however resulted in major differences in the structural 
nature and physiological properties of the two constructs. ScFv B7 appears as a monomer in solution, 
in comparison to C5, determined by calibrated SEC. C5 was shown to bind the human β1AR ECL2 
peptide H26R with an affinity of 10 µM using surface plasmon resonance. While 
immunohistochemistry of β1AR transfected cells showed binding of both C5 and B7, B7 had a 
significantly lower cAMP stimulating effect than (> 5 fold) than C5, and it was also shown to block the 
cAMP stimulation in the presence of isoprenaline. Tested on spontaneously beating cardiomyocytes, 
C5 induced a propranolol negatable 40 beat/min increase, while B7 alone did not cause any significant 
increase. Furthermore, B7 also prevented an isoprenaline caused increase in beating frequency. This 
establishes the monomeric form of the same antibody as a negative (with respect to isoprenaline 
agonism) or neutral (with respect to B7 alone) allosteric modulator, while the dimeric form as a 
positive allosteric modulator. In this respect, it is a primary objective to achieve a dimeric preparation 
of ScFv C5, the form which has been shown to achieve specific β1AR agonism. 
To estimate whether the purified ScFv was in a monomeric or the desired dimeric format, the target 
containing fractions 11-14 from the S200 separation were pooled and separated over a Superdex S75 
16/60 pg column. The S200 column is ideal for separating particles between 10 kDa to 600 kDa, while 
the S75 column is suited for molecules between 3 kDa to 70 kDa. Hence the range defined by the ScFv 
monomer of 27.9 kDa and dimer of 55.8 kDa is much better suited for separation on an S75 column, 
making it easier to distinguish between the two species.  This has resolved the S200 pooled fractions 
previously under one broad peak to two major peaks (labelled A and B above – Figure 4.10), with 
elution volumes of 53.91 mL and 63.41 mL, translating to a calibration size of 64.43 kDa and 31.8 kDa 
respectively. These deviate from the expected sizes by 8.63 kDa and 3.9 kDa. The accuracy of 
calibrated SEC in estimating molecular mass has been discussed earlier, however it is undeniable that 
a SEC-MALS measurement would provide more accurate masses. Given that both peaks show the 
expected 27.9 kDa band on the SDS-PAGE gel, and that in previous publications on purified ScFv C5 
the dimeric protein only manifested itself in solution through its solution size based on gel filtration, 
and that on a gel it appeared at the size of the monomer, it appears that peaks A and B correspond to 
a dimer and monomer respectively (230).  
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While this analysis suggests this purification method is able to produce the sought after ScFv dimer, 
another method of purification was tested with the aim of improving material purity. This replaced 
the second gel filtration step with a light-chain affinity step. Protein L is a bacterial protein isolated 
from Peptococcus magnus, and it is able to bind immunoglobulin kappa light chains (287). To this end 
it has been used for the affinity chromatography of suitable kappa-containing antibodies in an agarose 
conjugated format. In this case a 1 mL HiTrap Protein L column was used to bind the HisTrap eluate. 
As shown below (Figure 4.11), by SDS-PAGE and his-probe western blow, the use of the Protein L resin 
resulted in a very high purity preparation, from a very inhomogeneous starting material, 
demonstrating the specificity of the interaction. This method also achieves the goal of improving the 
purity compared to the previous nickel affinity-SEC approach.  
 
Figure 4.11 Protein L chromatography 
Protein L affinity chromatography and SEC analysis of the effect of salt on ScFv C5. 
A noteworthy technical consideration concerns the elution of protein from the Protein L column. 
Following manufacturer’s recommendation, the use of 100 mM sodium citrate pH 2.7 only eluted a 
small fraction (2-5% by peak volume) of the bound material and it was later found to elute in the post-
elution water wash. A second attempt of reducing the ionic strength of the elution buffer by using 
5 mM NaCitrate achieved complete elution. Similar results were achieved with 100 mM and 5 mM 
Glycine pH 2.7. This suggests that the interaction of protein L to the ScFv favours high ionic strength 
conditions, or that the dissociation of the two is not reliant on low pH per se, but also on a drop in 
ionic strength, such that water was able to elute the fragment alone.  
The gel filtration of the eluted protein in PBS (with a composition of 10 mM Phosphate pH 7.4, 137 mM 
NaCl, 2.7 mM KCl) showed a peak at 16.23 mL elution volume, corresponding to a size of 30.19 kDa 
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(blue trace above – Figure 4.11). This likely indicates a monomeric form. Arndt et. al. have 
demonstrated a link between the formation of ScFv dimers and the ionic strength of the buffer (288). 
In order to try and generate dimers from this preparation, the sample was desalted into a high salt 
buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 50 mM CaCl2). The solution was incubated overnight 
and ran on the same size exclusion column as the low salt sample, in the new buffer. This produced 
the orange trace, with a shifted elution volume of 15.92 mL, corresponding to a 35.0 kDa molecule. 
While the observed shift is in the increased molecular weight direction, it does not quite match the 
size of a dimer, however as discussed above, an S75 column would provide a much clearer separation 
between these two peaks. When compared to the HisTrap-SEC approach peaks from the S200 column, 
both low salt and high salt elution volumes fall under the same peak in fractions 12-13 (Figure 4.10), 
which were later resolved to two peaks on the S75 column. 
4.6 – Conclusions on the preparation of purified ScFv C5 
In conclusion, two purification approaches should be explored further for the production of dimeric 
ScFv C5. One option is to employ the HisTrap-SEC approach where the dimeric form of the higher 
molecular weight peak is confirmed. Alternatively the HisTrap-Protein L option is used, where the 
purity is superior, but the resulting product appears monomeric, which is not reported to bind the 
β1AR. The use of an S75 column (which was not available for the period this work was undertaken or 
was borrowable for a very limited time) would be highly preferable to judge the dimerisation status 
of the preparation. The immediate next goal is to produce high purity, confirmed dimers using a 
combination of the chromatography techniques here explored. 
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4.7 – Preparation of hECL2 β1AR chimera 
The bystander activation of β1AR by ScFv C5 was shown through its interactions with the ECL2 H26R 
peptide, which is a sequence found in the human β1AR. The figure below depicts a diagrammatic 
representation of the turkey and human ECL2 loop sequences, with differing residues shown by 
arrows. As it is unknown if ScFv C5 cross-reacts to the turkey ECL2 loop it is sensible to create a 
thermostabilised turkey-human-ECL2-chimera. 
 
 
Figure 4.12 Expressing the human ECL2 chimera 
Comparison of the human and turkey ECL2 loops and SDS-PAGE of a purified hECL2-
turkey-β1AR construct. 
This would be instrumental in using purified receptor for use in biophysical and structural studies of 
this interaction. To this end, the ECL2 of the tβ1AR-Met2-Δ5 and tβ1AR-Met2 constructs was replaced 
by PCR with the H26R sequence. The created constructs were transfected in Sf9 insect cells for the 
generation of baculovirus, and a 1 L culture was expressed. The Met2-hECL2 construct was purified by 
the same method as all other β1AR constructs in this study, and the SDS-PAGE of the HisTrap eluent 
shown above confirms the successful expression and purification of the construct. 
This makes another component available for the study of receptor agonism by cross-reacting anti-TcP 
protein antibodies. 
 127 
4.8 – Future directions 
Once the preparation of a dimeric ScFv C5 is confirmed the next step is to evaluate its binding to both 
the R13 peptide or to the H26R peptide (β1AR ECL2) in addition to preparations of purified β1AR in 
either detergent micelles or lipid nanodiscs. Understanding the quality and nature of this interaction 
(affinity, on/off rates) will help answer the following questions underpinning the mechanism of 
chronic Chagas’ heart disease. 
1. How do ligands modulate receptor agonism by cross-reacting antibodies? 
2. What is the molecular mechanism of this agonism? 
3. Does activation produce similar molecular signatures as does agonism achieved by ligands and 
G-proteins, G-protein mimics? 
4. Can we stabilise the agonistic conformation for study by structural biology techniques? 
The progress outlined in this chapter is far from answering these questions, but it does represent a 
starting point in terms of preparing the necessary materials needed to address these issues.  
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Chapter 5 – Methods  
 
5.1 – Transformation of chemically competent E. coli 
E. coli cells were made competent using either the Inoue buffer method or the rubidium chloride 
method (289, 290). The former is appropriate for ultracompetent DH5α cells, but it failed to produce 
long lasting competent cells of any other strain tested. All competent cells were suitable for long term 
storage and freezing at -80 °C. 
Chemically competent or ultracompetent E. coli cells were thawed in ice. DNA of appropriate volumes 
or quantities were added to the cells and incubated for 30 minutes on ice. The cells were then heat 
shocked at 42 °C for 60 seconds. The cells were then allowed to recover on ice for 2 mins. 750 µL of 
LB were added to the cells and the culture incubated at 37 °C for 15 to 60 minutes. Appropriate 
amounts of culture were plated in LB agar enriched with necessary selection. 
5.2 – PCR reaction  
PCR reactions were all carried out using NEB Q5 polymerase in a 50 µL reaction volume following the 
manufacturer’s protocol. Specific primers and deviating conditions are mentioned at relevant sections 
in the Results or Methods chapters.  
The following tables outline the reaction conditions.  
Table 5.1 PCR Reaction mixture 
5X Q5 Reaction buffer 10 µL 
10 mM dNTP mix 1 µL 
10 µM forward primer 2.5 µL 
10 µM reverse primer 2.5 µL 
Template DNA 1 ng 
Q5 polymerase 0.5 µL 
GC enhancer (if used) 10 µL 
Water Up to 50 µL total volume 
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Thermocycler conditions 
Table 5.2 PCR conditions 
1x Initial denaturation 98 °C 30 seconds 
30 cycles 
Denaturation 98 °C 7 seconds 
Annealing see note below* 20 seconds 
Extension  25 sec/kb 
1x Final extension  2 mins 
 Cooled hold  infinite 
 
*Annealing temperatures were calculated using the online NEBTm Calculator and were specific to 
each primer set. 
5.3 – Site Directed Mutagenesis 
For assignment purposes, methionine residues were substituted using site directed mutagenesis in a 
PCR reaction using Phusion DNA Polymerase (ThermoFisher). DpnI digested PCR product was 
transformed into DH5α E. coli cells along with the transfer plasmid and the resulting plasmid DNA 
construct was isolated using a commercial Miniprep kit (Qiagen) ready for transfection in insect cells. 
5.4 – Baculovirus generation 
Baculovirus was generated for expression using FlashBac viral DNA (Oxford Expression Technologies). 
β1AR containing pBacPAK8 plasmid was diluted to 100 ng/µl and 1.8 µL, together with 1.8 µl of 
FlashBac DNA, was added to 1.8 µL of previously dissolved and NaOH neutralised polyethylenimine 
(linear PEI 25000, Polysciences, 1 mg/ml concentration) and diluted with 360 µL of cell culture media 
(SF4, Bioconcept). The mixture was incubated at room temperature for 45 min to allow for DNA-
polymer complexes to form. The complex mixture was added to 1 mL of mid-log phase Sf9 cells, diluted 
to 0.5x106 cells/mL in serum free SF4 media and incubated at 27 °C shaking for 5 days. On day 5, a 
small sample was taken to confirm visual signs of infection. The resulting P0 viral stock was diluted to 
4 ml with fresh media and incubated for 48 h to generate P1 viral stock. 100 µL of P1 stock was used 
to infect 50 mL of cells at a density of 1x106 cells/mL, incubated at 27 °C, shaking for 48 h, generating 
a high titre P2 stock for protein expression. 
Alternatively some transfection reactions were carried out using Cellfectin II (ThermoFisher). For each 
transfection reaction 4 µL of Cellfectin II and 50 µL of media were mixed, and separately 0.25 µg of 
plasmid DNA was mixed with 2.5 µL of FlashBac viral DNA and 50 µL media. The two mixtures were 
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combined and incubated at room temperature for 15-30 minutes. Following this incubation the 
transfection mixture was added to cells in a 12 well flat bottom plate, dispensed at a density of 0.5x106 
cell/mL in 1 mL culture. The plate was not shaken for 3 hours, and the media was changed at this time 
by replacing it with 1 mL of fresh culture media two times. The generation of virus was identical to the 
PEI transfection from this point on.  
A positive control was used to verify the success of transfection, using an enhanced GFP construct in 
a pOET1. The vector is compatible with FlashBac through its ORF603 and truncated ORF1629 regions, 
which are sites of recombination with the viral DNA.  
 
Figure 5.1 GFP control vector for transfection into insect cells 
5.5 – β1AR Protein expression 
For β1AR expression, Sf9 or Sf21 cells, grown in serum free SF4 (Bioconcept) media were centrifuged 
(500 g, 10 min) and washed with sterile PBS, to reduce the carry-over of unlabelled methionine. The 
washed cells were diluted to a density of 3x106 cells/ml into methionine deficient SF4 media 
(Bioconcept) or ESF 921 media (Expression systems) at half the intended final culture volume. The 
culture was then infected with 4 ml/L of high density viral stock (P2), and incubated for 5 h, before 
supplementing the culture with 250 mg/l of 13C-methyl methionine and diluting to a final density of 
1.5x106 cells/ml. The initial reduction in culture volume ensured optimal aeration in the initial phase 
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of the viral infection. Cells were grown at 27 ᵒC for 48-72 hrs and were harvested by centrifugation 
(3500 g, 15 min), when viability dropped to 80%. 
For non-labelled expression the method was identical, except the cells were grown in unlabelled SF4 
(Bioconcept) or Insect XPRESS (Lonza) and no methionine supplementation took place. 
5.6 – Expression of Nanobodies 
Nb80 and Nb6b9 containing plasmids (pET28b(+) and pET26b(+) respectively) were transformed into 
chemically competent BL21 (DE3) cells and grown in LB media supplemented with the kanamycin at a 
final concentration of 50 µg/mL. Expression cultures were inoculated with a saturated overnight 
culture grown at 37 °C, to an OD600 density of 0.1 AU and grown to a density of 0.8 AU at 37 °C. 
Induction was achieved with isopropyl thiogalactopyranoside (IPTG) at a final concentration of 0.5 
mM. Expression cultures were grown at 25 °C for 16 h before harvesting by centrifugation (3500 g, 
20 min, 4 °C).  
Alternatively nanobodies were expressed in Superbroth auto-induction media (Formedium), where 
the overnight culture was prepared in LB, and 0.5 mL was used to inoculate the expression culture, 
regardless of overnight OD or culture volume.  
The following tables outline the composition of media used: 
Table 5.3 Composition of bacterial culture media used 
 Final concentration /(g/L) 
LB Media 
Tryptone  10 
Yeast Extract  5 
NaCl  10 
Superbroth Media 
Tryptone  32 
Yeast Extract  20 
NaCl  5 
SOB (Super Optimal Broth) 
Tryptone 0.5% W/V 5 
Yeast Extract 2% W/V 20 
NaCl 10mM 0.584 
KCl 2.5mM 0.186 
MgSO4 10mM 1.200 
MgCl2 10mM 0.952 
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Autoinduction Superbroth was either prepared from a commercial powder or made from the 
following constituents. Base ingredients were dissolved and autoclaved together. Trace elements 
were sterile filtered and the media was supplemented before use (291, 292).  
 
Table 5.4 Ingredients for autoinduction superbroth media (AIM SB) 
Base ingredients 
Component g/L 
Tryptone 35 
Yeast Extract 20 
(NH4)2SO4 3.3 
KH2PO4 6.8 
Na2HPO4 7.1 
Glucose 0.5 
α-Lactose 2.0 
MgSO4 0.15 
Glycerol  5 
 
Table 5.5 Composition of trace element mix for AIM SB 
Trace elements 
Ingredient [Stock] Added for 500 mL /(mL) 
FeCl3 5 mM 0.2 mL 
Salt mix 1000x 0.5 mL 
CaCl2 100 mM 0.5 mL 
NH4Cl 10% 5 mL (=1g/L) 
Antibiotics 1000x 0.5 mL 
 
Composition of 1000x 
salt mix 
ZnSO4 0.1 M 
MnCl2 0.1 M 
H3BO 0.1 M 
CuSO4 0.1 M 
 
5.7 – Purification of β1AR 
The frozen insect cell pellet was thawed with solubilisation buffer (20 mM Tris-HCl pH 8.0, 350 mM 
NaCl, 3 mM Imidazole, Complete Protease Inhibitor Cocktail (Roche), 2% LMNG) and stirred for 1 h. 
The solubilised cells were clarified by centrifugation (175,000 g, 45 min) and the soluble fraction was 
loaded onto a nickel affinity column. The column was washed with equilibration buffer (20 mM Tris-
HCl pH 8.0, 350 mM NaCl, 3 mM Imidazole, 0.02% LMNG) and weakly bound impurities were washed 
out with a 50 mM imidazole wash. The receptor was eluted with the same buffer supplemented with 
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250 mM imidazole. The final sample was exchanged into 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.04% 
LMNG using a HiPrep Desalting column. 
5.8 – Purification of Nanobodies 
Frozen cell pellets were thawed in 20 mM Tris-HCl pH 8.0, 150 mM NaCl with Complete Protease 
Inhibitor Cocktail (Roche) and lysed with an EmulsiFlex C5 homogeniser (Avestin). The solubilised cells 
were clarified by centrifugation (175,000 g, 15 min) and the soluble fraction was loaded onto a nickel 
affinity column. Unbound sample was removed with wash buffer (20 mM Tris-HCl pH 8.0, 150 mM 
NaCl), followed by a further wash of the same composition supplemented with 6 mM imidazole. 
Nanobodies were eluted with wash buffer containing 250 mM imidazole. A further size exclusion 
chromatography step on a Superdex S200 10/300 Increase column yielded a 90% pure protein 
preparation in 20 mM Tris-HCl pH 8.0, 150 mM NaCl.  
An alternative method of purification involved a nickel affinity chromatography step, followed by 
buffer-exchange dialysis, cation exchange chromatography and a final desalting step. 
Here, following the wash of any unbound material, the HisTrap column was washed with a 15 mM 
imidazole containing buffer, to remove weakly bound impurities. All further bound material was 
eluted by equilibration buffer supplemented with 250 mM imidazole. The eluate was dialysed 
overnight against 2 L of dialysis buffer (50 mM NaAcetate, pH 4.8, 75 mM NaCl) using a 3 kDa cutoff 
snakeskin membrane. Following dialysis, the solution was cleared of precipitate by centrifugation 
(4000 rcf, 10 mins) and the supernatant was loaded onto a 1 mL Resource S cation exchange column, 
pre-equilibrated with dialysis buffer at a rate of 2 mL/min. Subsequent to a column wash, bound 
species were separated using a liner gradient (60% target, 48 mL duration, 2 mL/min flowrate) using 
dialysis buffer supplemented with 1M NaCl. Nanobody elution peaked at 350 mM NaCl concentration. 
The eluted protein was desalted using a 5 mL HiTrap Desalting column into 20 mM Tris-HCl pH 8, 
150 mM NaCl. Nanobody samples were concentrated using a 3 kDa cutoff Amicon concentrator.  
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5.9 – SDS-PAGE and Western Blots 
SDS-PAGE gels were cast according to the following recipe: 
Table 5.6 Composition of SDS-PAGE gels 
12% Acrylamide Resolving Gel 
 Final concentration 2 Gels 4 gels 
Water - 4.92 mL 8.2 mL 
30% Acrylamide/Bis-Acryl 37.5:1 12% 6 mL 10 mL 
1.5 M Tris pH 8.8 375 mM 3.75 mL 6.25 mL 
10% SDS 0.1% 150 µL 250 µL 
10% APS 0.1% 150 µL 250 µL 
TEMED (Tetramethylethylenediamine) - 15 µL 25 µL 
TOTAL VOLUME - 15 mL 25 mL 
 
6% Acrylamide Stacking Gel 
Water - 2.73 mL 4.75 mL 
30% Acrylamide/Bis-Acryl 37.5:1 6% 1 mL 1.8 mL 
0.5 M Tris pH 6.8 125 mM 1.25 mL 2.25 mL 
10% SDS 0.1% 50 µL 90 µL 
10% APS 0.1% 50 µL 90 µL 
TEMED (Tetramethylethylenediamine) - 8 µL 15 µL 
TOTAL VOLUME - 5 mL 9 mL 
 
Samples were prepared with 1x final concentration of LDS loading buffer. Gels were run in NuPAGE 
MES buffer (Life technologies), or in equivalent custom made MES running buffer (50 mM MES, 50 mM 
Tris base, 1 mM EDTA, 0.1% SDS) at 200 V. The gels were stained with Instant Blue (Expedeon).  
For western blot analysis the resolved gels were transferred onto a 0.45 µm pore size methanol 
activated PVDF membrane in 1x NuPAGE Transfer buffer (25 mM bicine, 25 mM bis-tris pH 7.2, 1 mM 
EDTA, 0.05 mM chlorobutanol, 10% methanol) at 30 V for 1 hour. The membrane was then blocked in 
4% BSA in TBS-0.05% Tween20 (TBST) for 1 hour and subsequently washed with TBST for 5 minutes, 
repeated 3 times. The membrane was probed with nickel conjugated HRP in a 1:5000 dilution in TBST 
as instructed in the SuperSignal West HisProbe Kit (Pierce), for 1 hour. The probed membrane was 
washed extensively with TBST and incubated with 2 mL SuperSignal West Pico Luminol Enhancer and 
2 mL Stable Peroxide for 1 min. Probe binding was visualised on a Fuji RX X-ray film. 
5.10 – Dynamic Light Scattering 
Purified protein was dialysed into 10 mM Tris-HCl pH 8.0, 0.001% LMNG with varying amount of NaCl, 
ranging from 50 mM to 350 mM. 70 µL of buffer exchanged sample was placed into a ZEN0040 type 
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cuvette and measured on a Malvern Zetasizer NanoS instrument. Three repeat measurements were 
recorded with a 0 second delay. 
5.11 – Protein quantification 
Proteins quantified by NanoDrop relied on absorbance measurements at 280 nm, owing to the 
presence of tryptophan, tyrosine, phenylalanine or disulphide bonds all of which have an absorbance 
maximum at this wavelength. This method allows protein concentrations to be measured without 
dilution up to 400 mg/mL. A 0.1% protein solution (1 mg/mL) is assumed an absorption of 1.0 AU with 
a 10 mm path length. For each protein the actual absorption of a 0.1% solution varies depending on 
the number of absorbing residues present. To this end a correction factor is needed, as 1 AU will likely 
not equal a 1 mg/mL solution.  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 280 𝑛𝑚 (0.1% 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛)(𝐴𝑈) =
𝑀𝑤 (𝐷𝑎)
𝜀 (𝑀−1 𝑐𝑚−1)⁄  
Multiplying the measured A280 value by the inverse of the obtained 0.1% absorbance value will give 
the correct protein concentration for the given protein sample in units of mg/mL. 
Proteins measured using the Pierce BCA (bicinchoninic acid) assay followed manufacturers protocol 
using the microplate reader method. Firstly a standard curve is generated through serial dilutions of 
a 2 mg/mL stock of BSA as described in the manual. Each standard curve point and sample is prepared 
in triplicate, by mixing 20 µL sample or standard and 200 µL of working reagent. The working reagent 
is prepared by mixing Reagents A and B in a 50:1 ratio. The samples are mixed and incubated at 37 °C 
for 30 minutes and the absorbance is measured at 562 nm. 
Results were analysed using GraphPad Prism 6.01. Standard curve values were baseline corrected to 
blank measurements and fitted with a fourth-order polynomial non-linear regression. Unknown 
sample values were interpolated from this fit. LMNG was found not to be interfering with the assay, 
while DDM triggered a false positive readout even in the absence of protein.  
5.12 - Calibration of size exclusion columns 
In order to be able to use gel filtration as a means of estimating molecular mass and oligomeric 
composition the void volume (V0) and the elution volume of known molecular mass standards had to 
be established.  
The void volume was measured using blue dextran dissolved in 50 mM Tris-HCl pH 8, 150 mM KCl, to 
a final concentration of 2 mg/mL. Blue dextran has an approximate mass of 2000 kDa, therefore elutes 
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in the void volume. Calibration was done using the Gel filtration Molecular Weight Calibration Kit 
(Sigma, #MWGF200). 
The following proteins were dissolved in 1 mL of 50 mM Tris-HCl pH 8, 150 mM KCl to the indicated 
concentrations. 
Table 5.7 Calibration markers used for size exclusion chromatography (SEC) 
Marker Molecular Mass /kDa Concentration /(mg/mL) 
Cytochrome c 12.4 2 
Carbonic Anhydrase 29 3 
Albumin 66 10 
Alcohol Dehydrogenase 150 5 
β-Amylase 200 4 
The molecular masses were plotted against the ratio of measured retention volumes (Ve) to void 
volume (Ve/Vo). The points were fitted with an exponential curve. The fitting was done in Excel and 
Graph Pad Prism. 
A Superdex S200 Increase and a Superdex S75 16/60 pg columns were calibrated in this way. The 
resulting standard curves are shown below. 
 
Figure 5.2 SEC calibration curves 
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These standard curves can be described by the following equations. 
Table 5.8 Molecular mass and elution volume calculations for calibrated SEC columns. 
 Superdex S200 Increase 10/300 Superdex S75 16/60 
Void volume 8.465 mL 41.78 mL 
Molecular weight 𝑀𝑤 = 60244 ∗ 𝑒−3.946
𝑉𝑒
8.465 𝑀𝑤 = 3540 ∗ 𝑒−3.105
𝑉𝑒
41.78 
Elution volume 𝑉𝑒 = −
8.465
3.946
ln (
𝑀𝑤
60244
) 𝑉𝑒 = −
41.78
3.105
ln (
𝑀𝑤
3540
) 
 
5.13 - NMR experiments 
1H 1D experiments 
NMR experiments were recorded on a Bruker Avance AVIII 800 spectrometer (1H 800 MHz) equipped 
with a 5 mm TXI HCN/z cryoprobe. 1H 1D experiments were recorded with 8 scans and an acquisition 
time of 0.0512 seconds, recording 1024 data points. Water suppression was achieved with a 3-9-19 
180° Watergate sequence.  
[1H, 13C] HMQC experiments 
Spectra were recorded at 308 K using a SOFAST 1H,13C HMQC experiment with gradient coherence-
order selection, using non-uniform sampling (NUS) in the 13C dimension (293, 294). Gradient selection 
was required to reduce the intense LMNG detergent signals, while selective excitation of methyl 
groups enabled use of a short recycle delay of 0.5 s. Excitation used a 2.25 ms 120° PC9 pulse and 
inversion a 1.16 ms, 180° REBURP pulse (295, 296). A 60% Poisson-gap sampling schedule was used 
(60 complex points from total 100 complex points), with maximum acquisition time (tmax) 25 ms and 
spectral width (13C) of 4000 Hz. The direct (1H) dimension was acquired with 10,000 Hz spectral width, 
1024 points and tmax = 51.2 ms (297). Spectra were recorded with 368 scans, giving an acquisition time 
of 6.5 h. Where higher sensitivity was required, multiple experiments were recorded and added. 
Spectra were reconstructed using the iterative hard thresholding (IHT) compressed sensing (CS) 
implementation in the Cambridge CS package (Mark J. Bostock, unpublished) (298). Data was analysed 
using CCPN Analysis v2 (299). 
5.14 – ScFv C5 Restriction enzyme cloning 
Restriction enzyme cloning was employed to clone the ScFv C5 synthetic construct into the pMAL1-
Nb vector using the EcoRI and HindIII restriction sites. 1 µg vector (pMAL1-Nb) and insert (ScFv C5 in 
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pBSK) was digested in separate 20 µL reactions at 37 °C for 30 mins, using Thermo Fast digest green 
buffer and ThermoFisher fast digest enzymes. The vector was incubated for a further 30 minutes with 
alkaline phosphatase to prevent religation. The digested fragments were separated on a 1.1% agarose 
gel in TAE buffer (40 mM Tris base pH 8.5, 2 mM EDTA, 20 mM acetic acid).The vector produced a 
6692 bp fragment, while the C5 insert was 799 bp in size. The relevant fragments were excised from 
the agarose gel and extracted using an NEB Monarch DNA Gel Extraction Kit, following the 
manufacturer’s protocol. The ligation reaction was carried out using 50 ng linearised vector and 1:1, 
3:1 and 5:1 molar ratio of insert to vector in the presence of 1 U of T4 DNA ligase in 1x T4 DNA ligase 
buffer. The final reaction volume was 20 µL. The ligation reaction was carried out at room temperature 
for 30 minutes. 5 µL of reaction mixture was transformed into chemically ultracompetent DH5α cells. 
Cloning into the cell free vector pIVEX2.3d proceeded along identical lines, with the addition of a prior 
PCR step to introduce the NcoI and XhoI restriction sites, alongside extra bases on the overhanging 
side for enzyme binding. The primers were of the following sequence: XhoRev: 
cgcataactagctcgagttaatgatggtgatggtggtg, NcoFor: cgatctagaccatggaagttcagctggaagaaag. PCR reaction 
conditions were followed as described earlier. The PCR product was purified using a NEB Monarch PCR 
Purification Kit, to remove primers and enzymes. The purified PCR product was used in place of the 
insert as described above. Thermo fast digest NcoI and XhoI were used. 
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5.15 – HRV 3CP protease preparation and cleavage 
Human Rhinovirus 3CP protease (referred to as 3CP from hereon) was expressed and purified in 
house. The expression construct is shown below. The molecular weight is 47.3 kDa with a charge of  
-7.83 (pI 6.93) at pH 8.0, making it amenable to anion exchange chromatography at this pH. 
 
Figure 5.3 3C protease construct primary sequence 
 3CP was expressed in E. coli RIL cells, using autoinduction media. Harvested cells were washed and 
resuspended in PBS and lysed using an Avestin Emulsiflex C5 homogeniser. The supernatant was 
loaded onto a 5 mL capacity GSTrap FF column and washed with 20 mM Tris-HCl pH 8.0, 50 mM NaCl. 
The protein was eluted with the same buffer supplemented with 20 mM GSH. The eluate was loaded 
onto a 1 mL Resource Q anion exchange column and eluted using a linear salt gradient using 20 mM 
Tris-HCl pH 8.0, 500 mM NaCl. The final preparation was concentrated to 1 mg/mL, and supplemented 
with 10 mM EDTA and 10% glycerol and stored at -80 °C. No reducing agent was added to the stock.  
Cleavage reactions were carried out at 4 °C in the presence of reducing additives (DTT, TCEP, 
GSSG/GSH), described in more detail where used. 
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Appendix A – Development of turkey β₁AR constructs
P0 – WT-tβ1AR [NP_001290104.1] – 483 AA
MGDGWLPPDCGPHNRSGGGGATAAPTGSRQVSAELLSQQWEAGMSLLMALVVLLIV
AGNVLVIAAIGRTQRLQTLTNLFITSLACADLVMGLLVVPFGATLVVRGTWLWGSFLCEC
WTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQSLMTRARAKVIICTVWAISALVSFLPIMM
HWWRDEDPQALKCYQDPGCCDFVTNRAYAIASSIISFYIPLLIMIFVYLRVYREAKEQIRKI
DRCEGRFYGSQEQPQPPPLPQHQPILGNGRASKRKTSRVMAMREHKALKTLGIIMGVFT
LCWLPFFLVNIVNVFNRDLVPDWLFVFFNWLGYANSAFNPIIYCRSPDFRKAFKRLLCFPR
KADRRLHAGGQPAPLPGGFISTLGSPEHSPGGTWSDCNGGTRGGSESSLEERHSKTSRS
ESKMEREKNILATTRFYCTFLGNGDKAVFCTVLRIVKLFEDATCTCPHTHKLKMKWRFKQ
HQA
P0.1 – tβtrunc (1-424)-C116L
MGDGWLPPDCGPHNRSGGGGATAAPTGSRQVSAELLSQQWEAGMSLLMALVVLLIV
AGNVLVIAAIGRTQRLQTLTNLFITSLACADLVMGLLVVPFGATLVVRGTWLWGSFLCEL
WTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQSLMTRARAKVIICTVWAISALVSFLPIMM
HWWRDEDPQALKCYQDPGCCDFVTNRAYAIASSIISFYIPLLIMIFVYLRVYREAKEQIRKI
DRCEGRFYGSQEQPQPPPLPQHQPILGNGRASKRKTSRVMAMREHKALKTLGIIMGVFT
LCWLPFFLVNIVNVFNRDLVPDWLFVFFNWLGYANSAFNPIIYCRSPDFRKAFKRLLCFPR
KADRRLHAGGQPAPLPGGFISTLGSPEHSPGGTWSDCNGGTRGGSESSLEERHSKTSRS
ESKM
J. G. Baker, R. G. W. Proudman, C. G. Tate, The pharmacological effects…
Naunyn. Schmiedebergs. Arch. Pharmacol. 384, 71–91 (2011).
P1 – tβ1AR (20-424)-C116L-His6 – 411AAA
MGATAAPTGSRQVSAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGRTQRLQTLT
NLFITSLACADLVMGLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIETLCVIAI
DRYLAITSPFRYQSLMTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDP
GCCDFVTNRAYAIASSIISFYIPLLIMIFVYLRVYREAKEQIRKIDRCEGRFYGSQEQPQPPPL
PQHQPILGNGRASKRKTSRVMAMREHKALKTLGIIMGVFTLCWLPFFLVNIVNVFNRDL
VPDWLFVFFNWLGYANSAFNPIIYCRSPDFRKAFKRLLCFPRKADRRLHAGGQPAPLPG
GFISTLGSPEHSPGGTWSDCNGGTRGGSESSLEERHSKTSRSESKMHHHHHH
T. Warne, J. Chirnside, G. F. X. Schertler, Expression and purifica�on of
truncated, non-glycosylated turkey beta-adrenergic receptors for
crystallization. Biochim. Biophys. Acta - Biomembr. 1610, 133–140 (2003).
P2 – β6 (34-424)-C116L-His6 (=β1AR6, β6, β1ARΔNC) – 400 AA
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGRTQRLQTLTNLFITSLACADLV
MGLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQ
SLMTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYA
IASSIISFYIPLLIMIFVYLRVYREAKEQIRKIDRCEGRFYGSQEQPQPPPLPQHQPILGNGRA
SKRKTSRVMAMREHKALKTLGIIMGVFTLCWLPFFLVNIVNVFNRDLVPDWLFVFFNWL
GYANSAFNPIIYCRSPDFRKAFKRLLCFPRKADRRLHAGGQPAPLPGGFISTLGSPEHSPG
GTWSDCNGGTRGGSESSLEERHSKTSRSESKMHHHHHH
• 2G-19G DEL
• 425E-483A DEL
• C-term His-6
• C116L to increase
yield
• 22T-33A DEL
• 368H-424M DEL
• C358A remove
palmitoylation site
• m23
mutations:
o R68S
o M90V
o Y227A
o A282L
o F327A
o F338M
β6
(20-242)
tβtrunc
• 425E-483A DEL
• C116L
to increase
yield
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T. Warne, J. Chirnside, G. F. X. Schertler, Expression and purifica�on of
truncated, non-glycosylated turkey beta-adrenergic receptors for
crystallization. Biochim. Biophys. Acta - Biomembr. 1610, 133–140 (2003).
T. Warne, M. J. Serrano-Vega, C. G. Tate, G. F. X. Schertler, Development and
crystallization of a minimal thermostabilised G protein-coupled receptor.
Protein Expr. Purif. 65, 204–213 (2009).
B. Carpenter, C. G. Tate, Engineering a minimal G Protein to facilitate
crystallisa�on of G protein - coupled receptors in their ac�ve conforma�on
Protein Eng. Des. Sel. 29, 583–594 (2016).
P2.1 - β6-m23 (34-424)-(R68S, M90V, Y227A, A282L, F327A, F338M)-C116L-
His6 (=β1AR-m23, βAR34-424 in second reference)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLVV
GLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQSL
MTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYAIA
SSIISFYIPLLIMIFVALRVYREAKEQIRKIDRCEGRFYGSQEQPQPPPLPQHQPILGNGRAS
KRKTSRVMLMREHKALKTLGIIMGVFTLCWLPFFLVNIVNVFNRDLVPDWLFVAFNWLG
YANSAMNPIIYCRSPDFRKAFKRLLCFPRKADRRLHAGGQPAPLPGGFISTLGSPEHSPGG
TWSDCNGGTRGGSESSLEERHSKTSRSESKMHHHHHH
J. L. Miller, C. G. Tate, Engineering an ultra-thermostable β(1)-adrenoceptor. J.
Mol. Biol. 413, 628–38 (2011).
M. J. Serrano-Vega, F. Magnani, Y. Shibata, C. G. Tate, Conformational
thermostabiliza�on of the beta1-adrenergic receptor in a detergent-resistant
form. Proc. Natl. Acad. Sci. U. S. A. 105, 877–882 (2008).
P2.2 - JM3-(34-424)-(D200E, D322K, I129V, Y343L)-C116L-His6 – 400 AA
(44.78 kDa)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLVV
GLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASVETLCVIAIDRYLAITSPFRYQSL
MTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCEFVTNRAYAIA
SSIISFYIPLLIMIFVALRVYREAKEQIRKIDRCEGRFYGSQEQPQPPPLPQHQPILGNGRAS
KRKTSRVMLMREHKALKTLGIIMGVFTLCWLPFFLVNIVNVFNRDLVPKWLFVAFNWLG
YANSAMNPIILCRSPDFRKAFKRLLCFPRKADRRLHAGGQPAPLPGGFISTLGSPEHSPGG
TWSDCNGGTRGGSESSLEERHSKTSRSESKMHHHHHH
J. L. Miller, C. G. Tate, Engineering an ultra-thermostable β(1)-adrenoceptor. J.
Mol. Biol. 413, 628–38 (2011).
P3 - β34 (34-367)-(C116L, C358A) – 343 AA (39.3 kDa)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGRTQRLQTLTNLFITSLACADLV
MGLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQ
SLMTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYA
IASSIISFYIPLLIMIFVYLRVYREAKEQIRKIDRCEGRFYGSQEQPQPPPLPQHQPILGNGRA
SKRKTSRVMAMREHKALKTLGIIMGVFTLCWLPFFLVNIVNVFNRDLVPDWLFVFFNWL
GYANSAFNPIIYCRSPDFRKAFKRLLAFPRKADRRLHHHHHH
• 244C-271R
DEL (ICL3)
• 275R-278S
DEL (ICL3)
β34
• 244C-271R DEL
(ICL3)
• 275R-278S DEL
(ICL3)
β6-m23
β6-JM3
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T. Warne, M. J. Serrano-Vega, C. G. Tate, G. F. X. Schertler, Development and
crystallization of a minimal thermostabilised G protein-coupled receptor.
Protein Expr. Purif. 65, 204–213 (2009).
P4 - β35 (34-367)-(C116L, C358A) – ICL3 Del1
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGRTQRLQTLTNLFITSLACADLV
MGLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQ
SLMTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYA
IASSIISFYIPLLIMIFVYLRVYREAKEQIRKIDRASKRVMAMREHKALKTLGIIMGVFTLCWL
PFFLVNIVNVFNRDLVPDWLFVFFNWLGYANSAFNPIIYCRSPDFRKAFKRLLAFPRKADR
RLHHHHHH
T. Warne, M. J. Serrano-Vega, C. G. Tate, G. F. X. Schertler, Development and
crystallization of a minimal thermostabilised G protein-coupled receptor.
Protein Expr. Purif. 65, 204–213 (2009).
P5 - β36 (34-367)-(C116L, C358A) – ICL3 Del2
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGRTQRLQTLTNLFITSLACADLV
MGLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQ
SLMTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYA
IASSIISFYIPLLIMIFVYLRVYREAKEQIRKIDRASKRKRVMAMREHKALKTLGIIMGVFTLC
WLPFFLVNIVNVFNRDLVPDWLFVFFNWLGYANSAFNPIIYCRSPDFRKAFKRLLAFPRK
ADRRLHHHHHH
T. Warne, M. J. Serrano-Vega, C. G. Tate, G. F. X. Schertler, Development and
crystallization of a minimal thermostabilised G protein-coupled receptor.
Protein Expr. Purif. 65, 204–213 (2009).
P6 - β36-m23 (34-367)-(R68S, M90V, Y227A, A282L, F327A, F338M)-(C116L,
C358A)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLVV
GLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQSL
MTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYAIA
SSIISFYIPLLIMIFVALRVYREAKEQIRKIDRASKRKRVMLMREHKALKTLGIIMGVFTLCW
LPFFLVNIVNVFNRDLVPDWLFVAFNWLGYANSAMNPIIYCRSPDFRKAFKRLLAFPRKA
DRRLHHHHHH
T. Warne et al., Structure of a β1-adrenergic G-protein-coupled receptor.
Nature. 454 (2008), pp. 486–491.
R. Moukhametzianov et al., Two dis�nct conformations of helix 6 observed in
antagonist-bound structures of a beta1-adrenergic receptor. Proc. Natl. Acad.
Sci. U. S. A. 108, 8228–32 (2011).
P7 - β44-m23 (34-367)-(R68S, M90V, Y227A, A282L, F327A, F338M)-
(T277+S278)-(C116L, C358A)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLVV
GLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIETLCVIAIDRYLAITSPFRYQSL
MTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYAIA
SSIISFYIPLLIMIFVALRVYREAKEQIRKIDRASKRKTSRVMLMREHKALKTLGIIMGVFTLC
• 244C-271R
DEL (ICL3)
• 277T-278S
DEL (ICL3)
β36
• m23 mutations:
o R68S
o M90V
o Y227A
o A282L
o F327A
o F338M
β36-m23
β44-m23
• T277+S278 ADD
β35
160
WLPFFLVNIVNVFNRDLVPDWLFVAFNWLGYANSAMNPIIYCRSPDFRKAFKRLLAFPR
KADRRLHHHHHH
T. Warne et al., The structural basis for agonist and par�al agonist action on a
T. Warne, P. C. Edwards, A. G. W. Leslie, C. G. Tate, Crystal structures of a
stabilized β1-adrenoceptor bound to the biased agonists bucindolol and
carvedilol. Structure. 20, 841–849 (2012).
P7.1 – β1AR-JM50 (34-367)-(R68S, M90V, Y227A, A282L, F327A, F338M)-
(T277+S278)-(I129V, D322K, Y343L)-(C116L, C358A) (=β44-m23+JM50)
– 315 AA, (35.85 kDa)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLVV
GLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASVETLCVIAIDRYLAITSPFRYQSL
MTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYAIA
SSIISFYIPLLIMIFVALRVYREAKEQIRKIDRASKRKTSRVMLMREHKALKTLGIIMGVFTLC
WLPFFLVNIVNVFNRDLVPKWLFVAFNWLGYANSAMNPIILCRSPDFRKAFKRLLAFPRK
ADRRLHHHHHH
J. L. Miller-Gallacher et al., The 2.1 Å resolu�on structure of cyanopindolol-
bound β1-adrenoceptor iden�fies an intramembrane Na+ ion that stabilises
the ligand-free receptor. PLoS One. 9, e92727 (2014).
7.2 – β44-TS (34-367)-(R68S, M90V, Y227A, A282L, F327A, F338M)-
(T277+S278)-(I129V, E130W, Y343L)-(C116L, C358A) (=β44-m23+JM50)
– 315 AA, (35.9 kDa)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLVV
GLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASVWTLCVIAIDRYLAITSPFRYQS
LMTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYAI
ASSIISFYIPLLIMIFVALRVYREAKEQIRKIDRASKRKTSRVMLMREHKALKTLGIIMGVFTL
CWLPFFLVNIVNVFNRDLVPDWLFVAFNWLGYANSAMNPIILCRSPDFRKAFKRLLAFPR
KADRRLHHHHHH
T. Sato et al., Pharmacological Analysis and Structure Determina�on of 7-
Methylcyanopindolol-Bound β1-Adrenergic Receptor.Mol. Pharmacol. 88,
1024–34 (2015).
7.3 – TS-β1AR (34-367)-(R68S, M90V, Y227A, A282L, F327A, F338M)-
(T277+S278)-(I129V, Y343L, D200E)-(C116L, C358A) (=β44-m23+JM50)
– 315 AA, (35.9 kDa)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLVV
GLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASVETLCVIAIDRYLAITSPFRYQSL
MTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCEFVTNRAYAIA
SSIISFYIPLLIMIFVALRVYREAKEQIRKIDRASKRKTSRVMLMREHKALKTLGIIMGVFTLC
WLPFFLVNIVNVFNRDLVPKWLFVAFNWLGYANSAMNPIILCRSPDFRKAFKRLLAFPRK
ADRRLHHHHHH
S. Isogai et al., Backbone NMR reveals allosteric signal transduc�on networks
in the β1-adrenergic receptor. Nature. 314, 1–17 (2016).
JM50
• I129V
• D322K
• Y343L
• I129V
• E130W
• Y343L
β44-TS
TS-β1AR
• I129V
• D322K
• Y343L
• D200E
161
P8 - Met2 (34-367)-(R68S, F327A, F338M)-(V90M, A227Y, L282A)-(E130W,
D322K)-(TS)-(C116L, C358A)-His8 tag – 317 AA (36.33 kDa)
MGAELLSQQWEAGMSLLMALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLV
MGLLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIWTLCVIAIDRYLAITSPFRYQ
SLMTRARAKVIICTVWAISALVSFLPIMMHWWRDEDPQALKCYQDPGCCDFVTNRAYA
IASSIISFYIPLLIMIFVYLRVYREAKEQIRKIDRASKRKTSRVMAMREHKALKTLGIIMGVFT
LCWLPFFLVNIVNVFNRDLVPKWLFVAFNWLGYANSAMNPIIYCRSPDFRKAFKRLLAFP
RKADRRLHHHHHHHH
P8.1 - Met2-Δ5 (34-367)-(R68S, F327A)-(V90M, A227Y, L282A)-(E130W,
K322D)-(TS)-(C116L, C358A)-(M44L, M48L, M179L, M281A, M338A)-His8 tag –
317 AA (36.33 kDa) (also called as Met3)
MGAELLSQQWEAGLSLLLALVVLLIVAGNVLVIAAIGSTQRLQTLTNLFITSLACADLVMG
LLVVPFGATLVVRGTWLWGSFLCELWTSLDVLCVTASIWTLCVIAIDRYLAITSPFRYQSL
MTRARAKVIICTVWAISALVSFLPIMLHWWRDEDPQALKCYQDPGCCDFVTNRAYAIAS
SIISFYIPLLIMIFVYLRVYREAKEQIRKIDRASKRKTSRVAAMREHKALKTLGIIMGVFTLCW
LPFFLVNIVNVFNRDLVPDWLFVAFNWLGYANSAANPIIYCRSPDFRKAFKRLLAFPRKA
DRRLHHHHHHHH
Explanation of mutations: m23 set: R68S, F327A; m23 reversed: V90M,
A227Y, L282A; β44-TS mutation (Sato et al.): E130W (relevance to a β2AR Zn
bridge); salt bridge reversal: K322D; ICL3 adjustment: TS; increased
expression: C116L; palmitoylation site: C358A; coincidentally stabilising:
M338A
• Stabilisa�on
removed:
V90M, A227Y, L282A
• Added:
E130W, D322K (JM3)
Met2
Met2-Δ5
• Methionines
mutated:
M44L, M48L,
M179L, M281A,
M338A
• K322D
